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Individuals with cancer may experience cognitive symptoms related to the 
immune system’s response to the cancer and cancer treatments.  Specifically, 
inflammatory cytokines can induce clusters of physical symptoms and behavioral 
responses called ‘sickness behaviors’. Cognitive symptoms appear to occur alongside 
sickness behaviors in individuals with cancer.  Little research has examined cognitive 
symptoms and immune function in individuals with colorectal cancer (CRC).  The 
purpose of this cross-sectional comparative study was to 1) describe cognitive symptoms 
and inflammatory cytokine and biomarker expression in individuals with CRC, and 2) 
begin to characterize the relationship between cognitive symptoms and inflammatory 
cytokines and biomarkers.  A biobehavioral model was used to examine cancer-related 
cognitive symptoms and proposes that symptoms and physiologic changes share a 
common psychoneuroimmunologic mechanism. 
Participants included 50 men and women newly diagnosed with primary or 
recurrent CRC within the past six months (M = 55 years) and a comparison group of 50 
similar individuals without CRC (M = 58 years). Cognitive symptoms were measured 
using tests of attention (Attention Network Test), directed attention and working memory 
(Digit Span, Trail Making Test, Attentional Function Index), and long-term memory (Rey 
Auditory Verbal Learning Test, Everyday Memory Questionnaire).  Pro-inflammatory 
cytokines (interleukin-1beta, interleukin-6, tumor necrosis factor-alpha) and biomarkers  
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(interleukin-1 receptor antagonist, C - reactive protein, interleukin-10, transforming 
growth factor-beta1) were measured using standard commercial assays.   
 As hypothesized, CRC participants performed worse on measures of directed 
attention and working memory and had higher serum levels of interleukin-6, C-reactive 
protein, and interleukin-10 compared to healthy controls.  Unexpectedly, CRC 
participants had lower serum levels of transforming growth factor-beta1 compared to 
controls.  Significant relationships were found between cognitive and immune variables 
using multiple regression analyses.  Specifically, 1) higher serum C-reactive protein 
levels predicted poorer directed attention and working memory performance [F = (7, 91) 
= 6.17, p < 0.001], and 2) higher C-reactive protein and lower transforming growth 
factor-beta1 levels predicted poorer directed attention and working memory on self-report 
[F = (8, 90) = 9.92, p < 0.001] after controlling for covariates.  These novel findings have 
important implications for understanding the illness experience in CRC and developing 




Currently there are nearly 14 million individuals in the United States with a 
personal history of cancer (American Cancer Society, 2013).  Cancer and cancer 
treatments can affect the health and normal functioning of cancer survivors (Institue of 
Medicine, 2006).  Cognitive function is one such functional ability altered by cancer and 
cancer treatments. Cognitive processes consistently altered in this population include 
attention, working memory, and long-term memory (Wefel, Vardy, Ahles, & Schagen, 
2011). These cognitive processes are necessary for planning and carrying out tasks, 
learning, problem solving, interpersonal behavior, and effective functioning (Mesulam, 
2000). As such, they are critical for understanding and coping with cancer and cancer 
treatments as well as fundamental for everyday functioning.  Little is known about the 
mechanisms that may underlie cognitive symptoms and impaired function in individuals 
with cancer.  One potential mechanism is an increase in inflammatory cytokine 
expression secondary to the immune system’s response to the cancer cells and tissue 
injury (Cleeland et al., 2003; Kelley et al., 2003).  Specifically, pro-inflammatory 
cytokines (e.g. interleukin-1, interleukin-6, tumor necrosis factor-alpha) produced in the 
tumor’s microenvironment or by immune cells at the site of tissue injury (secondary to 
cancer treatments) can act on the central nervous system to elicit symptoms and 
behavioral responses that generally favor the recovery of the individual but can be 
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detrimental to health if excessive (Balkwill & Mantovani, 2012; Hart, 1988; Kumar, 
Abbas, Fausto, Robbins, & Cotran, 2005; Murphy, Travers, Walport, & Janeway, 2012).   
Cognitive symptoms and impaired function appear to occur alongside cytokine-
induced symptoms and behavior and have been associated with pro-inflammatory 
cytokines in preclinical and clinical studies (Ader, 2007; Smith, Tyrrell, Coyle, & 
Higgins, 1988; Spath-Schwalbe et al., 1998; Vollmer-Conna et al., 2004).  These studies 
suggest that alterations in attention and memory experienced by some individuals with 
cancer may be part of an immune response to the cancer and/or cancer-related treatments.  
The relationship between cytokines and cognitive function in individuals with cancer has 
been largely unexplored. Individuals with colorectal cancer may be particularly 
vulnerable to cytokine-induced cognitive changes given that colorectal cancer is 
characterized by large tumors capable of producing significant amounts of inflammatory 
cytokines.  After an extensive literature search, only a few studies were found that 
examined cognitive function in individuals with cancer during the initial phase of the 
illness (Bond, Dietrich, & Murphy, 2012; Cimprich, 1999; Hermelink et al., 2007; 
Meyers, Albitar, & Estey, 2005; Meyers, Byrne, & Komaki, 1995) and even fewer that 
examined cognitive function in colorectal cancer survivors (Vardy et al., 2007).  Further, 
only one preliminary study was found that examined the relationship between cognitive 
function and cytokine expression in individuals with cancer (Meyers et al., 2005). Thus, 
this dissertation study will begin to address these understudied and important areas of 
colorectal cancer survivorship. 
This dissertation paper consists of five chapters.  The introduction chapter will 
include: the dissertation study’s specific aim and three research questions, a brief review 
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of the literature examining cognitive impairment and systemic inflammation in cancer, 
and a novel biobehavioral model in which to study cognitive changes in individuals with 
cancer.  The subsequent three chapters will present completed research for each of the 
three research questions.  Finally, chapter five will summarize major research findings, 
discuss strengths and limitations of the work, and describe directions for future studies. 
Study Aim and Research Questions 
     The specific aim with corresponding hypotheses for this study:   
Aim 1. To examine if a relationship exists between deficits in attention and memory and 
alterations in the expression of pro-inflammatory cytokines and selected biomarkers of 
inflammation in individuals newly diagnosed with colorectal or recurrent colorectal 
cancer. 
Hypothesis 1a:  Compared to participants without colorectal cancer, individuals 
newly diagnosed with colorectal cancer or recurrent colorectal cancer will show 
alterations in the cognitive performance on measures of attention, working and 
long-term memory. 
Hypothesis 1b:  Compared to participants without colorectal cancer, individuals 
newly diagnosed with colorectal or recurrent colorectal cancer will show 
alterations in the expression of pro-inflammatory cytokines interleukin-1beta (IL-
1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), and selected 
biomarkers of inflammation.  
Hypothesis 1c:  Lower performance on objective measures of attention and 
memory will be related to elevated levels of pro-inflammatory cytokines 
interleukin-1beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha 
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(TNF-α), and selected biomarkers of inflammation in the combined group of 
individuals with and without colorectal cancer. 
Cognitive Impairment in Cancer Survivors 
Alterations in attention and memory have been observed in individuals with a variety 
of tumors including: breast, prostate, lung, colorectal, ovarian, testicular, melanoma, 
leukemia, and lymphoma (Skaali et al., 2011a; Vardy & Tannock, 2007; Wefel, Vardy, et 
al., 2011).  They have also been observed alongside focal neural deficits in individuals 
with central nervous system disease (primary and metastatic tumors) suggesting that a 
ubiquitous physiological response to the cancer may underlie changes in attention and 
memory (Correa, 2010).  The time course of cognitive decline and recovery for an 
individual cancer survivor is largely unknown.  Cross-sectional studies and longitudinal 
studies assessing treatment-associated effects suggest that cancer survivors can 
experience cognitive changes after diagnosis and before any treatment, during primary 
and adjuvant therapy, and up to 20 years post treatment (Koppelmans et al., 2012; Vardy 
& Tannock, 2007).  Not all cancer survivors experience cognitive changes or are equally 
affected suggesting that there may be additional patient characteristics that contribute to 
an individual’s ability to function (e.g. age, presence of comorbid health problems) 
(Cimprich, 1998; Wefel, Vardy, et al., 2011).  This section will: 1) review alterations in 
cognitive function in individuals with cancer and 2) describe patient characteristics 
associated with cognitive symptoms and impaired function in individuals with cancer.  




Cancer Associated Changes in Attention and Memory Function 
Several research studies have assessed cognitive function in individuals with cancer 
before any treatment (Bond et al., 2012; Cimprich, 1998, 1999; Cimprich & Ronis, 2001; 
Hermelink et al., 2007; Meyers et al., 2005; Meyers et al., 1995).   See Table 1.1.  Six of 
these seven studies found that individuals with leukemia, lung, breast, and head and neck 
cancers performed or perceived their function to be significantly worse on tasks requiring 
attention, working memory, and long-term memory (Digit Span, Trail Making Test A & 
B, Symbol Digit Modalities Test, d2, Regensberg Word Fluency Test, Verbal Selective 
Reminding test, Rey’s Auditory Verbal Learning Test, Hopkins Verbal Learning Test, 
Necker Cube Pattern Control test, Attentional Function Index) (Bond et al., 2012; 
Cimprich, 1999; Cimprich & Ronis, 2001; Hermelink et al., 2007; Meyers et al., 2005; 
Meyers et al., 1995).  One study by Cimprich (1998) did not observe significant 
alterations in attention and working memory in women with early stage breast cancer 
prior to surgery.  However, Cimprich (1998) did find that scores on a brief battery of 
neuropsychological tests were skewed to the lower end of the published normative range 
suggesting that subtle changes in attention and working memory were present (Digit 
Span, Digit Symbol Modalities Test, Necker Cube Pattern Control test).  
Together, the above studies provide evidence that individuals newly diagnosed with 
cancer can experience changes in attention, working memory, and long-term memory at 
diagnosis and before any treatment for the disease. These studies suggest that cognitive 
changes may be associated with the cancer itself.  Further research is needed to explore 
whether there is a subgroup of individuals that is particularly vulnerable to the effects of 
 6 
cancer or if cognitive changes are associated with how an individual responds to a new 
diagnosis of cancer. 
Cancer Treatment Associated Changes in Attention and Memory 
Surgery.  Although research studies have observed deficits in attention, working 
memory, and long-term memory after surgery and before adjuvant therapy, few studies 
have assessed the effects of surgery on cognitive function in individuals with cancer 
using a pre/post or longitudinal design (Cimprich, 1999; Cimprich et al., 2010; Cimprich 
& Ronis, 2001; Quesnel, Savard, & Ivers, 2009; Shilling, Jenkins, Morris, Deutsch, & 
Bloomfield, 2005; Wefel, Lenzi, Theriault, Davis, & Meyers, 2004; Wefel et al., 2011).  
To date, three studies were found that examined cognitive function before and after 
surgery (Cimprich, 1998; Cimprich & Ronis, 2001; Hedayati, Schedin, Nyman, 
Alinaghizadeh, & Albertsson, 2011).  See Table 1.2. Specifically, Cimprich (1998) 
assessed cognitive function in 74 women newly diagnosed with early stage breast cancer 
approximately 12 days before and 15 days after breast conserving surgery or mastectomy.  
She found that older women (65 - 79 years) as well as middle-aged women (46 – 64 
years) undergoing a mastectomy experienced a significant decline in performance on 
measures of attention and working memory from pre to post surgery (Composite Score: 
Digit Span, Symbol Digit Modalities Test, & Necker Cube Pattern Control Test) but not 
for middle aged women undergoing breast conserving surgery or younger women (25 – 
45 years). Hedayati and colleagues (2011) assessed cognitive function in 71 women 
newly diagnosed with breast cancer before diagnosis and 63 women without breast 
cancer.  Participants in the breast cancer group were assessed before diagnosis and one 
month after breast conserving surgery or mastectomy.  Researchers found that individuals 
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with breast cancer performed worse at baseline on measures of attention and working 
memory and failed to improve after surgery unlike women in the healthy control group 
who improved significantly at retest (Cognitive Stability Index).  Researchers noted that a 
failure to find a practice effect in women with breast cancer may suggest a subtle decline 
in function.  Finally, Cimprich and Ronis (2001) assessed cognitive function in 47 older 
women (55 to 79 years) newly diagnosed with early stage breast cancer (I, II) and 48 
women of similar age in a healthy control group.  Participants in the breast cancer group 
were assessed approximately 12 days before and at two time points after breast 
conserving surgery or mastectomy (two weeks, three months).  Researchers found that 
individuals with breast cancer performed significantly worse on measures of attention 
and memory at baseline compared to healthy individuals but that after surgery they 
gradually improved (between two weeks after surgery and three months after surgery) 
(Composite Score: Digit Span, Symbol Digit Modalities Test, & Necker Cube Pattern 
Control Test).   
These three studies suggest that some individuals with cancer can experience 
cognitive changes prior to surgery and that cognitive deficits can persist or gradually get 
better after surgery.  Further, these studies suggest that a subgroup of individuals (older 
age, more extensive surgery) can experience an acute decline in function after surgery 
(Cimprich, 1998; Cimprich & Ronis, 2001; Hedayati et al., 2011).  
From an immune perspective, the pattern of cognitive recovery observed in some 
individuals may be associated with a dampening down of the immune response secondary 
to a reduced tumor burden (surgical removal of the primary tumor).   Alternatively, the 
failure for attention and memory to improve to performance levels observed in healthy 
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controls as well as cognitive decline observed in other individuals may be associated with 
a continued immune response to the surgical intervention (extensive tissue injury) as well 
as other factors (e.g. aging immune and central nervous systems).   
Chemotherapy.  Eight studies were found that examined the effects of chemotherapy 
on cognitive function using a pre/post or longitudinal design (Bender et al., 2006; 
Hensley et al., 2006; Hermelink et al., 2007; Hess et al., 2010; Jansen, Dodd, 
Miaskowski, Dowling, & Kramer, 2008; Kaasa, Olsnes, & Mastekaasa, 1988; Skaali, 
Fossa, et al., 2011a; Skaali, Fossa, & Dahl, 2011).  See Table 1.3.  Excluded from this 
review were studies that included a population of individuals receiving multiple therapies 
(i.e. chemotherapy plus hormone therapy or radiation therapy).  Two of the eight studies 
included in this review assessed individuals prior to surgery or any other therapy 
(neoadjuvant chemotherapy or main treatment) and six studies assessed individuals after 
surgery and before initiating chemotherapy (adjuvant chemotherapy).  The majority of 
these studies observed cognitive decline in individuals with cancer or a subgroup of 
individuals with cancer over the course of the chemotherapy.  Specifically, Hermelink 
and colleagues (2007) assessed cognitive function in women before and prior to their 
final cycle of neoadjuvant chemotherapy (epirubicin, paclitaxel, cyclophosphamide) for 
breast cancer.  They found that individuals with breast cancer before any treatment for 
their disease performed significantly worse on measures of attention and memory 
compared to normative data.  Additionally, they observed cognitive decline in a subgroup 
of individuals with breast cancer.  Specifically, researchers found that 27 of 101 women 
newly diagnosed with breast cancer had a significant decline in cognitive function over 
the course of chemotherapy on a battery of neuropsychological tests that included tests of 
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attention and memory (Logical Memory I & II, Digit Span, d2, Trail Making A & B, 
Regensberg Word Fluency Test).  Kaasa and colleagues (1988) assessed cognitive 
function in 62 men and women with inoperable non-small cell lung cancer before main 
treatment with chemotherapy and five weeks after the last course of chemotherapy 
(cisplatin, etoposide).  In this study researchers observed a decline in attention and 
memory function (lower scores from baseline) in a subgroup of individuals on a variety 
of neuropsychological measures including: Trail Making Test A (29), Trail Making Test 
B (50), Verbal Learning Test – 10 trial (32), Verbal Learning Test - 5 trial (6), Benton 
Visual Retention Test - correct answers (43), and Benton Visual Retention Test - 
incorrect answers (50).  Hess and colleagues (2010) assessed cognitive function in 27 
individuals newly diagnosed with ovarian cancer at three time points:  after surgery and 
before chemotherapy, after three cycles of chemotherapy and after six cycles of 
chemotherapy (platinum-based therapy).  Researchers found that 92 of participants at 
time two and 86 of participants at time three showed a decline in at least one of three 
subtests of the Cognitive Stability index (a decrease of one or more standard error of the 
mean [SEM] from baseline).  Jansen and colleagues (2008) assessed cognitive function in 
30 individuals with breast cancer at two time points:  before the initiation of 
chemotherapy and after four cycles of chemotherapy (doxorubicin, cyclophosphamide).  
Researchers found that 33 of participants demonstrated a decline in attention and memory 
function (a decrease of one or more standard deviation [SD]) (Repeatable Battery of 
Adult Neuropsychological Status, RBANS). Finally, Skaali and colleagues (2011a) 
assessed 122 individuals with testicular cancer after orchiectomy and before 
chemotherapy and 12 months after chemotherapy (bleomycin, etoposide, cisplatin).  
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Researchers found that 38 of participants receiving one to four cycles of chemotherapy 
showed a decline of > 10 on measures of attention and memory (CANTAB).  
Additionally, Skaali and colleagues (2011b) found that approximately a quarter of 
participants reported an increase in attention and memory problems one year after 
treatment (two questions:  How is your attention/memory; four response alternatives).  
In contrast to the above, two studies were found that did not observe a decline in 
attention and memory in individuals with cancer receiving chemotherapy for their 
disease.  The first study by Bender and colleagues (2006) assessed cognitive function in 
women with early stage breast cancer receiving chemotherapy alone (n = 19), receiving 
chemotherapy and hormone therapy (n = 15) and not receiving chemotherapy or hormone 
therapy (n = 15).  Participants were assessed at three time points: after surgery and before 
chemotherapy, within one week of completing chemotherapy or similar time in 
individuals not receiving chemotherapy, and one year after completing chemotherapy or a 
similar time in individuals not receiving chemotherapy. Researchers did not observe any 
difference on cognitive measures at baseline between the groups nor did they observe any 
significant decline in performance in women receiving chemotherapy only (Rey Auditory 
Verbal Learning Test, Four Word Short Memory Test, Rey Complex Figure Test).   In 
the second study by Hess and colleagues (2007) cognitive function was assessed in 20 
women with ovarian cancer before chemotherapy and after their 2nd and 5th cycles of 
chemotherapy.  Researchers observed a non-significant trend toward improved 
performance on measures of attention and working memory over the course of 
chemotherapy (Trail Making A & B, Digit Span Forward).  Interestingly, highly educated 
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participants in this study reported a decline in attention and memory function after two 
cycles of chemotherapy and a return to baseline after five cycles of chemotherapy. 
Together the above studies provide evidence that some individuals with cancer 
experience a decline in attention and memory function over the course of chemotherapy 
while other individuals may experience improved or no change in attention and memory 
function.  Given the observation that individuals with cancer may also experience deficits 
in their attention and memory before chemotherapy, these studies may also suggest that 
individuals with deficits in attention or memory before chemotherapy can:  1) improve 
and possibly return to baseline function over the course of chemotherapy, 2) not improve 
nor decline but remain with deficits over the course of chemotherapy, and 3) decline and 
experience further losses in attention and memory over the course of the chemotherapy.  
Further research is needed to examine attention and memory function in individuals with 
cancer receiving chemotherapy and an individual’s pattern of cognitive functioning from 
pre-treatment to completion of the therapy. 
From an immune perspective, cognitive recovery and stability may be associated with 
reduced tumor burden (effects of chemotherapy on primary tumor or micrometastatic 
disease).  Declines in cognitive function may be associated with a continued 
inflammatory immune response to the cancer (progression, metastatic disease) and/or 
tissue injury associated with the chemotherapy as well as other unidentified factors.   
Radiation Therapy.  Two studies were found that examined the effects of non-CNS 
radiation therapy on cognitive function.    Similar to the review above, studies were 
excluded if they included a population of individuals receiving a mix of therapies (e.g. 
radiation therapy plus hormone therapy).  One of the two studies was excluded from this 
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review because of concern that findings may be related to incidental cerebral irradiation 
(nasopharyngeal carcinoma) (Lam, Leung, & Chan, 2003).  The remaining study by 
Kaasa and colleagues (1988) assessed cognitive function in 34 individuals with 
inoperable non-small cell lung cancer receiving radiation therapy to the site of the 
primary tumor.  Participants were tested before radiation therapy and 11 weeks after 
treatment was ended.  See Table 1.3.  Researchers did not compare pretreatment 
performance on cognitive measures to normative data or a control group.  Researchers 
found a decline in attention and memory function in a subgroup of participants (lower 
scores from baseline) (24 on Trail Making Test A, 31 on Trail Making Test B, 41 on the 
Verbal Learning Test – 10 trials, 41 on the Verbal Learning Test - 5 trials, 38 on the 
Benton Visual Retention Test- correct answers, and 21 on the Benton Visual Retention 
Test- incorrect answers). Findings from this study provide preliminary evidence that 
some individuals newly diagnosed with cancer receiving local radiation therapy for non- 
CNS tumors can experience changes in cognitive function over the course of radiation 
therapy.  
From an immune perspective, declines in cognitive function may be associated with 
the cancer, tissue injury associated with the radiation therapy, and/or other unidentified 
factors.  Further research is needed to assess cognitive and immune function individuals 
receiving local radiation therapy for non-CNS tumors. 
Immunotherapy.  Three studies were found that examined cognitive function in 
individuals receiving immunotherapy for cancer using a pre/post or longitudinal study 
design (Bender et al., 2000; Capuron et al., 2002; Capuron, Ravaud, & Dantzer, 2001).  
See Table 1.4.  Excluded from this review were studies that included individuals 
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receiving a mix of other therapies (i.e. immunotherapy plus chemotherapy or radiation 
therapy).  Two of the three studies included in this review assessed individuals after 
surgery and before any other therapy.  Specifically, Bender and colleagues (2000) 
assessed cognitive function in 18 individuals with melanoma receiving postoperative 
adjuvant interferon-alpha 2b (high dose, low dose) and a control group of individuals 
with melanoma not receiving adjuvant therapy.  The authors observed a non-significant 
decline in attention and working memory function in individuals receiving high dose 
interferon-alpha 2b (TMT B).  In a second study by Capuron and colleagues (2002), 
researchers assessed cognitive function of 20 men and women with melanoma receiving 
postoperative adjuvant interferon-alpha therapy with or without paroxetine for interferon-
associated symptoms.  Researchers found a significant increase in cognitive symptoms in 
individuals receiving interferon alone 12 weeks after initiating therapy (Neurotoxicity 
Scale:  memory disturbances & poor concentration).  Further, the percentage of 
individuals experiencing moderate to severe intensity of cognitive symptoms during 
interferon therapy alone were as follows:  30 loss of concentration, 15 memory 
disturbances, 15 word-finding problems, 10 episodes of confusion and 10 indecisiveness.  
Finally, the third study by Capuron and colleagues (2001) assessed cognitive function in 
47 individuals with renal cell cancer and melanoma receiving interleukin 2 and/or 
interferon alpha. Researchers found that individuals receiving IL-2 monotherapy 
experienced an acute decline in performance on the measures of attention and memory 
five days after initiating therapy that appeared to persist at one month (Spatial Working 
Memory test, Stockings of Cambridge test).  Individuals receiving high dose interferon-
alpha therapy showed an acute decline in performance on a measure of attention 
 14 
(multiple choice task) five days after initiating therapy that tended to persist at one month 
as well.  Together, these studies provide preliminary evidence that individuals with 
cancer receiving immunotherapy can experience changes in attention and memory early 
in the course of therapy that can persist while receiving treatment. 
From an immune perspective, declines in cognitive function may be associated with 
the immunotherapy and/ or stimulation of the immune response. Further research is 
needed to assess the long-term effects of immunotherapy on cognitive function in cancer 
survivors and whether attention and memory function improves after cessation of 
therapy. 
Summary 
The above studies provide evidence that individuals with cancer can experience 
changes in attention, working memory, and long-term memory at diagnosis and before 
any treatment for the disease and during/after treatment for the disease.  Alterations in 
immune function may underlie these changes.  Specifically, a robust production of 
inflammatory cytokines related to the cancer pathogenesis or cancer treatments may 
induce cognitive changes. Continued research is needed to assess cognitive function in 
cancer survivors with a variety of tumors over the trajectory of the illness.  Further, 
research is needed to describe the subgroup of cancer survivors who experience cognitive 
changes and whether immune responses to the cancer and cancer treatments contribute to 
these cognitive changes. 
Patient Characteristics Associated with Cognitive Impairment 
To date, most studies assessing cognitive function in individuals with cancer have 
controlled for patient characteristics in the statistical analysis (covariates) but few studies 
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have assessed the potential effect of patient characteristics on cognitive function in 
individuals with cancer (possible risk factors).  Eight studies were found that assessed the 
impact of patient characteristics on cognitive functioning in cancer survivors (Ahles et 
al., 2010; Ahles et al., 2003; Cimprich, 1998; Cimprich, So, Ronis, & Trask, 2005; 
Merriman et al., 2010; Schilder et al., 2010; Small et al., 2011; Vearncombe et al., 2009).  
These studies assessed patient characteristics across the disease trajectory from after 
diagnosis and before any treatment to up to five years after diagnosis. See Table 1.5.  
Characteristics associated with an increase in vulnerability to cognitive impairment in 
individuals with cancer include: older age, genotype (APOE ε4 allele, COMT Val allele), 
presence of other health problems, changes in hormones, and psychological distress.  
These characteristics will be discussed further below.  
 Age.  Older age has been associated with poorer performance on measures of 
attention and working memory and is a significant predictor of attention and memory 
function in individuals newly diagnosed with breast cancer prior to treatment (Cimprich 
et al., 2005). Older age has also been associated with cognitive decline in women with 
breast cancer undergoing surgery and adjuvant chemotherapy (with or without radiation 
therapy, endocrine therapy) (Ahles et al., 2010; Cimprich, 1998). Cognitive changes in 
older adults may be related to both an aging brain and immune system.  An aging brain 
has been associated with neurobiological decline and more recently functional changes.  
Recent research from neuroimaging studies suggests that an older brain may be 
functionally different or reorganized compared to a younger brain (Reuter-Lorenz & 
Lustig, 2005).  Specifically, older adults appear to show more widespread brain 
activation (recruit more neural circuitry) than younger adults performing similar tasks.  
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This difference in activation may allow an older individual to compensate for efficiency 
or functional declines elsewhere in the brain and effectively perform a task (Reuter-
Lorenz & Cappell, 2008).  However, these functional changes may not always be 
sufficient to overcome deficits on high demand tasks or conditions requiring sustained 
use of neural circuitry. 
 An aging immune system may also contribute to cognitive changes.  Specifically, 
an aging immune system is associated with low-level inflammation characterized by 
circulating cytokines (TNF-alpha, IL-6) and an increase in white cells (neutrophils, 
monocytes and natural killer cells) (Bruunsgaard, 2006).   Cancer and cancer treatments 
can further stimulate the immune system resulting in an increased systemic cytokine 
response and alterations in attention and memory.  Older age has also been associated 
with more reactive immune cells in the CNS (microglia).  These immune cells appear to 
produce an exaggerated CNS inflammatory cytokine response to a peripheral immune 
challenge.  An amplified inflammatory cytokine response in the brain can negatively 
affect neural plasticity and the neural substrate that supports attention and memory 
function (Corona, Fenn, & Godbout, 2012).   
 Interestingly, younger age has been associated with perceptions of poorer 
functioning on tasks that require attention and working memory in women newly 
diagnosed with breast cancer as well as women with breast cancer receiving adjuvant 
radiation therapy (Cimprich et al., 2005; Merriman et al., 2010). These findings suggest 
that younger women with breast cancer may also experience subtle changes in their 
attention and memory function (possibly related to inflammation and/or psychological 
distress) that are not detectable on standard tests of neuropsychological function.  
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Genotype.  The APOE ε4 allele and the COMT-VAL allele have been associated 
with lower performance on measures of attention and memory in individuals with breast 
cancer (Ahles et al., 2003; Small et al., 2011).  Other genetic factors that may affect 
cognitive function in individuals with cancer include polymorphisms in genes affecting 
the expression of inflammatory cytokines.  Specifically, TNF-α-308 promoter single 
nucleotide polymorphism (SNP) has been associated with cognitive complaints in women 
treated with chemotherapy for breast cancer (Ganz et al., 2013).  Further, IL-1β and IL-6 
polymorphisms have been associated with cancer-related symptoms (fatigue, pain, sleep 
disturbances) but not yet explored in relation to cognitive impairment (Miaskowski & 
Aouizerat, 2012).  Continued research is needed to assess the effect of immune-related 
genetic factors on cognitive function in cancer survivors. 
Other Health Problems and Behaviors.  Presence and number of health 
problems has been associated with poorer performance on measures of attention and 
memory function as well as perception of attention and memory function in women with 
breast cancer prior to any treatment and after surgery before adjuvant therapy (Cimprich 
et al., 2005; Schilder et al., 2010; Vearncombe et al., 2009).  Further, a decline in 
hemoglobin coupled with increased anxiety over the course of chemotherapy in women 
with breast cancer was found to significantly predict impairment in attention and memory 
function (Vearncombe et al., 2009).  Inflammation and systemic cytokine expression can 
underlie some health problems and behaviors.  Specifically, systemic inflammatory 
cytokine expression has been observed in individuals with infection, cardiovascular 
disease, diabetes, obesity, rheumatoid arthritis and other immune-mediated inflammatory 
diseases, smoking, alcohol consumption, and sleep disturbances (Calle & Fernandez, 
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2012; Giamarellos-Bourboulis & Raftogiannis, 2012; O'Connor & Irwin, 2010; Tedgui & 
Mallat, 2006; Williams & Meyers, 2002; Wisse, 2004).  Individuals with cancer and 
other health problems or behaviors that induce systemic inflammatory cytokine 
expression may experience increased levels of circulating inflammatory cytokine and be 
more vulnerable to cognitive changes. 
Hormones.  Estrogen/androgen deprivation therapy for breast and prostate cancer 
has been associated with subtle but significant declines in cognitive function (Jamadar, 
Winters, & Maki, 2012; Walker, Drew, Antoon, Kalueff, & Beckman, 2012).  
Chemotherapy may also induce menopause in breast cancer survivors and individuals 
who experience treatment-induced menopause appear to be more vulnerable to cognitive 
decline than women who were post-menopausal at time of treatment initiation (Jenkins et 
al., 2006).  To date, only one study was found that assessed the impact of hormones as a 
risk factor for cognitive changes in individuals with cancer.  The study by Schilder and 
colleagues (Schilder et al., 2010) assessed the effect of lifetime estrogen exposure 
(number of reproductive years) and use of hormone replacement therapy (ever) on 
cognitive function in post-menopausal women with and without breast cancer.  Breast 
cancer survivors were assessed after surgery and before adjuvant systemic therapy.  
Researchers found that a higher number of reproductive years in women with breast 
cancer predicted worse performance on attention and working memory measures.  There 
were no significant findings associated with hormone replacement therapy and the study 
did not describe time since last menses. Estrogen and testosterone deficiency has been 
associated with subtle increases in pro-inflammatory cytokines (Maggio et al., 2005; 
Pfeilschifter, Koditz, Pfohl, & Schatz, 2002).  These increases may be limited to the first 
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few years following age-related hormone changes when symptoms and other related 
conditions (bone loss) are most prominent.  Individuals with cancer who have recently 
experienced a decline in estrogen or testosterone (natural or treatment-induced) may 
experience increased systemic inflammatory cytokine expression.  Cancer and cancer 
treatments may further increase systemic cytokine expression leading to alterations in 
attention and memory.   
Psychological Distress.  At this time, psychological distress remains a poorly 
understood risk factor for impaired cognitive function in cancer survivors. However, 
anxiety and depressed mood have been correlated with poor performance on 
neuropsychological tests (word list learning, digit symbol, TMT) and perceived attention 
and memory function in individuals with cancer before any treatment and during/after 
therapy (Bender et al., 2006; Bond et al., 2012; Cimprich, 1999; Hermelink et al., 2007; 
Skaali, Fossa, et al., 2011b; Wefel, Vidrine, et al., 2011). Additionally, a study by 
Musselman and colleagues found that individuals with cancer who were depressed had 
higher levels of plasma IL-6 compared to individuals with cancer without depression and 
healthy controls (Musselman et al., 2001).  This finding suggests that individuals with 
cancer experiencing psychological stress (a precipitant of mood disorders) can experience 
greater systemic inflammatory cytokine expression compared to individuals not 
experiencing psychological stress and thus may be more vulnerable to cognitive changes 
(Kendler, Karkowski, & Prescott, 1999).   Immunologic models of psychological stress 
propose that persistent activation of the HPA axis and sympathetic nervous system can 
lead to a decreased ability to restrain the pro-inflammatory response and/or hyperactivity 
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resulting in the systemic expression of pro-inflammatory cytokines which can affect 
cognitive function (Elenkov, 2008). 
Summary.  The above studies provide preliminary evidence that patient 
characteristics including age, genotype, presence of other health problems, changes in 
hormones, and psychological stress can increase vulnerability to cognitive impairment in 
individuals with cancer.   Alterations in immune function and an over expression of pro-
inflammatory cytokines may be associated with these characteristics. Further research is 
needed to 1) assess the potential effect of patient characteristics on cognitive function in 
individuals with cancer (risk factors) and 2) examine whether an increased expression of 
inflammatory cytokines may underlie certain patient characteristics associated with 
cognitive decline. 
The Immune Response:  Inflammation and the Acute Phase Reaction 
The immune system protects an individual from harmful stimuli and conditions 
and has a critical role in eradicating malignant cells as well as reducing immunogenicity 
of tumors (Chow, Moller, & Smyth, 2012).  The immune system responds to noxious 
stimuli (i.e. infection, malignant cells) through inflammation.  The goal of the 
inflammatory response is to destroy and/or remove the inciting stimulus, limit injury to 
the individual, and initiate the repair of injured tissues (Kumar et al., 2005).  The 
inflammatory response is characterized by both local and systemic responses. The 
systemic response, also known as the acute phase reaction (APR), occurs when there is 
significant injury or threat to the individual and provides an additional level of defense 
against noxious stimuli.  It consists of metabolic changes (negative nitrogen balance, 
decreased gluconeogenesis, increased lipolysis), physiologic changes (fever, altered 
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concentration of plasma constituents; hematopoietic changes, hepatic changes), and 
behavioral changes (anorexia, fatigue, somnolence) (Gabay & Kushner, 1999). These 
systemic effects provide additional support by enhancing leukocyte emigration and 
function, sustaining the immune response, limiting local tissue injury, creating a hostile 
environment for microbes, and reducing energy demands (Gabay & Kushner, 1999; Hart, 
1988). The APR is mediated by inflammatory cytokines originating from immune cells, 
hematopoietic cells (platelets), stromal cells, and tumor cells in the tumor 
microenvironment or at sites of tissue injury. Inflammatory cytokines associated with the 
APR include:  interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-
α), interleukin-10 (IL-10), and Transforming Growth Factor-β1 (TGF-β1).  These 
cytokines can act on one or more target cells locally or at distant sites in the body to 
induce effects. 
The Acute Phase Reaction in Individuals with Cancer 
Individuals with cancer appear to experience an acute phase reaction (APR) to the 
cancer and cancer treatments. Specifically, research studies have observed cytokine-
induced metabolic changes (increased energy expenditure, muscle wasting, and lipolysis), 
physiologic changes (fever, increased acute phase proteins, hypoalbuminemia, anemia, 
leukocytosis and thrombocytosis) and behavioral changes (anorexia, fatigue, changes in 
sleep, depressed mood) in individuals with cancer (Argiles, Busquets, Felipe, & Lopez-
Soriano, 2005; Bower, 2008; Buergy, Wenz, Groden, & Brockmann, 2012; Dalal & 
Zhukovsky, 2006; Spivak, 2005; Wilcox, 2010).  Additionally, an over expression of 
APR-associated inflammatory cytokines has been observed in individuals with cancer 
both after diagnosis and before any treatment and in response to cancer therapies.  
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Research studies examining cytokine expression in the systemic circulation of individuals 
with cancer before any treatment have found interleukin-1β (IL-1β), interleukin-6 (IL-6), 
and tumor necrosis factor-α (TNF-α) to be consistently elevated in a variety of tumors 
including: breast, prostate, colorectal, gastric, melanoma, leukemia, lymphoma, ovarian, 
cervical, testicular, kidney, and sarcoma (Chopra, Dinh, & Hannigan, 1998; Dosquet et 
al., 1994; Duffy et al., 2008; Dymicka-Piekarska, Matowicka-Karna, Gryko, Kemona-
Chetnik, & Kemona, 2007; Esfandi, Mohammadzadeh Ghobadloo, & Basati, 2006; 
Gaiolla, Domingues, Niero-Melo, & de Oliveira, 2011; Ikeguchi et al., 2009; Jablonska et 
al., 2001; Kabir & Daar, 1995; Kaminska et al., 2005; Lambeck et al., 2007; Maccio et 
al., 2005; Meyers et al., 2005; Nikiteas et al., 2005; Porter et al., 2001; Rutkowski, 
Kaminska, Kowalska, Ruka, & Steffen, 2003; Shariat et al., 2001; Yeon et al., 2011).  
See Table 1.6.  Interestingly, elevated IL-6 levels also appear to be related to tumor stage 
and prognosis with higher levels being associated with advanced disease and poor 
prognosis.  Research studies have also observed an increase in APR-associated cytokines 
secondary to cancer treatments including surgery, chemotherapy, and radiation (Baker, 
El-Gaddal, Williams, & Leaper, 2006; Bower et al., 2009; Mettler et al., 2004; Nakazaki, 
1992; Sleijfer, Vujaskovic, Limburg, Schraffordt Koops, & Mulder, 1998; Tang et al., 
1996; Tsavaris, Kosmas, Vadiaka, Kanelopoulos, & Boulamatsis, 2002).  Together these 
studies suggest that individuals with cancer experience a systemic inflammatory response 
to the cancer and cancer treatments. 
The Acute Phase Reaction: Communication Pathways to the Brain 
Peripheral inflammatory cytokines can communicate with the brain through 
several pathways including: 1) active transport across the blood brain barrier, 2) 
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activation of blood brain barrier cells to induce the synthesis and release of secondary 
immune messengers (e.g. prostaglandins), 3) activation of immune cells in the 
circumventricular organs to induce the synthesis and release of cytokines, 4) activation of 
peripheral afferent nerves to transmit an immune message to the brain, and 5) infiltration 
of activated peripheral immune cells into the brain (D'Mello, Le, & Swain, 2009; 
Dantzer, Konsman, Bluthe, & Kelley, 2000; Konsman, Kelley, & Dantzer, 1999; Quan & 
Banks, 2007; Quan, Whiteside, & Herkenham, 1998). These pathways are not mutually 
exclusive but rather appear to complement each other.  It has been proposed that the rapid 
immune to brain cytokine signaling via peripheral afferent nerves may prime the brain for 
additional immune messages via other pathways (Dantzer et al., 2000; Konsman et al., 
1999).  Transmission of the immune message to the brain results in locally produced 
cytokines within the brain (Dantzer et al., 2000).  These cytokines can activate local 
neurons as well as recruit immune cells (microglial cells, perivascular macrophages) in 
adjacent brain regions to propagate the immune message to distant regions of the brain 
(Dantzer et al., 2000; Konsman et al., 1999; Vitkovic et al., 2000). Production of 
inflammatory cytokines in the brain is generally transient, however, if there is no 
resolution of the peripheral immune challenge, prolonged inflammatory cytokine 
expression and activated glial cells can contribute to a persistent altered brain 
environment (Godbout & Johnson, 2006). 
The Acute Phase Reaction:  Neural Function  
The relationship between pro-inflammatory cytokine expression and neural 
function has been primarily assessed in preclinical studies.  These studies suggest that an 
overexpression of cytokines is associated with impaired function (Ader, 2007; McAfoose 
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& Baune, 2009).  Potential pathways by which increased levels of pro-inflammatory 
cytokines alter neural processes and the substrate that supports attention and memory 
include: 1) inhibiting long-term potentiation or the strengthening of synaptic contacts 
between neurons, 2) activating the HPA axis and altering the production of 
corticosteroids necessary for memory processes (inverted U-shaped relationship), 3) 
altering the concentration, metabolism, and/or reuptake of neurotransmitters in the 
prefrontal cortex, hippocampus, and hypothalamus (dopamine, norepinephrine, 
acetylcholine, serotonin and glutamate), and 5) impairing neurogenesis (Ader, 2007; 
Dunn, 1992; Godbout & Johnson, 2006; Hayley, Brebner, Lacosta, Merali, & Anisman, 
1999; Ida et al., 2008; Kabiersch, del Rey, Honegger, & Besedovsky, 1988; Lacosta, 
Merali, & Anisman, 1998; Linthorst, Flachskamm, Muller-Preuss, Holsboer, & Reul, 
1995; McAfoose & Baune, 2009; Rada et al., 1991; Zalcman et al., 1994).  In humans, 
preliminary research in neurodegenerative conditions characterized by activated 
microglia and inflammatory cytokine expression in the brain (Alzheimer’s and 
Parkinson’s Disease) suggests that persistent inflammatory cytokine expression can 
impair neurogenesis and neuronal maturation (Hoglinger et al., 2004; Johnston, Boutin, 
& Allan, 2011; Li et al., 2008; Panaro & Cianciulli, 2012; Ziabreva et al., 2007). Further 
research is needed to build on these findings and examine how persistently increased pro-
inflammatory cytokine expression in the brain can affect neural functions in humans.   
Summary 
          Individuals with cancer can experience increased systemic inflammatory cytokine 
expression secondary to the immune system’s response to the cancer and cancer 
treatments. Pro -inflammatory cytokines originating in the periphery can communicate 
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with the brain resulting in increased brain cytokines.  Inflammatory cytokines within the 
brain can alter neural processes that support attention and memory function including 
neural plasticity, neuroendocrine function, neurotransmitter function and neurogenesis. If 
there is no resolution of a peripheral immune challenge (i.e. cancer) prolonged 
inflammatory cytokine expression within the brain has the potential to alter the brain 
environment.  Continued research is needed to 1) describe the acute phase response in 
individuals with cancer, and 2) describe the communication pathways and effects of 
inflammatory cytokines on neural processes in humans.  
The Acute Phase Reaction:  Cognitive Function 
Inflammatory cytokines have been associated with changes in cognitive 
functioning.  Evidence for cytokine-induced changes in cognitive function comes from 
preclinical and clinical studies.  Research studies using animal models have exclusively 
focused on alterations in learning and memory. Findings from these studies suggest that 
increased levels of inflammatory cytokines can impair hippocampal dependent memory 
processes.  Importantly, findings from these studies also suggest that older age may be 
associated with an exaggerated neuroinflammatory response and increased vulnerability 
to cytokine-induced cognitive changes.  For a review, see Huang & Sheng (2010). In 
humans, studies have assessed the cognitive behavior of individuals with minor illnesses 
and individuals with experimentally induced inflammation (Brydon, Harrison, Walker, 
Steptoe, & Critchley, 2008; Capuron, Lamarque, Dantzer, & Goodall, 1999; Exton et al., 
2002; Krabbe et al., 2005; Reichenberg et al., 2001; Smith et al., 1988; Smith, 1992;  
Smith, Tyrrell, Coyle, & Willman, 1987; Spath-Schwalbe et al., 1998; Vollmer-Conna et 
al., 2004).  Additionally, one study was found that assessed the relationship between 
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cytokine expression and cognitive function in individuals newly diagnosed with leukemia 
and myelodysplastic syndrome (Meyers et al., 2005).  These studies will be reviewed 
below. 
Individuals with Minor Illnesses.  Studies of cognitive behavior have been done 
in both healthy individuals injected with influenza and sick individuals with acute 
bacterial and viral infections(Capuron et al., 1999; Smith, 1992; Smith et al., 1987; 
Vollmer-Conna et al., 2004).  See Table 1.7.  Individuals with experimentally induced 
minor illnesses (influenza A & B) reported feeling drowsy and were impaired on 
objective measures of attention two to four days after injection with the virus.  
Alterations in attention included:  a decreased ability to detect and respond to stimuli and 
an impaired ability to block irrelevant stimuli during an attention-demanding task 
(Stroop, Variable Fore-Period Simple Reaction Time task, Fives Detection Task) (Smith, 
1992; Smith, et al., 1987).  Attention and memory have also been found to be impaired in 
individuals with flu-like symptoms (Capuron et al., 1999).  In a study by Capuron and 
colleagues(Capuron et al., 1999), individuals presenting with flu-like symptoms to a 
health clinic were assessed for cognitive changes and found to be impaired on three 
subtests of the Extended Rivermead Behavioral Memory Test (ERBMT) .  Specifically, 
sick individuals were impaired on their ability to remember previously presented pictures 
and on their ability to recall a short newspaper article that they had just read (immediate 
and delayed recall).  These cognitive tasks were significantly impaired in individuals with 
and without a fever suggesting that fever is not a necessary condition for cognitive 
impairment in sick individuals. Finally, the specific relationship between cytokines and 
cognitive function in individuals with minor illnesses has been relatively unexplored.   
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Only one research study was found that examined the relationship between cytokines and 
subjective reports of cognitive symptoms in individuals with acute bacterial and viral 
illnesses.  This study found a strong positive correlation between IL-6 and poor 
concentration (Vollmer-Conna et al., 2004).  
Interestingly, not all individuals with minor illnesses appear to experience 
cognitive changes.  Specifically, Smith (1992) and Smith and colleagues (1987) assessed 
the cognitive function of healthy individuals injected with a cold virus (corona virus, 
rhinovirus) and observed that individuals with a cold did not perform significantly worse 
on measures of attention compared to individuals without (Stroop).  These findings, along 
with the observation of attention and memory deficits in individuals with other minor 
illnesses, suggest that an individual’s cognitive response to an immune challenge may 
depend on the nature and/or severity of the illness.   
Individuals with Inflammation.  Attention and memory of individuals with 
inflammation has been examined in healthy individuals injected with inflammatory 
cytokines or endotoxins (Brydon et al., 2008; Exton et al., 2002; Krabbe et al., 2005; 
Reichenberg et al., 2001; Smith et al., 1988; Spath-Schwalbe et al., 1998).  See Table 1.7.   
Findings from these studies have been mixed with some studies finding a significant 
deterioration in attention, working memory and long-term memory function and other 
studies finding no change.  Four studies were found that suggest a role for inflammatory 
cytokines in changes in attention and memory experienced by acutely ill individuals.  
First, Brydon and colleagues (2008) assessed the effects of peripheral inflammation 
following typhoid vaccination on cognitive function using a double blind crossover 
design.  Researchers found that individuals who experienced a greater inflammatory 
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response (higher IL-6 levels) to the vaccination had significantly impaired performance 
on a measure of attention (Stroop). Second, Reichenberg and colleagues (Reichenberg et 
al., 2001) found that healthy young men injected with low dose salmonella abortus in a 
double blind crossover design experienced an impaired ability to recall story items 
(immediate & delayed), recall figures (immediate & delayed) and learn a 15 word list. 
These memory disturbances were significantly and positively correlated with cytokine 
expression in the first few hours after endotoxin administration.  Interestingly, 
Reichenberg and colleagues (Reichenberg et al., 2001) also found that memory 
disturbances were evident 10 hours after endotoxin administration when all other 
behavioral responses to the endotoxin had subsided (fever, anorexia, depressed mood, 
anxiety).  A third study by Smith, Tyrrell, Coyle, & Higgins (1988) examined the effects 
of varying doses of the cytokine interferon-alpha (IFN-α) on performance of a measure 
of attention (variable fore-period simple reaction-time task) and a measure of simple 
reasoning (Baddeley’s syntactic reasoning tasks).  Researchers found that healthy men 
and women given a higher dose of IFN-α (1.5 MU) were slower to detect and respond to 
stimuli but were not impaired on reasoning performance.  These findings suggest that 
IFN-  may selectively alter attentional processes.  Additionally, these findings suggest 
that the dose of cytokine can affect the expression of cognitive deficits.  The fourth study 
by Spath-Schwalbe and colleagues (1998) assessed the effects of IL-6 on subjective 
feelings of concentration and found that subjects reported greater difficulties with 
concentration three hours after IL-6 administration compared to controls but that these 




In contrast to the above, two studies were found that did not find a significant 
change in cognitive function after administration of cytokines and cytokine inducers to 
healthy individuals.  Krabbe and colleagues (2005) examined the effects of low dose 
Escherichia coli endotoxin on attention and working memory in healthy young men in a 
double blind crossover design.  They found that low dose endotoxemia did not result in 
any significant changes in attention and memory function within the first 24 hours after 
endotoxin administration (Word List, Letter-Number Sequencing, Digit Span, Digit 
Symbol Coding Test, & Trail Making Test). However, they did report that poorer 
performance on the word-list learning test was related to higher levels of IL-6 and soluble 
tumor necrosis factor receptor.  The second study by Exton and colleagues (2002) used a 
cross over design to examine the effects of a single dose of the cytokine interferon-beta-
1b (IFN- -1b) on attention and short-term memory in healthy male medical students and 
found that subcutaneous administration of IFN- -1b at a dose which induced responses 
such as fever (8 MU) was not associated with changes in cognitive performance on 
objective measures of attention and memory (Trail Making Test, Digit Span, & d2).  
Unfortunately, the results of this study were limited by the finding that the scores on 
objective measures were high at all time points suggesting that the measures may have 
lacked sensitivity to subtle changes over the testing period (ceiling effect).  These two 
studies were limited by a small sample size, a sample consisting of young men only, and 
an experimental design that examined the acute effects of a single dose of endotoxin or 
cytokine.  
Individuals with Cancer.  Only one study was found that assessed the 






cancer.  The study by Meyers and colleagues (2005) assessed attention and memory 
function and measured serum levels of pro-inflammatory cytokines in individuals newly 
diagnosed with acute myelogenous leukemia or myelodysplastic syndrome.  Researchers 
found that higher levels of IL-6 were associated with worse performance on measures of 
attention and working memory (Trail Making Test B).  This finding suggests that 
cognitive changes in cancer survivors may be related to cytokine expression and systemic 
immune system activation. 
Summary.  The above studies provide evidence that immune activation and 
systemic inflammatory cytokine expression can affect attention, working memory, and 
long-term memory. The observation that experimentally induced cold viruses as well as 
experimentally induced low levels of inflammation (low dose cytokine administration) 
did not affect cognitive performance suggest that the nature of immune challenge as well 
as severity of the immune response or amount of systemic cytokines are important factors 
in the expression of cognitive deficits and symptoms.   Unfortunately, only one study was 
found that observed the effects of peripheral immune activation and cytokine expression 
on cognitive function in individuals with cancer.  Continued research is needed to 
describe: 1) the relationship between types of immune challenges and inflammatory 
cytokine expression and cognitive deficits, 2) the quantitative relationship between 
circulating inflammatory cytokine and cognitive deficits, and 3) the relationship between 






Toward A Biobehavioral Model of Cognitive Symptoms in Individuals in Cancer 
This review has described research at the interface of immunology, oncology, and 
cognitive neuropsychology and neuroscience and directed the conceptualization of a 
novel biobehavioral model in which to study cognitive changes in individuals with 
cancer.  See Figure 1.  This biobehavioral model suggests that individuals with cancer 
can experience an increase in inflammatory cytokine expression secondary to the cancer, 
tissue injury associated with cancer treatments, immunotherapy, infection, and from other 
health problems. Inflammatory cytokines originating from local sites in the body can 
communicate with the brain and alter neural and cognitive function.  Specifically, 
peripheral inflammation and inflammatory cytokine expression has been associated with 
changes in attention, working memory and long-term memory.  Cognitive symptoms and 
impaired attention and memory function in individuals with cancer have been observed 
alongside other cytokine induced physical symptoms and behavioral responses known as 
Sickness Behavior suggesting that alterations in cognitive function may be a part of a 
cluster of immune mediated physical symptoms and behavioral responses (Bower, 2008; 
Cleeland et al., 2003; Hart, 1988; Meyers et al., 2005).  Sickness behavior refers to 
fatigue, anorexia, decreased general and social activity, hyperalgesia, and changes in 
sleep pattern and architecture (Dantzer, 2004; Watkins & Maier, 200; Hart, 1988). 
Cognitive function modifiers that have been associated with poorer performance on 
measures of attention and memory function in individuals with cancer include:  older age, 
fewer years of education, anemia, symptom distress, anxiety, depression and menopause 
(Cimprich, 1999, Cimprich et al., 2005; Vearncombe et al., 2009).  Immune function 
 32 
modifiers that have been associated with alterations in inflammatory cytokine expression 
include:  older age, advanced stage of disease, anxiety, depression, smoking history, and 
an increase in body mass index (BMI) (Belluco et al., 2000; Bruunsgaard & Pedersen, 
2003; Chung & Chang, 2003; Cottam et al., 2004; Cull et al., 1996; Krabbe, Pedersen & 
Bruunsgaard, 2004; Lutgendorf et al., 2008; Musselman et al., 2001; Thorton, Andersen 
Crespin, & Carson, 2007). 
Definitions of Attention, Working Memory, and Long-term Memory  
Directed Attention and Working Memory.  Attention, specifically directed or 
controlled attention, allows an individual to focus attention on important information in 
the environment while actively inhibiting other stimuli in the environment (James, 1892; 
Kaplan & Berman, 2010).  Directed attention is necessary for goal-oriented behaviors and 
social functioning, and allows an individual to interact in the world in a purposeful way 
(Kaplan & Berman, 2010).  Working memory shares a close functional connection with 
directed attention.  It is a cognitive process that allows a limited amount of information to 
be maintained and manipulated so that higher cognitive functions can be achieved 
(Mesulam, 2000).  Working memory is critical for learning, comprehension, verbal 
fluency, retrieving memories, reasoning, and problem solving (Mesulam, 2000). The 
neural substrate that supports directed attention and working memory and is responsible 
for exerting control over stored contents includes the dorsolateral prefrontal cortex and 
the anterior cingulate cortex (Bush, Luu, & Posner, 2000; Posner, Rothbart, & Sheese, 
2007; Smith && Jonides, 1999).  
Long-term Memory.  Long-term Memory, specifically declarative memory, is a 
cognitive process that supports a longer retention of information than working memory, 
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  Alterations in Attention and Memory Before Cancer Treatment 
Reference Time  Sample  
  No.  Patient/  
Controls 




After Diagnosis 70 HNC 
 
M & F M = 55 y Attention & WM:  scores significantly lower than expected norms (TMT A 
& B, SDMT). 




(M = 12 days)  
74 BC 
 
F M = 56 y Attention & WM:  scores within published norms but skewed to lower range 




(M = 11 days)  












M = 64 y  
M = 61 y  
Attention & WM:  scores within published norms for BC & HC groups. 
Women with BC performed significantly worse than women without breast 





(M not reported) 
109 BC 
 
F M = 49 y Attention & WM:  scores significantly worse than published norms (D2 test, 
TMT B, & RWT).  One measure significantly better than published norms 
(Digit Symbol).  Individually, 56 had mild cognitive impairment (> 1 test 
result < 1SD), 32 had moderate cognitive impairment (> 1 test result < 2 SD) 





(M not reported) 
21 SCLC M & F M = 55 y 
 
Attention, WM, & LTM: a significant percentage of participants scored > 
1.5 SD below published norms (33 on TMT A, 38 on TMT B, 38 on VSRT-






(M not reported) 
54 AML, MDS  M & F M = 60 y Attention, WM, & LTM:  a significant percentage of participants scored > 
1.5 SD below the normative mean (28 on TMT A, 29 on TMT B, 44 on 
HVLT total recall, 41 on HVLT delayed recall). 
Note. AFI = Attentional Function Index; AML = Acute Myelogenous Leukemia; BC = Breast Cancer; BVRT = Benton Visual Retention Test; F = Female; HC 
= Healthy Controls; HCN = head and neck cancer; HVLT = Hopkins Verbal Learning Test; LTM = Long-term Memory; M =Male; M = mean; MDS = 
Myelodysplastic Syndrome; NCPC = the Necker Cube Pattern Control test; RWT = Regensburg Word Fluency Test; SCLC = small cell lung cancer; SDMT = 





 Table 1.2 
  Alterations in Attention and Memory Associated with Cancer Treatment:  Surgery 
Reference Study Design Sample 
 
 
  No. of 
Subjects 
Patient Group +/- 
Controls 





T1: Before Surgery  







F M = 37 y 
M = 57 y 
M = 71 y 
Before Surgery:  Performance on DS, NCPC, & 
SDMT individuals with BC were within published 
norms but skewed to lower range. 
Change Over Time:  Older women and middle/older 
women undergoing mastectomy experienced a 
significant decline in performance on an attention 





T1: Before Surgery 
T2: After Surgery, 2 weeks 










M = 64 y 
M = 61 y 
Before Surgery:  Performance on DS, NCPC & 
SDMT for individuals in the BC& HC groups were 
within published norms but skewed to lower range. 
BC group scored significantly lower on SDMT, 
NCPC, and an attention and WM Composite Score 
(DS, NCPC, SDMT) 
Change Over Time:  Significantly improved 
performance in BC group from T2 - T3 but not HC 





T1: Before Diagnosis 





F M = 59 y 
M = 51 y 
Before Surgery:  BC group significantly slower on 
CSI domains response time and processing speed 
compared to HC group (measures correlate with 
TMT and SDMT) 
Change Over Time:  BC group did not have any 
changes in performance on cognitive measures 
(CSI).  Healthy controls performed significantly 
better on CSI domains attention and processing 
speed (measures correlate with DS and SDMT). 
Note. BC = breast cancer; F = female; CSI = Cognitive Stability Index; DS = the Digit Span test; F = female; HC = healthy controls; M = mean; NCPC = the 
Necker Cube Pattern Control test; SDMT = Symbol Digit Modalities Test; T = time; TMT A & B = the Trail Making Test Part A & B; WM = Working 





  Table 1.3   
  Alterations in Attention and Memory Associated with Cancer Treatments:  Chemotherapy and Radiation Therapy 
Reference Study Design Sample  
  No.       
Participants 





T1: Before CT  





BC, CT  HT 
BC 
F M = 40 y 
M = 44 y 
M = 45 y 
Before Chemo:  No significant difference between groups on 
any cognitive measure at baseline. 
Change Over Time. Performance on 4WSTM (15s and 30 s) 




T1: Before CT 
T2-3: After CT, 3 & 6 cycles 
20 OC F M = 54 y Before Chemo:  Cognitive test z scores on all measures were 
average to high average suggesting no impairment. 
Change Over Time:  Performance on TMT A & B and DS 
forward improved but was not significant in individuals with 
OC.   No significant change in DS backward in individuals with 
OC.  Highly educated participants with OC reported a decline in 






T1:  Before CT 
T2:  Before Final CT 
 
101 BC F M = 49 y Before Chemo:  Performance on d2 test, TMT B, RWT Lexical 
Search, RWT Semantic Search, and RWT Lexical Search with 
Change in Category was significantly poorer in individuals with 
BC compared to test norms. 
Change Over Time: Performance on Logical Memory I & II, DS 
backward, Digit Symbol, d2 test, and RWT Semantic Search 
significantly improved over time in individuals with BC.  
Performance on RWT Semantic Search with Change in Category 
significantly declined over time in individuals with BC.  In 
individual analyses, a decline in cognitive ability was observed 
in 27 BC participants, improvement in cognitive ability was 
observed in 28 BC participants, and no change in cognitive 
ability in 45 BC participants. Self-report on the FEDA and 
EORTC significantly increased at T2 in BC participants. 
Hess, 2010  
 
Longitudinal 
T1: Before CT 
T2-3: After CT, 2, 5 cycles 
27 OC & PC F M = 59 y Before Chemo:  Performance on cognitive measures not 
compared to normative data or healthy controls. 
Change Over Time:  Performance on one of three cognitive 
domains from a modified battery of the Cognitive Stability index 
declined in 92 of individuals with cancer at Time 2 and 86 of 
individuals with cancer at Time 3 (> 1 SEM).  
(continued) 
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Table 1.3. Alterations in Attention and Memory Associated with Cancer Treatments:  Chemotherapy and Radiation Therapy (continued) 
Reference Study Design Sample  





T1: Before CT  
T2: After CT, 4 cycles  
30 BC  F M = 50 y Before Chemo:  Mean test scores for all cognitive measures 
were within published norms. Four participants did score 1.5 SD 
below published norms on two or more tests or two SDs on one 
test suggesting impairment prior to any treatment. 
Change Over Time: Performance on RBANS visuospatial skills 
subtest and RBANS total score significantly decreased over 
time.  Performance on Stroop significantly improved over time.  
In individual analyses, 10 women with BC had a decrease in one 
or more SDs on two or more cognitive measures after the 
completion of chemotherapy.  In contrast, 5 women with BC had 
an increase in one or more SDs for two or more cognitive 




T1: Before CT 





M, F M = 62 y 
M = 61 y 
Before Chemo:  Performance on cognitive measures not 
compared to normative data or control group.  No significant 
differences on any cognitive measure between individuals with 
NSCLC receiving CT and individual with NSCLC receiving RT. 
Change Over Time: Performance on Verbal Learning 5 test 
declined in individuals receiving CT and did not change in 
individuals with RT (not significant).  Performance on Benton 
error declined in individuals receiving CT and improved in 
individuals receiving RT (not significant).  Performance on Trail 
Making A & B, Verbal Learning and Benton Correct did not 
significantly change over time in individuals receiving CT or 
RT.  Individually, performance on the Benton Visual Retention 
test - error decreased in 14 individuals receiving CT and 6 
individuals receiving RT.  Performance on the Benton Visual 
Retention test - correct decreased in 12 individuals receiving CT 
and 11 individuals receiving RT.  Performance on Trail Making 
A decreased in 8 individuals receiving CT and 7 individuals 
receiving RT.  Performance on Trail Making B decreased in 14 
individuals receiving CT and 9 individuals receiving RT.  
Performance on the Verbal Learning test - 10 word trial 
decreased in 9 individuals receiving CT and 12 individuals  
(continued) 
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Table 1.3.  Alterations in Attention and Memory Associated with Cancer Treatments:  Chemotherapy and Radiation Therapy (continued) 
Reference Study Design Sample  
  No.   Participants Gender        Age Results 
      receiving RT.  Finally, performance on the Verbal Learning test 
- 5 word trial decreased in 17 individuals receiving CT and 12 




T1: Before CT 




TC +/- RT 
TC + 1CT 




Md n= 32 y 
Mdn = 35 y 
Mdn = 30 y 
Before Chemo:  Performance on cognitive measures not 
compared to normative data.  Performance on the CANTAB 
spatial working memory subtest was significantly better in 
individuals with TC not receiving CT 
Change Over Time:  Performance on CANTAB, HVLT, GP, 
TMT A & B, CW, or COWAT did not significantly change over 
time for any group.  No significant group difference were 
observed in proportions of individuals showing a decline of > 10 
on test measures or overall decline.  In contrast significantly 
larger proportions of individuals in the CT groups (+1 CT and > 
1 CT) had improvement of > 10 on test measure.  Specifically, 
38 TC + CT showed a decline of > 10  & 51  TC + CT showed 





T1: Before CT 




TC +/- RT 
TC + 1CT 




Mdn = 32 y 
Mdn = 35 y 
Mdn = 30 y 
Before Chemo:  Not reported. 
Change Over Time:  29 of individuals with TC receiving 1 CT 
and 25 of individuals with CT receiving multiple CT had an 
increase in self-reported cognitive problems  (2 questions, 4 
responses) 
Note. AFI = Attentional Function Index; BC= breast cancer; BVR = Benton Visual Retention test; CANTAB = Cambridge Neuropsychological Test Automated 
Battery; CT = chemotherapy; F = female; CSI = Cognitive Stability Index; DS = the Digit Span test; EORTC QLQ C30 = European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire C30; F = female; FEDA = Fragebogen erlebter Defizite der Aufmerksamkeit [Questionnaire of 
Experienced Attention Deficits]; HT = hormone therapy; IT = immunotherapy;  M = male; NSCLC = non small cell lung cancer; OC = ovarian Cancer; PC = 
peritoneal cancer; RBANS = Repeatable Battery of Adult Neuropsychological Status; RT = radiation therapy; RWT = Regensburg Word Fluency Test; SD, 
standard deviation, SEM = standard error of mean; T = time; TC = testicular cancer; TMT A & B = the Trail Making Test Part A & B; VLT = Verbal Learning 








Alterations in Attention and Memory Associated with Cancer Treatments:  Immunotherapy 
Reference Study Design Sample  




T1: After Surgery Before IT 





Melanoma HD IFN 
Melanoma LD IFN  
Melanoma  
- ‘Adult’ Before immunotherapy:  Performance on cognitive measures 
not compared to normative data or healthy controls.  
Change Over Time:  Performance on TMT A & B, GP, DSS, 
and DV did not significantly change from among participants 
for any group.  Performance on TMT B declined over the 





T1: Before IT 
T2: After IT, 5 days  





RCC, IL-2  
RCC, IL-2+IFN 
RCC, LD IFN 
Melanoma, HD IFN  
M, F M = 56 y 
M = 51 y 
M = 57 y 
M = 41 y 
Before immunotherapy: Performance on cognitive measures not 
compared to normative data/healthy control group.  
Performance on the simple choice task, multiple choice task, 
and spatial working memory was not significantly different 
between treatment groups at baseline.  Performance on the 
Stockings of Cambridge test was significantly worse in 
individuals with IL2 + IFN compared to IL2 only at baseline. 
Change Over Time: Performance on simple-choice task 
significantly improved on day 5 for individuals in IL-2 group 
but was no longer present at 1 month.  Performance on the 
multiple-choice task significantly declined in individuals 
receiving HD IFN and tended to persist at 1 month.  
Performance on complex trials of the Spatial Working Memory 
task significantly declined in individuals receiving IL-2 on day 
5 and tended to persist at 1 month.  Performance on the 
Stocking of Cambridge test significantly declined on day 5 in 





T1: After Surgery Before IT 
T2: After IT, 2 weeks 
T3: After IT, 8 weeks  
T4: After IT, 12 weeks  
20 Melanoma, IFN + 
Paroxetine 
Melanoma, IFN + 
Placebo 
M, F M = 52 y 
 
M = 50 y 
 
Before Immunotherapy:  Performance on cognitive  
measures not compared to normative data or healthy controls. 
Change Over Time:  Individuals receiving IFN only reported 
significantly more memory disturbances and poor concentration 
at T4 compared to baseline (NRS).  Frequency of cognitive 
symptoms in IFN only group:  30 loss of concentration, 15 
memory disturbances, 15 word finding problems, 10 episodes 
of confusion, & 10 indecisiveness (NRS). 
Note. DS = the Digit Span test; DSS = the Digit Symbol Substitution test; GP = the Grooved Pegboard test; HD= high dose; IFN = interferon; IL-2 = interleukin-
2; IT = immunotherapy; M = mean; RCC = renal cell cancer; T = time; TMT A & B = the Trail Making Test Part A & B; y = year. 
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Table 1.5  
Patient Characteristics Associated with Alterations in Attention and Memory 
Reference Study Design Sample  




T1: > 5yr after diagnosis 
17 
63  
BC /Lymphoma + APOE 
ε4 
BC/ Lymphoma - APOE ε4 
M, F M = 58 y 
M = 55 y 
Significantly lower attention and memory function in 
cancer survivors with APOE ε4 compared to without 




T1-4: Before and 1, 6, 




BC+ CT +/- RT +/- HT 
BC +/- RT +/- HT 
Healthy 
F M = 53 y 
M = 52 y 
M = 57 y 
Older individuals with lower cognitive reserve exposed 
to CT had a significantly lower attention and memory 




T1-2: Before and 2 






Breast Cancer, Older 
F M = 37 y 
M = 57 y 
M = 71 y 
Older women and middle/older women undergoing 
mastectomy demonstrated a significant decline in 





T1:  Before Treatment 
 
 
184 BC F M = 55 y Older age, fewer years of education, chronic health 
problem, and post-menopausal status was associated 
with worst performance on tests of attention & WM 
(DS, TMT A & B, TSTW). Younger age was associated 




T1: Before RT 
73 BC + RT F M = 55 y Younger age, not working, higher number of 
comorbidities and greater anxiety was significantly 











BC + HT +/- RT – CT 
Healthy 
F M = 69 y 
M = 66 y 
Comorbidities, fewer hours on cognitive activities, and 
higher number of reproductive years were significantly 
associated with poorer performance on measures of 
attention and memory in BC group (CF, LNS, Stroop 









BC CT +/- RT +/- HT 
BC RT +/- HT 
Healthy 
F M = 51 y 
M = 57 y 
M = 57 y 
Individuals with BC + CT & COMT-Val allele 
performed significantly worse on DS, Spatial Span and 




T1-2: Before and 4 
weeks after CT 
138 
21 
BC + CT +/- RT +/- HT 
BC +/- RT +/- HT 
F M = 49 y 
M = 54 y 
A decline in hemoglobin and an increase in anxiety 
significantly predicted impairment on in BC + CT 
Note. AFI = Attentional Function Index; APOE ε4 = Apolipoprotein E; BC = breast cancer; CT = Chemotherapy; CF = the Category Fluency test; CWI = the 
Color Word Interference test; CWT, the Color Word test; DS = the Digit Span test; DSC = the Digit Symbol Coding test; GP = the Grooved Pegboard test; HT, 
Hormone Therapy; F, female; LNS = the Letter Number Sequencing test; M, male; M, mean; NCPC = the Necker Cube Pattern Control test; RAVLT = the Rey 
Auditory Verbal Learning Test; RT = Radiation Therapy; SDMT = the Symbol Digit Modalities Test; TMT A & B = the Trail Making test Part A & B; TSTW =  
the Three Shapes Three Words test; VAT = the Visual Association Test; WM = Working Memory; y, year. 
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Table 1.6 
Circulating Inflammatory Cytokines in Individuals with Cancer Prior to Any Treatment (Serum, Plasma) 
Cancer Reference No.  Sample Results  




Significantly higher IL-6 & TNF-α levels in stage II BC compared to HC. Significantly 
higher IL-6 & TNF-α levels late stage compared to early stage BC.  
Breast Chod, 2008 36/20 BC/HC Significantly higher TGF-β1 levels in BC compared to HC 
 Merendino, 1996 20 BC Significantly higher IL-10 levels compared to controls. 
 Yeon, 2011 134/149 BC/HC Significantly higher IL-1β and IL-6 levels in BC group compared to controls.   
Cervical Chopra, 1998 61/20 CC/HC Significantly higher TNF-α, and higher TGF-β, & IL-10 compared to early stage/controls.   





CRC/HC Significantly higher IL-6 levels in CRC group compared to HC.  Significantly higher IL-6 
levels in individuals with metastasis than individuals without metastasis. 
 Esfandi, 2006 50 CRC Significantly higher IL-6 levels in individuals with stage IV CRC than early stage. 
 Galzia, 2002 50/25 CRC/HC Significantly higher IL-6 and IL-10 levels compared to controls. 
 Kaminska, 2005 157/50 
 
CRC/HC Significantly higher IL-6, TNF-α, and IL-1RA in CRC group compared to HC.  IL-6 and 
IL-1RA significantly increased with stage and bowel wall invasion.  
 Nikiteas, 2005 74/25 CRC/HC Significantly higher IL-6, TNF-α, and CRP levels in CRC group compared to HC.   
Gastric Kabir, 1995 21/17 
 
GC/HC Significantly higher IL-1α, IL-1β and IL-6 levels in GC group compared to HC.  
Significantly lower TNF-α levels in GC group compared to HC. 
 Ikeguchi, 2009 90/9 
 
GC/HC Significantly higher IL-6 levels in GC group compared to HC.  IL-6 levels in significantly 
correlated with advanced disease. 
Leukemia Myers, 2005 54 AML/MDS  Significantly higher IL-1, IL-1RA, IL-6 & TNF-α in individuals with AML/MDS  
Lymphoma Gaiolla, 2011 27/26 HL/HC Significantly higher IL-6 & IL-10 levels in individuals with cancer 
Melanoma Krasagakis, 1998 25/12 MC/HC Significantly higher TGF-β1 and TGF-β2 levels compared to HC. 
Melanoma Porter, 2001 218/90 MC/HC Significantly higher IL-6, & IL-10 levels in melanoma group.  
Ovarian Lambeck, 2007 187/45/50 OC/BD/HC Significantly higher IL-6 & IL-10 levels compared to HC as well as BD. 
 Maccio, 2005 91/95 
 
OC/HC Significantly higher IL-1β and TNF-α levels in individuals with advanced ovarian cancer 




Table 1.6.  Circulating Inflammatory Cytokines in Individuals with Cancer Prior to Any Treatment (Serum, Plasma) (continued) 
Cancer Reference No.  Sample Results  




Significantly higher IL-6 and IL-6sR in PC + regional lymph node metastasis compared to 
PC – regional lymph node metastasis and HC. 
Renal Dosquet, 1994 78/56 RCC/HC Significantly higher levels of TNF- α, IL-6, & IL-10 levels in RCC compared to HC. 
Renal Wunderlich, 1998 20/20 RCC/HC Significantly higher levels of TGF-β1 in RCC compared to HC 
Sarcoma 
 




Significantly higher IL-1RA, IL-6, IL-10, TNF RI & TNF RII levels in sarcoma compared 
to HC. Significantly higher IL-6 & IL-1RA levels in sarcoma group compared to BD. 
Note. AML = acute myelogenous leukiemia; BC = breast cancer; BD = benign disease; CC = cervical cancer, CRC = colorectal cancer; CRP = C-reactive 
protein; GC = gastric cancer, HC = healthy controls; HL = Hodgkin's Lymphoma; HNC = head and neck cancer; IL-1α = interleukin-1 alpha; IL-1β = 
interleukin-1 beta; IL-1RA = interleukin-1 receptor antagonist; IL-6 = interleukin-6; IL-10 = interleukin-10, MC = melanoma; MDS = myelodysplastic 





























Reference Study Design Sample  
  No.  Group Gender Age  Results 
Cognitive Function of Individuals with Minor Illnesses 








M = 23 y 
M = 22 y 
Significantly lower scores in flu group +/- fever 
compared to healthy (ERBMT) 
Smith, 1992 Pre/Post Design 




Influenza A  
M, F 
M 
- Significantly more errors individuals with flu.  No 
differences cold group (Stroop). 
Smith, 1987 Pre/Post Design 
T1-2: Before & 6-7 days after virus 
10 
35 




M = 39 y 
M = 39 y 
Significantly impairment flu group.  No difference 














M = 40 y 
M = 21 y 
M = 39 y 
All participants reported impaired concentration.  
IL-6 from PBMC significantly correlated with 
reports of poor concentration. 
Cognitive Function of Individuals with Inflammation 
Brydon, 2008  
 
Cross-over Design  
T1-2: Before & 2 h after endotoxin 
16 Salmonella  M M = 25 y After endotoxin, greater increases in IL-6 from 
baseline associated impaired attention (Stroop). 
Exton, 2002 Cross-over Design  




M M = 25 y After endotoxin, no changes (TMT, DS, d2). 
Krabbe, 2005 Cross-over design 
T1-5: Before & 1.5, 6, 24 h after 
endotoxin 
12 E. coli  M M = 26 y After endotoxin, no changes (WLW, LNS, DS, 
DSCT, TMT).  Negative correlation IL-6 levels 
and LTM at T3 (WLL) 
Reichenberg, 
2001 
Cross-over Design  





M M = 24 y After endotoxin, significant decline attention & 
memory (SR, FR, WLL). Impaired performance 
was correlated with IL-1RA, TNF-alpha, & IL-6 . 
Smith, 1988 Pre/Post Design 
T1-12: Before & q3h after cytokine  
18 Interferon-α   M, F M = 44 y Significant decrease in attention and memory 
function (VFPT) in high dose interferon alpha 
group.  No differences on reasoning task (BSR). 
Spath-Schwalbe, 
2006 
Cross-over Design  
T1-2:  3 & 9 h after cytokine 





Table 1.7.  Inflammatory Cytokines and Cognitive Function (continued) 
Note.  AML = Acute Myelogenous Leukemia, BSR = the Baddley Syntactical Reasoning Task; DS = the Digit Span test; DSCT = the Digit Symbol Coding Test; 
EBV = Epstein Barr Virus, ERBMT = the Extended Rivermead Behavioral Memory Test; F = female, FDT = the Fives Detection test; FR = the Figure Recall 
test; LNS = the Letter-Number Sequencing test; M = male; M = mean; MDS = myelodysplastic syndrome; PBMC = peripheral blood mononuclear cell; RRV = 
Ross River Virus, SPTT = the Square Pursuit Tracking Task; SR = Story Recall; T = time; TMT A & B = the Trail Making Test Part A and B; VFRTT = the 




















Reference Study Design Sample  
  No.  Group Gender Age  Results 
Cognitive Function of Individuals with Cancer 
 Pre/Post Design 
T1: Before treatment 
54 AML or 
MDS 
M, F M = 60 y Higher IL-6 levels associated with worse attention 
& working memory performance (TMT B).  






COGNITIVE SYMPTOMS IN COLORECTAL CANCER SURVIVORS 
Introduction 
  Colorectal cancer is the third most common cancer in the United States with an 
estimated 142, 820 new cases in 2013 (American Cancer Society, 2013).  Surgery is the 
main treatment for colorectal cancer, although chemotherapy or radiation therapy may 
also be used.  Cancer and cancer treatments can negatively affect daily functioning of an 
individual.  Cognitive function is a key functional ability that can be altered. 
Altered cognitive function is a distressing experience reported by some individuals 
with cancer. A growing body of research has observed cognitive deficits in cancer 
survivors early in the disease trajectory - at diagnosis and before any treatment and 
during main and adjuvant therapies (Cimprich, 1998; Cimprich & Ronis, 2001; Hedayati, 
Schedin, Nyman, Alinaghizadeh, & Albertsson, 2011; Kaasa, Olsnes, & Mastekaasa, 
1988; Wefel, Vardy, Ahles, & Schagen, 2011).   These cognitive deficits can alter an 
individual’s ability to work, achieve personal goals, and maintain interpersonal 
relationships (Boykoff, Moieni, & Subramanian, 2009).  As such, cognitive changes can 
have a significant impact on not only the cancer survivor but also his/her family and 
community. 
Changes in cognitive function in individuals with colorectal cancer have been largely 
unexplored.  After an extensive literature search, only a few studies were found that 
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assessed cognitive function in individuals with colorectal cancer (Patti, Saitta, Cusumano, 
Termine, & Di Vita, 2011; Vardy, 2007; Walker et al., 1996).   The first study, by Vardy 
and colleagues (2007), assessed cognitive function in individuals with localized cancer 
receiving surgery alone or surgery plus chemotherapy.  The longitudinal study assessed 
participants at three time points:  at baseline after surgery and/or before chemotherapy (n 
= 182), at 6 months (n = 71) and at 12 months (n = 39). Researchers found that at 
baseline 30% of participants were cognitively impaired on traditional neuropsychological 
tests.  Additionally, at 12 months participants receiving chemotherapy tended to have 
worse performance on traditional neuropsychological measures and reported more 
cognitive problems. Researchers did not describe neuropsychological measures or how 
they defined cognitive impairment. The second study by Walker and colleagues (1996) 
assessed cognitive function in 17 individuals with advanced colorectal cancer receiving 
chemotherapy alone or chemotherapy plus immunotherapy (interleukin-2) during the first 
12 weeks of therapy.  Researchers found that participants in both groups experienced 
cognitive decline from baseline on measures of attention and memory from the Cognitive 
Drug Research System (Walker et al., 1996). Additionally, two patients receiving 
chemotherapy plus immunotherapy developed severe neuropsychological problems 
(hallucinations, persistent confusion) that were attributed to the interleukin-2 therapy and 
resolved with discontinuation of therapy.  Finally, a third study by Patti and colleagues 
(2011) assessed postoperative delirium in 100 individuals undergoing colorectal surgery 
for carcinoma.  Researchers found that 18% of participants developed postoperative 
delirium using the established Confusion Assessment Method.  Postoperative delirium 
was associated with a history of postoperative delirium, older age, alcohol abuse, low 
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albumin, intra-operative hypotension, intra-operative blood loss, and elevated intra-
operative infusion volume.  
Together these studies suggest that cognitive impairment may be an important 
symptom experienced by some individuals with colorectal cancer.  Interpretation of 
findings, however, is difficult because of heterogeneous measures and definitions of 
cognitive impairment that were used as well as the diversity among cancer-treatments 
(standard and experimental therapies).   Additionally, two of the three studies were 
limited by a small sample size or significant attrition over time.  As such, further research 
is needed to investigate cognitive function and to precisely describe affected cognitive 
domains by using:  1) current cognitive neuroscience theory to guide the investigation 
and interpretation of findings, 2) a sample size that has sufficient power to detect deficits 
in cognitive function, 3) neuropsychological and self-report measures that are sensitive to 
subtle cognitive impairment in individuals with cancer, and 4) a healthy comparison 
group to determine whether cognitive deficits are present. 
Cognitive domains that appear to be most vulnerable to the effects of cancer and 
cancer treatments include attention, working memory, and long-term memory (Wefel, 
Vardy, et al., 2011).  Selective attention is a basic cognitive process that allows an 
individual to focus on certain stimuli in the environment.  Directed or controlled attention 
is a form of selective attention that allows an individual’s personal intention to determine 
what important information is actively focused on in the environment while inhibiting 
other distracting information (Kaplan & Berman, 2010).  It is characterized by mental 
effort and an ability to actively inhibit stimuli that may be of interest to the individual but 
are irrelevant to completing a task or achieving a goal. Working memory shares a close 
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functional connection with directed or controlled attention and is a cognitive process that 
allows an individual to hold online a limited amount of information and to perform 
cognitive operations on it (Smith & Jonides, 1999).  Long-term memory, specifically 
declarative memory, is a cognitive process that allows an individual to acquire and use 
information about personal experiences or knowledge about the world (Squire & Wixted, 
2011).  Together, directed or controlled attention and memory are necessary for planning 
and carrying out tasks, problem solving, and effective social functioning.  As such, they 
are critical for everyday functioning as well as coping with a new diagnosis of cancer and 
making informed decisions about treatment.   
The objective of this study was to assess attention and memory function in 
individuals newly diagnosed with colorectal cancer or recurrent colorectal cancer.  This 
study tested the hypothesis that when that compared to individuals without colorectal 
cancer, individuals with colorectal cancer would show alterations in performance on 
measures of directed or controlled attention, working memory, and long-term memory. 
Methods 
Study Design, Sample, and Setting 
This study used a cross-sectional comparative design to describe differences in 
cognitive function in individuals newly diagnosed with primary or recurrent colorectal 
cancer and individuals without colorectal cancer.  Participants were recruited from a 
university medical center in the Midwest and included 50 men and women newly 
diagnosed with stage I-IV colorectal cancer and 50 men and women without colorectal 
cancer.  The sample included approximately equal numbers of men and women in each 
group.  Patients were assessed at one time point within six months after a new diagnosis 
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of primary or recurrent colorectal cancer.  Participants in the healthy comparison group 
were assessed at one time point within twelve months after a negative screening 
colonoscopy. 
Eligible participants were at least 30 years old and were able to read and write 
English.  All participants were excluded for a history of conditions that could influence 
cognitive function including:  untreated or unstable mental disorder, head injury, alcohol 
or drug abuse, learning disability, and central nervous system disease.  Finally, patients 
were excluded for a diagnosis of malignancy other than colorectal cancer or skin cancer.  
Participants in the healthy comparison group were excluded for a diagnosis of 
malignancy other than skin cancer. 
Measures 
Cognitive Function Screen 
The Mini-Mental State Exam (MMSE) is a standardized test that includes 11 questions 
measuring orientation, memory, attention, and language. A score of greater than 24 was 
used to indicate no serious cognitive impairment (Folstein, Folstein, & McHugh, 1975;  
Folstein, Folstein, & Fanjiang, 2000).   The measure has been used as a screening 
measure for dementia (Lezak, Howieson, & Loring, 2004) 
Attention 
 The Attention Network Test (ANT) is a computerized test measuring the three 
networks of attention including alerting, orienting, and executive control.  The executive 
control network is closely aligned with the theoretical definition of directed attention 
(Fan, McCandliss, Sommer, Raz, & Posner, 2002; Kaplan & Berman, 2010).  The ANT 
asks participants to determine if an arrow in the center of the screen points to the left or 
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right.  The arrows are accompanied by flankers that point in the same direction and/or 
cues that provide information on when or where the arrow will occur in random 
sequence.  The three networks are assessed by measuring accuracy and response times, 
and how responses are influenced by flankers, alerting cues and spatial cues. Scores 
include an overall mean accuracy and mean response time for correct answers as well as 
mean response times for correct answers on the three networks.  Specifically, the alerting 
network was calculated by subtracting the double-cue condition scores from the no-cue 
condition scores, the orienting network was calculated by subtracting the spatial cue 
condition scores from the center cue scores, and the executive control network was 
calculated by subtracting the congruent flanker scores from the incongruent flanker 
scores.  For a detailed description of the measure and how it is scored see Fan and 
colleagues (2002).  The instrument has established reliability and validity (Fan et al., 
2002; Mahoney, Verghese, Goldin, Lipton, & Holtzer, 2010).   
Directed Attention and Working Memory  
Digit Span (DS) is a standardized test that asks participants to repeat a series of 
numbers in the order they were given (Digit Span Forward, DSF) or in reverse order 
(Digit Span Backward, DSB).  The score is the number of sequenced numbers repeated 
before two failed attempts.  Digit Span is a valid and reliable measure that has been used 
in individuals with cancer to detect deficits in directed attention and working memory 
(Cimprich, 1998; Cimprich & Ronis, 2001; Lezak et al., 2004; Small et al., 2011) 
The Trail Making Test (TMT) asks participants to draw a line to connect 
consecutively numbered circles (TMT A) or consecutively lettered and numbered circles 
alternating between the two (TMT B).  The score is the time taken to complete the task.  
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The trail making test is a valid and reliable measure that has been shown to be sensitive 
in detecting directed attention and memory deficits in individuals with cancer (Bond, 
Dietrich, & Murphy, 2012; Hermelink et al., 2007; Meyers, Byrne, & Komaki, 1995; 
Reitan, 1979). 
The Attentional Function Index (AFI) is a self-rating scale consisting of 13 items on 
which respondents rate their function on common tasks requiring directed attention and 
working memory from 0  (not at all) to 10 (extremely well or a great deal).   Scores 
include:  a single overall score computed by taking the average of all 13 items as well as 
mean scores for each of the three subscales namely effective action, attentional lapses, 
and interpersonal effectiveness.  The AFI has correlated positively with objective 
measures of directed attention and working memory.  It is a valid and reliable measure 
with an internal consistency coefficient ranging from 0.76 to 0.94 in cancer patients and 
healthy individuals (Cimprich, Visovatti, & Ronis, 2011).  In this study, the internal 
consistency coefficient was 0.91, indicating good reliability. 
Long-term Memory 
The Rey Auditory Verbal Learning Test (RAVLT) asks participants to recall 15 words 
from a list.  There are five presentations of one list of words (list A) followed by a sixth 
presentation of a second list of words (list B).  Participants are asked to recall the words 
on the list after each presentation.  After recalling the presentation of list B, participants 
are asked to recall list A immediately and after a 30 minute delay.  The score used for 
long-term memory was the number of words recalled on the 30 minute delayed recall 
trial.  The RAVLT is a valid and reliable measure (Schmidt, 1996).  Word list measures 
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have been shown to be sensitive measures in individuals with cancer (Wefel, Vardy, et 
al., 2011). 
The Everyday Memory Questionnaire (EMQ) is a self-rating scale consisting of 28 
items on which respondents rate their frequency of memory lapses for a specific activity 
of a 7-point scale scored from 1 (not at all in the last month) to 7 (several times a day).  
The single overall score is computed by taking the average of the 28 items.  The EMQ 
has correlated positively with objective measures of long-term memory in older adults 
and has an internal coefficient of 0.90 in healthy young adults (Cornish, 2000; 
Sunderland, Watts, Baddeley, & Harris, 1986).  In this study, the internal consistency 
coefficient was 0.90, indicating good reliability 
Adjunct Measures  
The Profile of Mood States-Brief Form, a demographic questionnaire, and a medical 
chart audit form were used to describe the sample population and measure participant 
characteristics that might affect cognitive function.  Characteristics that have been 
associated with poorer performance on cognitive measures include:  age, fewer years of 
education, presence of other health problems, changes in hormones, and psychological 
distress (anxiety and depressed mood) (Ahles et al., 2010; Bender et al., 2006; Bond et 
al., 2012; Cimprich, 1998, 1999; Cimprich, So, Ronis, & Trask, 2005; Hermelink et al., 
2007; Merriman et al., 2010; Schilder et al., 2010; Skaali, Fossa, & Dahl, 2011; 
Vearncombe et al., 2009).   
The Profiles of Mood States- Brief Form (POMS-BF) is a self-rating scale consisting 
of 30 items on which respondents read a list of words (i.e. tense) and rate how they have 
been feeling in the past week on a scale from 0 (i.e. not at all tense) to 4 (i.e. extremely 
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tense).  The instrument has six subscales, each with 5 items.  The subscales include:  
anxiety, depression, anger, vigor, fatigue, and confusion (McNair, 2012).  Scores on each 
of the subscales are computed by calculating the sum of each subscale.  Scores on the 
total scale (total mood disturbance) are computed by summing the scores on the anxiety, 
depression, anger, fatigue, and confusion subscales and subtracting the score on the 
subscale vigor.  The internal consistency coefficient for the total POMS-BF has been 
reported at 0.87 and 0.86 to 0.93 for the anxiety and depression subscales in individuals 
with cancer suggesting satisfactory reliability (Cimprich, 1999; Cimprich et al., 2005; 
Lehto & Cimprich, 1999).  In the current study, the internal consistency coefficient for 
the total POMS-BF was 0.80 and for the anxiety and depressed mood subscales were 0.76 
and 0.81 respectively. 
 Selected demographic and medical characteristics were obtained from participants 
using a demographic questionnaire and from the medical records using a medical chart 
audit form.  Demographic characteristics included age, race, ethnicity, marital status, 
educational level, occupation, and employment status.  Medical characteristics included 
type and stage of colorectal cancer, current medical conditions, current medications, past 
history of estrogen replacement therapy, and menopausal state. 
Study Procedures 
 The institutional review board of the university and health system approved the 
study. Written informed consent was obtained from all study participants.  Following 
consent, participants underwent neuropsychological testing and completed self-report 
questionnaires in a private room in the ambulatory care area.  A trained investigator 
administered the tests.  Testing procedures were as follows:  1) the immediate recall trials 
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of the RAVLT were administered first; 2) objective measures of directed attention and 
working memory in random order (ANT, DS, TMT); 3) self-report measures and adjunct 
measures in random order (AFI, EMQ, POMS-BF, and Demographic Characteristics); 
and 4) the delayed recall and recognition trail of the RAVLT. Time to complete testing 
was about 60 minutes. 
Data Analysis 
 Descriptive analyses and independent t-tests were used to describe the sample and 
determine if there were any significant differences between individuals with and without 
colorectal cancer on cognitive variables and potential covariates. Multiple regression 
analyses were used to assess the relationship between cognitive variables and group 
controlling for covariates which differed between the two groups and which may be 
related to cognitive function (i.e. age, education, menopause, anxiety).  For some 
analyses, a standardized composite score of directed attention and working memory was 
computed.  This composite score was computed by transforming raw scores on DS and 
TMT to Z scores based on the sample mean and standard deviation of the measures and 
summing the Z scores.  Given that higher scores on DS and lower scores on TMT 
indicated better functioning, scores on the TMT were reversed. 
Results 
Sample Characteristics 
 On the cognitive function screen, the MMSE, individuals with colorectal cancer 
(M = 29.28, SD = 0.83) and individuals without colorectal cancer (M = 29.60, SD = 0.73) 
scored > 24 indicating intact cognitive function.  The demographic and medical 
characteristics of participants with and without colorectal cancer can be found in Table 
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2.1.  No significant differences were found in age (t (98) = - 1.63, p = 0.11), years of 
education (t (98) = - 1.28, p = 0.20), or presence of health problems (χ2  (1, 100) = 2.34, p 
= 0.13) between these two groups.  For female participants, there was no significant 
difference in menopausal status  (χ2 (1, 51) = 0.60, p = 0.44) or hormone replacement 
therapy (χ2 (1, 51) = 0.18, p = 0.67) between the two groups. There was a significant 
group difference on the variable taking medication that could affect cognitive function 
with more individuals in the cancer group (n = 26) compared to the healthy group (n = 
12) taking medication that could affect cognitive function (χ2 (1, 100) = 9.38 p = 0.00).  
Medications that could affect cognitive function included narcotics, antidepressants, and 
sedatives for insomnia.   
The disease and treatment characteristics of participants with colorectal cancer 
can be found in Table 2.2.  Participants with colorectal cancer were assessed anywhere 
from 6 days to six months after diagnosis (M + SD:  67 + 49 days).  All participants were 
diagnosed with invasive adenocarcinoma, 48 with a new diagnosis of colorectal cancer 
and 2 with a new diagnosis of recurrent colorectal cancer. Most colorectal cancer 
participants were assessed after diagnosis and before any treatment (n = 20), some 
participants were assessed after surgery only (n = 13), and the remaining participants 
were receiving chemotherapy or radiation therapy (n = 17) at the time of the research 
visit.   
Group Comparisons in Psychological and Symptom Distress 
  Scores on the POMS-BF total mood disturbance scale and subscales are presented 
in Table 2.3.  Individuals with colorectal cancer reported greater total mood disturbance, 
anxiety, confusion and fatigue, and less vigor than the healthy comparison group. 
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Group Comparisons on Attention and Memory Measures 
 Scores on neuropsychological and self-report measures of directed attention, 
working memory, and long-term memory are presented in Tables 2.4 and 2.5.  Group 
mean scores on the standard neuropsychological measures (DS, TMT, RAVLT) were 
within normal limits (Folstein et al., 1975; Lezak et al., 2004; Reitan, 1979; Schmidt, 
1996).  No normative data were available for older adults on the ANT, however, mean 
scores for individuals with and without cancer were similar to findings reported by other 
researchers (Mahoney et al., 2010).   
On the measure of attention, ANT, there were no significant differences between 
the groups on overall accuracy (p = 0.14) or response times (p = 0.06).  There were also 
no significant differences on the attentional networks including alerting (p = 0.61), 
orienting (p = 0.58) or executive control (p = 0.63).   Additional analyses, however, 
found that mean response times for the neutral flanker condition (overall mean RT and 
mean RT for each cue condition) were significantly longer in individuals with colorectal 
cancer compared to controls.  This finding suggests that individuals with colorectal 
cancer had more difficulty discriminating the direction of an arrow when flanked by two 
straight lines on either side, a task that requires directed attention (Eriksen, 1974; Fan et 
al., 2002).  See Table 2.4. 
On measures of directed attention and working memory, individuals with 
colorectal cancer performed significantly worse on DS Forward (p = 0.01), TMT part A 
(p = 0.03), and the Standardized Total Composite Score (p = 0.047) compared to 
individuals without.  There were no significant differences between the groups on DS 
Backward (p = 0.26) or TMT part B (p = 0.06).  Additionally, compared to individuals 
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without colorectal cancer, individuals with colorectal cancer had significantly lower 
scores on the AFI total score (p < 0.001) and two of the three subscales.  Specifically, 
mean scores for individuals with colorectal cancer (M = 6.94, SD = 2.29) were 
significantly lower than individuals without colorectal cancer (M = 8.18, SD = 1.25) on 
the effective action subscale (t (98) = - 3.37, P < 0.001).  Likewise, mean scores for 
individuals with colorectal rectal cancer (M = 7.02, SD = 2.27) were significantly lower 
than individuals without colorectal cancer (M = 7.95, SD = 1.81) on the effective 
interpersonal relations (t (98) = - 2.26, p = 0.03).  As such, individuals with cancer 
reported having significantly more problems carrying out basic tasks that require focused 
attention (i.e. keeping your mind on what you are doing) and interacting in a deliberate 
manner that depends on attentional or inhibitory effort (i.e. being patient with others).  
See Table 2.5. 
 On the measures of long-term memory, there were no significant differences 
between groups on the RAVLT delayed word recall trial (p = 0.86) or perceived function 
on the EMQ (p = 0.47).  See Table 2.5. 
Predictors of Directed Attention and Working Memory  
Multiple regression analyses were performed to further assess the relationship 
between the cognitive variables (the standardized total composite score, AFI) and group 
controlling for possible covariates.  These covariates included  taking medication that 
could affect cognitive function, age, gender, education, anxiety, depressed mood, and 
fatigue.  Correlations between the directed attention and working memory variables and 
selected covariates are presented in Table 2.6.  Regression analyses are found in Table 
2.7 and 2.8. 
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The Standardized Total Composite Score.  Having colorectal cancer was found to 
be a significant predictor of directed attention and working memory after controlling for 
possible covariates.  Specifically, having colorectal cancer (t = 2.18, p = 0.03), older age 
(t = - 2.85, p = 0.01), and fewer years of education (t = 3.53 , p < 0.001) predicted poorer 
actual performance, accounting for  27% of the variance in the standardized total 
composite score, multiple R = 0.52, F (8, 91) = 4.29, p < 0.001.  See Table 2.7. 
Attentional Function Index (AFI).  Fatigue severity was found to be a significant 
predictor and the only predictor of lower scores on the self-report AFI regardless of 
colorectal cancer diagnosis.  Specifically, greater fatigue  (t = -4.26, p < 0.001) predicted 
lower perceived effectiveness on common tasks requiring directed attention and working 
memory, accounting for 38% of the variance in the self-report AFI, multiple R = 0.62, F 
(8.91) = 6.91, p < 0.001.  See Table 2.8.   
Discussion 
This study examined differences in cognitive function between individuals newly 
diagnosed with primary or recurrent colorectal cancer receiving standard treatment for 
the disease and individuals without colorectal cancer.  In the first six months after 
diagnosis, individuals with colorectal cancer performed and perceived their function to be 
worse on tests of directed or controlled attention and working memory but not long-term 
memory. When controlling for possible covariates, having colorectal cancer remained an 
independent predictor of worse cognitive function.  In contrast, fatigue significantly 
predicted perceptions of effectiveness on tasks requiring directed attention and working 
memory regardless of whether or not the individual had colorectal cancer.   
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 Participants in this sample were similar on most demographic and medical 
characteristics except for taking medication that can affect cognitive function.  Compared 
to the healthy comparison group, significantly more individuals with colorectal cancer 
were taking narcotics, antidepressants, and sedatives for insomnia.  Because of this 
difference, the variable taking medication that could affect cognitive function was 
included in multiple regression models.  Interestingly, taking psychoactive medication 
was not a significant predictor of performance or perceived effectiveness on measures of 
directed attention and working memory.  Nevertheless, this variable warrants further 
investigation in future studies examining cognitive function in individuals with colorectal 
cancer.  Specifically, the influence of the medication as well as symptom distress (i.e. 
pain, depressed mood, insomnia) on cognitive function needs to be further examined. 
 Participants with colorectal cancer also reported significantly greater 
psychological and symptom distress than healthy controls as measured by the POMS-BF 
including anxiety, fatigue/less vigor, and confusion.  Psychological distress has been 
associated with poor performance and perception of effectiveness on tasks requiring 
attention and memory in other cancer populations (Bender et al., 2006; Bond et al., 2012; 
Cimprich, 1999; Hermelink et al., 2007; Skaali et al., 2011; Wefel et al., 2011).   
However, in this study, anxiety and depressed mood did not predict performance or 
perceptions of effectiveness on objective or subjective measures.  Scores on the anxiety 
and depressed mood subscales were in the low to moderate range and it may have been 
possible that these low levels of distress were not sufficient to affect attention and 
memory function or may have even improved performance (Lezak et al., 2004).   As 
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such, continued research is needed to investigate the effect of psychological distress on 
cognitive function in individuals with cancer.   
Symptom distress, specifically fatigue, was also assessed as a potential modifier 
of cognitive performance in this study.  Unexpectedly, fatigue alone independently 
predicted lower scores on the subjective measure of directed attention and working 
memory.  One possible explanation for this finding is that participants reporting fatigue 
may be experiencing a common physiologic immune response to the cancer or another 
health condition and/or behavior (such as rheumatoid arthritis, obesity, smoking) that can 
the brain and cause subtle declines in function as well as feelings of fatigue.    In this 
regard, individuals with fatigue may be experiencing a cluster of cytokine-induced 
symptoms and changes in behavior (Cleeland et al., 2003; Kent, Bluthe, Kelley, & 
Dantzer, 1992).   Another perspective, proposed by Cimprich and colleagues (2002), is 
that individuals with cancer can experience mental or attentional fatigue secondary to the 
multiple cognitive demands associated with adapting to a new diagnosis of cancer, living 
with uncertainty about cancer control, and making treatment decisions.  Attentional 
fatigue may manifest as difficulties in completing tasks of daily living and contribute to 
overall distress.   The finding that fatigue was not a significant predictor of objective 
performance on neuropsychological measures suggests that objective measures may have 
been less sensitive to subtle deficits in directed attention and working memory perceived 
by the individual.  Continued research is needed to examine the relationship between 
symptom distress and cognitive function in individuals with colorectal cancer. 
The finding of cognitive deficits in individuals with colorectal cancer is consistent 
with the three previous studies examining cognitive function in individuals with 
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colorectal cancer (Patti et al., 2011; Vardy et al., 2007; Walker et al., 1996).  
Unfortunately, these disparate studies are not easily compared.   However, this study used 
cognitive neuroscience theory and previous research findings in individuals with other 
cancers to guide the assessment of cognitive function in individuals with colorectal 
cancer.  This approach, begins to more clearly define affected cognitive domains and 
potential patient characteristics that may contribute to an individual’s ability to function.   
Continued research is warranted to describe cognitive deficits and the effects of diagnosis 
and treatment on cognitive function in individuals with colorectal cancer. 
The finding of directed attention and working memory deficits in individuals with 
colorectal cancer early in the disease trajectory is consistent with studies examining 
cognitive impairment in other cancer survivors  (Wefel, Vardy, et al., 2011).   In contrast, 
individuals with colorectal cancer in this study did not experience deficits in long-term 
memory compared to individuals in the healthy comparison group.  This may have 
occurred in part because age, education and gender are known to affect performance on 
the RAVLT and the colorectal cancer group had a cluster of high performing younger 
women (< 45 years) who had a minimum of 16 years education (n = 7).  Further, the 
colorectal cancer group (n = 12) had more young adults (< 50 years) than the healthy 
comparison group (n = 1).  For a comprehensive understanding of long-term memory 
function in individuals with colorectal cancer, subsequent analyses of memory should 
consider including a variety of memory tasks that may be more robust with regards to 
gender differences for example the Complex Figure test (Lezak et al., 2004). 
Limitations of the study include a cross-sectional design, use of a convenience 
sample, and inclusion of participants receiving multiple types of cancer therapies 
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(surgery, chemotherapy, and/or radiation therapies).  Also, while the study examined 
differences in attention and memory between individuals with and without cancer, it 
could not answer questions related to potential differences in responses related to stage of 
cancer because it was not sufficiently powered to do so.   
Despite the above limitations this study provides preliminary evidence that some 
individuals with colorectal cancer may be vulnerable to deficits in directed attention and 
working memory.  Future longitudinal studies are warranted to assess the effects of 
cancer and cancer treatments on cognitive function in individuals with varying stages of 
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Table 2.1 
Medical and Demographic Characteristics of Individuals With and Without Colorectal Cancer (N = 100) 
Measures Colorectal Cancer Group 
(n = 50) 
Healthy Comparison Group 
(n = 50) 
 M + SD N (%) M + SD N (%) 
Age  55 + 12  58 + 7  
Education 16 + 3  16 + 3  
Gender     
     Male  24 (48)  25 (50) 
     Female  26 (52)  25 (50) 
Racea     
     Caucasian  38 (76)  42 (84) 
     Other  10 (20)  7 (14) 
Current Marital Status     
     Single  16 (32)  10 (20) 
     Married/Committed  34 (68)  40 (80) 
Employment     
     Unemployed outside home  25 (50)  34 (68) 
     Unemployed  25 (50)  16 (32) 
Annual household incomeb     
     < $31,000  8 (16)  4 (8) 
     $31,000 - $75,000  16 (32)  21 (42) 
     > $ 75,000  21 (42)  24 (48) 
Other Health Problems     
     Yes  37 (74)  44 (88) 
     No  13 (26)  6 (12) 
Medication:  Cognitive Function*     
     Yes  28 (56)  12 (24) 
     No  22 (44)  38 (76) 
aTwo colorectal cancer and one healthy participant declined.  bFive colorectal cancer and one healthy participant declined. 
*p < 0.05. 
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Table 2.2   
Disease and Treatment Characteristics of Individuals with Colorectal Cancer (n = 50) 
Measures Colorectal Cancer Group 
(n = 50) 
 M + SD N (%) 
Time from Diagnosis (day) 67 + 49  
Tumor Location   
     Colon  27 (54) 
     Rectum  15 (30) 
     Rectosigmoid Junction  8 (16) 
Stage of Cancer   
     Stage I & II  16 (32) 
     Stage III  19 (38) 
     Stage IV & Recurrent  15 (30) 
Treatment   
     Before Any Treatment  20 (40) 
     After Surgery Only  13 (26) 















Table 2.3   
Means and Standard Deviations of Physical and Psychological Symptoms (N = 100) 
 Colorectal Cancer Group 
(n = 50) 
Healthy Comparison Group 
(n = 50) 
 Mean + SD Range Mean + SD Range 
Total Score     
     Total Mood 
Disturbance a 
13.30 + 16.14* -10 - 51 0.14 + 9.60 - 19 - 37 
Subscale Scores     
     Anxiety  4.76 + 3.24* 0 - 14 2.58 + 1.94 0 - 8 
     Depression  3.00 + 3.30 0 - 14 1.90 + 2.30 0 - 10 
     Anger  2.98 + 3.53 0 - 17 2.38 + 1.98 0 - 9 
     Vigor  8.20 + 4.92* 0 -20 12.94 + 3.59 6 - 20 
     Confusion  4.56 + 2.93* 1 - 13 2.64 + 1.65 0 - 8 
     Fatigue  6.20 + 4.24* 0 - 17 3.58 + 2.48 0 - 10 
aScores on the Total Mood Disturbance Scale computed by summing the anxiety, depressed mood, anger, confusion and fatigue 
subscales and subtracting the vigor subscale.  Range of scores for this scale is between – 20 and 100. 















Table 2.4  
Means and Standard Deviations of Overall Attention Measures (N = 100) 
 Colorectal Cancer Group (n = 50) Healthy Comparison Group (n = 50) 
 Mean + SD Range Mean + SD Range 
Cognitive Screen 
     Mini Mental State Exam  29.28 + 0.83* 27 - 30 29.60 27 - 30 
Overall Attentiona     
Attention Network Test:  Overall      
     Overall Accuracyb  0.98 + 0.06 0.64 – 1.00 0.99 + 0.01 0.95 – 1.00 
     Overall Response Timec 673.08 + 113.13 501.08 – 1003.16 635.97 + 74.98 510.11 – 872.53 
Attention Network Test:  Networksc     
      Alerting Network  35.77+ 22.70 -2.51 – 88.61 33.42 + 22.51 - 5.20 – 89.47 
     Orienting Network 44.59 + 29.20 - 3.55 – 113.68 47.70 + 26.87 - 15.46 – 113.39 
     Executive Control Network  119.08 + 45.19 48.26 – 311.92 114.85 + 43.59 44.26 – 270.42 
Neutral Flanker Conditionc     
     No Cue 661.38 + 113.35* 481.33 – 930.91 619.22 + 74.49 480.92 – 847.13 
     Center Cue 639.74 + 121.28* 472.46 – 1024.96 598.11 + 69.49 472.39 – 776.83 
     Double Cue 619.03 + 110.22* 460.13 – 935.00 579.60 + 64.62  461.78 – 792.17 
     Up/Down Cue 605.01 + 110.74* 435.16 – 930.63 565.64 + 76.47 441.38 – 871.13 
     Mean 631.12 + 111.40* 464.50 – 950.90 590.54 + 68.55 466.61 – 821.81 
a Two male colorectal cancer cases completed practice and session 1 of the Attention Network Test only secondary to insufficient time 
or decline.  bScores are in percentage.  cScores are in milliseconds. 











Means and Standard Deviations of Attention and Memory Measures (N = 100) 
 Colorectal Cancer Group (n = 50) Healthy Comparison Group (n = 50) 
 Mean + SD Range Mean + SD Range 
Directed or Controlled Attention and Working Memory 
Digit Span Forwarda 6.28 + 1.29* 3.00 - 9.00  7.00 + 1.47 4.00 – 9.00 
Digit Span Backwarda 4.68 + 1.27 3.00 – 8.00 4.98 + 1.36 3.00 – 8.00 
Trail Making Ab 33.37 + 12.03* 15.00 – 68.60 28.84 + 8.20 16.30 – 46.90 
Trail Making Bb 75.49 + 37.57 30.30 – 224.40 63.88 + 21.95 31.00 – 162.00 
Standardized Total Composite Scorec - 0.51 + 2.71* - 7.57 – 5.27 0.51 + 2.31 - 7.60 -5.85 
Attentional Function Index Total Score 7.07 + 1.83* 3.23 – 10.00 8.09 + 1.16 4.15 – 9.85 
Long-term Memory     
RAVLT Delayed Word Recalld, e 8.49 + 3.51 0.00 – 14.00 8.38 + 2.81 2.00 – 15.00 
Everyday Memory Questionnaire 49.64 + 20.88 28.00 – 136.00 46.32 + 10.23 30.00 – 74.00 
aScore are the number of digits recalled before two failed attempts.  bScores are time to complete task in seconds.  cStandardized Total 
Composite Scores = zDSF + zDSB – zTMT A – z TMT B.  dScores are number of words recalled.  eOne male colorectal cancer case 
did not complete task. 





Pearson Correlation Coefficients Between Directed or Controlled Attention and Working Memory and Selected Covariates (N = 100) 
 Age Education Gendera Anxiety b Depressed Mood b Fatigue b 
Standardized Total Composite Score - 0.25 * 0.38 * 0.07 - 0.08 -0.21 * - 0.09 
Attentional Function Index Total Score 0.07 0.22 * -0.17 - 0.37 * - 0.35 * - 0.57 * 
a Gender: male = 1, female = 2.  bProfile of Mood States – Brief Form subscales. 






Predictors of Attention and Working Memory Standardized Total Composite Score (N = 100) 
Variable B SE B β p 
Group 1.17 0.54 0.23 0.03 
Age - 0.07 0.03 - 0.27 0.01 
Gender 0.21 0.49 0.04 0.67 
Education 0.31 0.09 0.33 0.00 
Medication: affecting cognitive function 0.16 0.52 0.03 0.76 
Anxiety 0.09 0.11 0.10 0.43 
Depressed mood - 0.21 0.11 - 0.24 0.06 
Fatigue 0.05 0.08 0.08 0.52 




Predictors of Attention and Working Memory Attentional Function Index Self-report 
Variable B SE B β p 
Group 0.29 0.31 0.09 0.36 
Age - 0.01 0.02 - 0.03 0.76 
Gender - 0.30 - 0.29 - 0.09 0.30 
Education 0.70 0.05 0.12 0.18 
Medication:  affecting cognitive function - 0.26 0.31 - 0.08 0.39 
Anxiety - 0.04 0.07 - 0.07 0.54 
Depressed mood - 0.01 0.06 - 0.01 0.94 
Fatigue - 0.20 0.05 - 0.46 0.00 




INFLAMMATORY CYTOKINES AND BIOMARKERS IN COLORECTAL 
CANCER 
Introduction 
Currently, it is estimated that there are 1,140,000 men and women in the United 
States living with a colorectal cancer diagnosis (American Cancer Society, 2011).  Both 
the cancer and treatments for the disease are associated with many distressing symptoms 
that can affect an individual’s ability to function and negatively influence his/her quality 
of life (Institute of Medicine, 2006).  Preventing and/or treating symptoms without 
compromising cancer control, requires an understanding of potential mechanisms that 
underlie symptoms.  One potential mechanism underlying colorectal cancer-related 
symptoms is the immune system’s response to the cancer and/or cancer treatments 
(Kelley et al., 2003).  Specifically, a growing body of research suggests that 
inflammation-related cytokines are associated with fatigue and other non-specific 
symptoms in individuals with cancer (Cleeland et al., 2003).   These cytokine-induced 
symptoms and behaviors have been named ‘sickness behavior’ (Hart, 1988). 
Studies examining sickness behaviors suggest that interleukin-1 (IL-1), tumor 
necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are the primary pro-inflammatory 
cytokines that communicate with the brain to induce symptoms and behavioral changes 
(Dantzer, Meagher, & Cleeland, 2012; Hart, 1988; Kelley et al., 2003).  Studies 
examining sickness behaviors in individuals with cancer have observed a relationship 
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between IL-6 and TNF-α and fatigue (Inagaki et al., 2008; Meyers, Albitar, & Estey, 
2005; Wang et al., 2010).  Additionally, indirect markers of inflammation have been 
associated with sickness behavior in individuals with cancer including pro-inflammatory 
target molecules (C-reactive protein, CRP), molecules related to pro-inflammatory 
cytokine pathways  (interleukin-1 receptor antagonist, IL-1RA), and other 
immunosuppressive cytokines involved in the regulation of the immune response 
(transforming growth factor-α, TGF-α) (Bower, Ganz, Aziz, & Fahey, 2002; Bower et 
al., 2011; Bower et al., 2009; Collado-Hidalgo, Bower, Ganz, Cole, & Irwin, 2006; 
Inagaki et al., 2008; Meyers et al., 2005; Orre et al., 2009; Wang et al., 2010).  
At this time, few research studies have assessed circulating inflammatory 
cytokines and biomarkers in individuals with colorectal cancer.  Identification of 
alterations in pro-inflammatory cytokines, indirect biomarkers of inflammation, and 
immunosuppressive cytokines in colorectal cancer is the first step in examining sickness 
behavior in individuals with cancer.  The purpose of this study is to determine if selected 
inflammatory cytokines and biomarkers are over expressed in individuals with colorectal 
cancer compared to individuals without.  Specifically, the study tested the hypothesis that 
compared to individuals without colorectal cancer, individuals with colorectal cancer will 
show alterations in the expression of pro-inflammatory cytokines (IL-1, IL-6, TNF-α), 
indirect pro-inflammatory biomarkers (CRP, IL-1RA) and immunosuppressive cytokines 
(interleukin-10, IL-10; transforming growth factor-β1, TGF-β1).  Further, the study 
hypothesized that having colorectal cancer would independently predict inflammatory 
cytokine and biomarker expression controlling for pertinent covariates. 
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Methods 
Study Design, Sample, and Setting 
 The study design was a cross-sectional comparative design and assessed 
participants with and without colorectal cancer at one time point.   Participants were 
recruited from a Midwest university hospital between May 2011 and September 2012.  
Participants included 50 men and women newly diagnosed with primary or recurrent 
colorectal cancer and 50 men and women without colorectal cancer.  Each group had 
approximately equal numbers of men and women.  Participants in the colorectal cancer 
group were tested within six months of diagnosis and participants in the healthy 
comparison group were tested within twelve months of a negative colonoscopy.   Eligible 
participants were at least 30 years of age and had sufficient command of the English 
language to provide informed consent and permit testing.  Individuals were excluded if 
they had a secondary diagnosis of a debilitating medical disorder (i.e. advanced cardiac 
or respiratory disease), unstable mental or psychiatric disorder, CNS disease, or substance 
abuse.  Patients with colorectal cancer were also excluded for a diagnosis of cancer other 
than colorectal or skin cancer and those without colorectal cancer were excluded for a 
previous history of cancer other than skin cancer.  To enable recruitment and accrual in 
an ill population, participants were not excluded for medications that might affect 
cognitive and immune function such as psychoactive medications including narcotics and 






Inflammatory Cytokines and Biomarkers 
Serum inflammatory cytokines and biomarkers measured in this study included 
interleukin (IL)-1β, IL-6, IL-10, IL-1 receptor antagonist (IL-1RA), tumor necrosis factor 
– alpha (TNF-α), transforming growth factor-β1 (TGF-β1) and C-reactive protein (CRP).  
This panel, which includes pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) and 
indirect biomarkers of pro-inflammatory cytokine activity (IL-1RA, CRP), was chosen 
based on previous research on inflammation and cancer-related symptoms (Lee et al., 
2004; Meyers et al., 2005; Orre et al., 2009; Rich et al., 2005; Wang et al., 2012).  
Further, immunosuppressive cytokines (IL-10, TGF-β1) appear to be important in the 
cancer pathogenesis of colorectal cancer so were included to gain a greater understanding 
of the systemic inflammatory response in colorectal cancer (Bellone et al., 2001; 
Berghella, Pellegrini, Del Beato, Adorno, & Casciani, 1997; Narai et al., 2002; Shim, 
Kim, Han, & Park, 1999). 
Blood samples for inflammatory cytokine and biomarker assays were obtained 
from each participant in the morning or early afternoon and with routine blood draws for 
individuals with colorectal cancer.  Five milliliters of blood for serum were collected in 
corvac tubes.  Collected blood was allowed to clot for at least 30 minutes and no more 
than 2 hours before processing.  Processing included centrifuging at 1000 g for 15 
minutes at room temperature, removing serum, and storing serum at < - 70 °C for batch 
analyses after all participants were enrolled.   
Inflammatory cytokines and biomarkers were assayed in duplicate using 
commercially available cytometric bead array assays and enzyme-linked immunosorbent 
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assays (ELISA).  Specifically, IL-1β, IL-6, TNF-α, and IL-10 were analyzed with 
Millipore’s High Sensitivity Human Cytokine Magnetic Bead panel (HSCYTMAG-
60SK), IL-1RA was analyzed with Millipore’s Human Cytokine/Chemokine Magnetic 
Bead panel (HCYTOMAG-60K), TGF-β1 was analyzed with R & D System’s DuoSet 
ELISA development kit (DY240) and C-reactive protein was analyzed with R & D 
System’s DuoSet ELISA development kit (DY 1707).  All inflammatory cytokines and 
biomarker results are the mean of the two measurements. 
Adjunct Measures 
The Profile of Mood States-Brief Form (POMS-BF), the Inventory of Functional 
Status Cancer (IFS-CA), a demographic questionnaire and a medical chart audit form 
were used to measure participant characteristics that might affect immune function.  
Characteristics that have been associated with higher circulating levels of inflammatory 
cytokines and biomarkers include:  older age, fewer years of education, advanced 
colorectal cancer, psychological distress, current tobacco use, a higher body mass index, 
and reduced exercise (Belluco et al., 2000; Chung & Chang, 2003; Galizia et al., 2002; 
Musselman et al., 2001; Narai et al., 2002; O'Connor et al., 2009).  
 The POMS-BF is a 30 item self-rating scale with an overall total mood 
disturbance score and six subscale scores (McNair, 2012).  The depression and anxiety 
subscales were used in this study. Individuals rate themselves on how they have been 
feeling in the past week on a 4-point scale from 0 (not at all) to 4 (extremely).  The 
POMS-BF has an internal consistency of 0.87 for total mood disturbance and 0.86 to 0.93 
for the anxiety and depression subscales in individuals with cancer (Cimprich, 1999; 
Cimprich, So, Ronis, & Trask, 2005; Lehto & Cimprich, 1999). In this study, the internal 
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consistency coefficient was 0.80 for the total score and 0.76 and 0.81 for the anxiety and 
depression subscales respectively. 
 The IFS-CA is a self-rating scale consisting of 39 questions which assess an 
individual’s ability to perform everyday activities (Tulman, Fawcett, & McEvoy, 1991).  
The exercise item in the personal care activities subscale was used to assess the extent to 
which usual exercise had been carried out in the last few weeks.  Responses were made 
on a 4-point scale from 1 (not at all/never exercise as much as usual) to 4 (all the 
time/fully exercise as much as usual).  This instrument has been previously used to 
examine cytokine-induced changes in behavior in individuals with cancer (Visovatti, 
Cimprich, & Metzger, 2009). 
 The demographic questionnaire and medical chart audit form were used to assess 
the following patient characteristics:  age, education level, sex, marital status, race, body 
mass index, current tobacco use, type and stage of colorectal cancer, current medical 
conditions, and current medications. 
Study Procedures 
 The study was approved by the institutional review board of the university and 
health system.   Following consent, participants completed self-report measures in a quiet 
private room in the outpatient area and had blood specimens collected. For most 
participants all research testing was completed on the same day but for a few participants 
it was more convenient to collect blood specimens on a separate day.  All blood 
specimens were collected within 14 days of the self-report measures. The principal 
investigator obtained informed consent and administered the self-report measures.  
Trained phlebotomy staff collected the blood specimens.  
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Data Analysis 
 Initial analyses used independent t-tests and Chi-square tests to describe 1) 
participant characteristics that may differ between individuals with and without cancer, 
and might affect inflammatory cytokine and biomarker expression, and 2) any differences 
between individuals with and without cancer on inflammatory cytokine and biomarker 
expression.  Pearson correlation coefficients were used to assess the relationship between 
inflammatory cytokines and biomarkers and selected covariates.  Finally, separate 
multiple linear regression models were constructed to explore whether having cancer 
independently predicted serum levels of inflammatory cytokines and biomarkers after 
controlling for covariates which may differ between individuals with and without cancer 
and which may be related to immune function (i.e. age, education, psychological distress, 
BMI current tobacco use, exercise).   Because inflammatory cytokines and biomarkers 
had a skewed distribution, data were log transformed using a natural log transformation.  
Transformation procedures were consistent with other studies assessing inflammatory 
cytokines and biomarkers in individuals with cancer to permit comparison across studies 
(Bower et al., 2011; Bower et al., 2009; Wang et al., 2010).  Data are presented using log 
transformed values rather than raw data.  For some analyses, an inflammatory ratio was 
computed.  The pro-inflammatory cytokine ratio was calculated by dividing TNF-α 
levels by IL-10 levels. The anti-inflammatory cytokine ratio was calculated by dividing 







 Participant demographic and medical characteristics are presented in Table 3.1.  
Participants (N = 100) were middle aged (M + SD:  56 + 10 years), highly educated (M + 
SD:  16 + 2.7 years) and predominantly Caucasian (80%). There were no significant 
differences found on age (t (98) = -1.63, p = 0.11), education (t (98) = -1.28, p = 0.20), 
gender (χ2 (1, 100) = 0.00, p = 1.00), marital status (χ2 (1, 100) = 1.30, p = 0.25), race (χ2 
(1, 98) = 0.13, p = 0.72), other health problems (χ2 (1, 100) = 2.34, p = 0.13), body mass 
index (t (98) = - 0.51, p = 0.61), or current tobacco use (χ2 (1, 100) = 0.10, p = 0.76) 
between these two groups. 
 Participant’s reports of psychological and symptom distress as well as frequency 
of usual exercise are presented in Table 3.1.  Compared to individuals without colorectal 
cancer, individuals with colorectal cancer reported significantly greater total mood 
disturbance (t (98) = 4.95, p < 0.001).  Further analysis of distress indicated that 
individuals with colorectal cancer reported significantly more anxiety (t (98) = 4.09, p < 
0.001), fatigue (t (98) = 3.77, p < 0.001), and confusion (t (98) = 4.04, p < 0.001) as well 
as significantly less vigor (t (98) = - 5.50, p < 0.001). The two groups did not 
significantly differ on feelings of depressed mood (t (98) = 1.93, p = 0.06) or anger (t 
(98) = 1.05, p = 0.30).  Finally, individuals with colorectal cancer reported participating 
in usual exercise significantly less frequently than individuals without colorectal cancer (t 
(97) = - 6.05, p < 0.001). 
 Medical and treatment characteristics of individuals in the colorectal cancer group 
are presented in Table 3.2.  The mean number of days from diagnosis to assessment was 
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67 days (SD = 49 days).  Most individuals with colorectal cancer had localized disease 
(stage I, II, & III) (70%) and were assessed before any chemotherapy or radiation therapy 
(66%).   
Group Differences in Inflammatory Cytokines and Biomarkers 
 Scores on inflammatory cytokines and biomarkers are presented in Table 3.3. As 
hypothesized, individuals with colorectal cancer had significantly higher levels of pro-
inflammatory cytokines (IL-6), indirect pro-inflammatory biomarkers (CRP), and 
immunosuppressive cytokines (IL-10) providing evidence of a systemic inflammatory 
response in individuals with colorectal cancer.  Unexpectedly, individuals with colorectal 
cancer had significantly lower levels of the immunosuppressive cytokine, TGF-β1.  To 
address this, a within group analysis of variance (ANOVA) was conducted to explore the 
impact of treatment on levels of TGF- β1 in individuals with colorectal cancer.  Patients 
were divided into three groups:  before any treatment (group 1), after surgery only (group 
2), and receiving chemotherapy and/or radiation therapy (group 3).  A statistically 
significant difference at the p < 0.05 level in the levels of TGF-β1 was found for the three 
treatment groups; F (2, 47) = 5.00, p = 0.01.  Post hoc comparisons using the Tukey HSD 
test indicated that the mean score for group 1 (M = 3.41, SD = 0.24) was significantly 
higher than group 3 (M = 3.11, SD = 0.35).  Group 2 fell in between group 1 and 3 and 
did not significantly differ from either (M = 3.22, SD = 0.32). The actual difference 
between groups was quite large with an effect size of 0.18 using eta squared.  This 
finding suggests that treatment did have an impact on TGF-β1 levels with individuals 
receiving chemotherapy and/or radiation therapy having significantly lower TGF-β1 
levels than individuals before any treatment.  Finally, no group differences were found on 
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IL-1β, IL-1RA or TNF-α.  However, it should be noted that serum levels of IL-1β and 
IL-1RA were very low and fell outside the detectable range in 23% and 45% of 
participants respectively.  Detection of group differences on these assays was limited by 
assay sensitivity. 
 Scores on inflammatory cytokine ratios are presented in Table 3.3.  Interestingly, 
individuals with colorectal cancer had significantly lower pro-inflammatory cytokine 
ratio (TNF-α/IL-10) and a significantly higher anti-inflammatory ratio (IL-10/TNF-α) 
suggesting a shift toward a more immunosuppressive phenotype of systemic cytokines in 
colorectal cancer. 
Predictors of Inflammatory Cytokine and Biomarker levels 
 Multiple linear regression analyses were performed to further assess the 
relationship between the immune variables (TNF-α, IL-6, CRP, IL-10, TGF-β1, TNF-
α/IL-10, IL-10/TNF-α) and group controlling for possible covariates.  These covariates 
included:  age, education, body mass index, current tobacco use, anxiety, depressed 
mood, and exercise as much as usual.  Because of very low detection, IL-1 and IL-1RA 
were not included in regression analyses.  Correlation between immune variables and 
selected covariates are presented in Table 3.4.   
 Pro-inflammatory Cytokines.  To determine possible predictors of TNF-α and IL-
6 levels, separate multiple linear regression models were constructed using these pro-
inflammatory cytokines as the dependent variable.  Group and selected covariates were 
entered as independent variables.  Interestingly when controlling for covariates, having 
colorectal cancer (t = 2.12, p = 0.01) was a significant independent predictor for TNF-α. 
In addition, greater anxiety (t = 3.01, p < 0.001), less depressed mood (t = - 2.29, p = 
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0.02) and not exercising as much as usual (t = - 2.77, p = 0.01) were also significant.  
These variables together accounted for 19% of the variance in TNF-α, multiple R = 0.44, 
F (8, 90) = 2.69, p = 0.01.  For IL-6, not exercising as much as usual (t = -3.42, p < 0.01) 
alone predicted higher levels accounting for 22% of the variance in IL-6 levels, multiple 
R = 0.47, F (8,90) = 3.11, p < 0.01).  Findings from correlation analyses are presented in 
Table 3.4 and findings from regression analyses are presented in Tables 3.5 and 3.6. 
Indirect Pro-inflammatory Biomarkers.  To determine possible predictors of CRP 
levels, multiple linear regression was performed using this indirect pro-inflammatory 
biomarker as the dependent variable.  Group and selected covariates were entered as 
independent variables.  For CRP, having colorectal cancer (t = - 2.85, p = 0.01) and not 
exercising as much as usual (t = - 2.44, p = 0.02) predicted higher levels accounting for 
30% of the variance, multiple R = 0.55, F (8, 90) = 4.79, p < 0.001).  Findings from 
correlation and regression analyses are presented in Tables 3.4 and 3.7 respectively. 
 Immunosuppressive Cytokines.  To determine possible predictors of IL-10, and 
TGF-β1 levels, separate multiple linear regressions were performed using these 
immunosuppressive cytokines as the dependent variable.  Group and selected covariates 
were entered as independent variables.  The IL-10 and TGF-β1 models did not reach 
significance.   Findings from correlation analyses are presented in Table 3.4 and findings 
from regression analyses are presented in Tables 3.8 and 3.9. 
 Inflammatory Cytokine Ratios.  Finally, to determine possible predictors of TNF-
α/IL-10 and IL-10/TNF-α ratios, separate multiple linear regressions were performed 
using these inflammatory cytokine ratios as the dependent variables.  Group and selected 
covariates were entered as independent variables.  Neither of the models reached 
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significance.  Findings from correlation analyses are presented in Table 3.4 and findings 
from regression analyses are presented in Tables 3.10 and 3.11. 
Discussion 
 Activation of the immune system and inflammatory cytokine expression has been 
associated with some cancer and cancer treatment related symptoms.  This study assessed 
inflammatory cytokines and biomarkers in individuals with colorectal cancer as a first 
step toward examining cytokine-induced symptoms and behaviors or sickness behavior in 
individuals with colorectal cancer.  The study found significantly higher levels of 
interleukin-6 (IL-6), C-reactive protein (CRP) and interleukin-10 (IL-10) in individuals 
with colorectal cancer compared to healthy controls.  Unexpectedly, this study also found 
significantly lower transforming growth factor – beta1 (TGF-β1) in individuals with 
colorectal cancer compared to healthy controls, possibly related to cancer treatments.  
When controlling for possible covariates, having colorectal cancer was an independent 
predictor of higher circulating levels of TNF-α and CRP.  These findings will be 
discussed further below. 
Serum Levels of Inflammatory Cytokines and Biomarkers 
 Higher inflammatory cytokines and biomarkers in colorectal cancer:  IL-6, CRP, 
and IL-10.  Consistent with studies examining the diagnostic and prognostic role of 
cytokines in colorectal cancer, this study found significantly elevated levels of IL-6, 
CRP, and IL-10 in individuals with colorectal cancer compared to individuals without 
(Chung & Chang, 2003; Dymicka-Piekarska, Matowicka-Karna, Gryko, Kemona-
Chetnik, & Kemona, 2007; Galizia et al., 2002; Ito & Miki, 1999; Kaminska et al., 2005; 
Kantola et al., 2012; Kinoshita, Ito, & Miki, 1999; Nikiteas et al., 2005; Ueda, Shimada, 
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& Urakawa, 1994).   However, after controlling for covariates, having colorectal cancer 
remained a significant predictor of higher CRP levels but not IL-6 or IL-10 levels.  This 
finding suggests that human biobehavioral factors can have an effect on the measurement 
of circulating cytokines and influence the reliability and interpretation of findings.  
Interestingly, only a few of the above studies assessed and controlled for potential 
covariates (exclusion criteria, statistical control) that may affect inflammatory cytokine 
and biomarker levels (Chung & Chang, 2003; Kantola, et al., 2012; Ueda, et al., 1994).  
As such, further research is needed to elucidate patterns of inflammatory cytokine and 
biomarker expression in individuals with colorectal cancer. 
Lower inflammatory cytokines and biomarkers in colorectal cancer:  TGF-β1.  In 
contrast to other studies assessing the role of TGF-β1 in individuals with colorectal 
cancer, this study found significantly lower levels of TGF-β1 in individuals with 
colorectal cancer compared to healthy controls (Bellone et al., 2001; Narai et al., 2002; 
Shim et al., 1999). Studies examining TGF-β1 in patients with colorectal cancer 
measured this immunosuppressive cytokine before any treatment unlike this study that 
measured TBF-β1 levels in patients before and during treatment for the disease.  A within 
group analysis of variance was conducted to explore the impact of treatment on levels of 
TGF-β1 and found an actual difference in levels between patients who had not yet been 
treated and those who were receiving chemotherapy and radiation therapy.  Specifically, 
patients receiving chemotherapy and radiation therapy had significantly lower TGF-β1 
levels compared to patients who had not yet been treated.  Levels of TGF-β1 in patients 
after primary surgery fell in between the other two treatment groups and was not 
significantly different. This novel finding suggests that cancer treatments may influence 
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TGF-β1 levels.  Further research is needed to assess the effects of cancer treatments on 
TGF-β1 in individuals with colorectal cancer.  
When controlling for possible covariates, the regression model for TGF-β1 did 
not reach significance.  Similar to the above studies assessing IL-6, IL-10 and CRP in 
colorectal cancer, studies examining TGF-β1 in colorectal cancer did not control for 
potential covariates that may influence levels of TGF-β1 (Bellone et al., 2001; Narai et 
al., 2002; Shim et al., 1999).  As such further research is needed to assess TGF-β1 
expression in individuals undergoing varying forms of treatments for colorectal cancer. 
No group differences were observed in this sample:  TNF-α, IL-1β, and IL-1RA.  
No group differences were observed on levels of TNF-α between individuals with and 
without colorectal cancer.  However, when controlling for possible covariates, having 
colorectal cancer independently predicted higher levels of TNF-α along with greater 
anxiety and less depressed mood.  Some studies examining TNF-α have found 
significantly higher levels of circulating TNF-α in individuals with colorectal cancer 
compared to healthy controls and other studies have excluded this cytokine from analyses 
because of poor detection (Chung & Chang, 2003; Kaminska et al., 2005; Kantola et al., 
2012; Nikiteas et al., 2005; Ueda et al., 1994).  One of the strengths of this study was the 
detection of TNF-α within the assay’s working range in all participants.  This may have 
been in part due to the use of a newly available high sensitivity human cytokine magnetic 
bead panel (see methods section for details) as well as careful sample collection and 
handling methods.  The finding that having colorectal cancer predicted levels of TNF-α 
after controlling for potential covariates provides evidence for a role for this cytokine in 
the pathogenesis of the disease and/or treatment for the disease.  It also exemplifies why 
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it is important to assess and control potential covariates.  Further research to replicate the 
above finding is needed. 
No group differences were observed in levels of IL-1β and IL-1RA in individuals 
with and without colorectal cancer.  However, serum levels of both these cytokines were 
very low and fell outside the detectable range in 23% of participants for IL-1β and 45% 
of participants for IL-1RA.  Thus, detection of differences on these cytokines may have 
been limited by assay sensitivity.  Future research with a larger sample size is 
recommended.   
Inflammatory cytokine ratios:  TNF-α/IL-10 and IL-10/TNF-α.  In this study, 
individuals with colorectal cancer had significantly lower pro-inflammatory cytokine 
ratios (TNF-α/IL-10) and significantly higher anti-inflammatory cytokine ratios (IL-
10/TNF-α) compared to individuals without.  These findings suggest that in addition to 
alterations in the levels of cytokines in colorectal cancer there also appears to be a shift in 
the balance of the inflammatory cytokines toward a more suppressive phenotype.   To 
date, no research studies were found that have examined TNF-α/IL-10 or IL-10/TNF-α 
ratios in individuals with cancer.  This novel finding may provide preliminary evidence 
of the systemic effects of tumor-induced dysfunction of the innate and adaptive immune 
systems in colorectal cancer (Whiteside, 2010).    
Demographic and Biobehavioral Predictors of Inflammatory Cytokines and 
Biomarker Levels  
Separate multiple linear regression models were constructed to assess the 
relationship between inflammatory cytokines and biomarkers (TNF-α, IL-6, CRP, IL-10, 
TGF-β1, TNF-α/IL-10, IL-10/TNF-α) and having colorectal cancer controlling for 
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potential covariates.   Participants with and without cancer were similar on most 
demographic and medical characteristics except for anxiety and not exercising as much as 
usual. Anxiety and not exercising as much as usual were also found to be correlated with 
certain cytokines and thus were included in regression models.  Additionally, a review of 
the literature found that age, education, body mass index, current tobacco use, and 
depressed mood may also be potential covariates so these variables were also included as 
independent variables in the regression models.  When controlling for covariates having 
colorectal cancer, higher anxiety, lower depressed mood, and not exercising as much as 
usual were significant predictors of greater pro-inflammatory cytokine activity (higher 
TNF-α Levels, higher CRP levels). Age, education, body mass index, and current 
tobacco use did not predict inflammatory cytokine and biomarker levels.  These results 
will be discussed below.   
 Having colorectal cancer.    After controlling for possible covariates, having 
colorectal cancer was a significant predictor of higher levels of TNF-α and CRP.  Having 
colorectal cancer also predicted higher levels of the anti-inflammatory cytokine ratio IL-
10/TNF-α as well as lower levels of TGF-β1 and the pro-inflammatory cytokine ratio 
TNF-α/IL-10 although these regression models did not reach significance. Finally, 
having colorectal cancer did not predict IL- 6 or IL-10 levels.   
This study hypothesized that having colorectal cancer would be a significant 
predictor of inflammatory cytokine and biomarker levels as cancer and cancer treatments 
have been associated with the activation of the immune system and inflammatory 
cytokine expression (Cleeland et al., 2003).   Having colorectal cancer was a significant 
predictor of higher levels of the pro-inflammatory cytokine TNF-α and the indirect pro-
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inflammatory biomarker CRP.  These findings are important.  TNF-α is produced early in 
the response to an immune challenge and is responsible for the production of other pro-
inflammatory cytokines including IL-1β and IL-6 and amplification and maintenance of 
the inflammatory response (Cavaillon, Adib-Conquy, Fitting, Adrie, & Payen, 2003; 
Mant et al., 2008).  Further, TNF-α along with IL-1β and IL-6 are thought to have a 
primary role in inducing the expression of sickness behaviors (Konsman, Parnet, & 
Dantzer, 2002).  Indirect markers of TNF-α activity have been associated with fatigue in 
individuals with cancer (Bower al., 2002; Bower et al., 2011).   
CRP is an acute phase protein produced by hepatocytes in the liver and is under 
the transcription control of cytokines originating at sites of pathology- mainly IL-6  
(Gabay & Kuscher, 1999).  CRP binds with a variety of ligands including components of 
bacteria, fungi and parasites as well as damaged cell membranes and apoptotic cells and 
activates the complement system (Pepys & Hirschfield, 2003).  It has been described as 
an exquisitely sensitive biomarker of systemic inflammation and has been used in 
cardiovascular disease alongside other clinical and pathologic results to evaluate disease 
(Pepys & Hirschfield, 2003).  Increased levels of circulating CRP have been associated 
with fatigue in individuals with cancer and may be a sensitive biomarker of sickness 
behavior. (Bower et al., 2009; Orre et al., 2009; Wratten et al., 2004)   
The finding that having colorectal cancer significantly predicted CRP and not IL-
6 is an interesting finding and may reflect the complex role of IL-6 in cancer 
pathogenesis as well as aging, health behaviors, psychological distress, and other health 
problems.  Similarly, the finding that having colorectal cancer did not predict levels of 
immunosuppressive cytokines (IL-10, TGF-β1) or inflammatory cytokine ratios may 
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reflect the complex role of these cytokines in cancer pathogenesis as well as aging and 
other health problems and behaviors.  Further research is needed to assess inflammatory 
cytokine and biomarker expression as well as biobehavioral factors that might affect their 
expression in colorectal cancer to gain a better understanding of the systemic 
inflammatory response and sickness behavior in individuals with colorectal cancer. 
 Psychological distress. In this study, individuals with colorectal cancer reported 
significantly more anxiety but not depressed mood compared to individuals without 
colorectal cancer.  Additionally, higher anxiety and lower depressed mood were 
significant predictors of higher TNF-α levels across groups.   These finding are 
consistent with that of other researchers assessing psychological distress in healthy 
individuals as well as individuals with cancer (Arranz, Guayerbas, & De la Fuente, 2007; 
Kim et al., 2012; Maes et al., 1998; Pitsavos et al., 2006). Both anxiety and depressed 
mood have been associated with activation of the inflammatory response and may be part 
of the immune system’s response to the cancer and threat to survival (Miller, 2009).  
Specifically, anxiety is associated with arousal and increased activity and is important for 
protection against future threats while depressed mood allows for the shutting down of 
behavioral activity and conservation of resources.  It has been proposed that cytokine 
expression associated with the source or nature of the threat as well as genetics and past 
experiences determine the individual’s response to a threat (Miller, 2009).  In this regard, 
anxiety in colorectal cancer survivors may be part of sickness behavior responses that 
support an individual’s survival and adaptation to a life threatening diagnosis of cancer.  
Further research is needed to examine the relationship between anxiety and TNF-α in 
individuals newly diagnosed with colorectal cancer.  
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 Exercising as much as usual. In this study, individuals with colorectal cancer 
reported decreased physical activity or not exercising as much as usual compared to 
individuals without colorectal cancer. Additionally, the study found that not exercising as 
much as usual alone independently predicted higher levels of IL-6 and predicted higher 
levels of CRP and TNF-α across groups.  Not exercising as much as usual also predicted 
higher levels of the immunosuppressive cytokine IL-10 although the regression model 
did not reach significance. 
Consistent with these findings, engagement in regular aerobic and resistance training has 
been associated with lower circulating levels of IL-6, CRP, and TNF-α in healthy and 
patient populations (Balducci et al., 2010; O'Connor et al., 2009).  However, no research 
has examined the effect of reducing exercise frequency or intensity in individuals with 
cancer or other populations.  Decreased physical activity has been described as an 
immune mediated sickness behavior that permits the reduction of energy demands so that 
fever and other physiologic immune responses that require energy and are necessary for 
the survival of the individuals can be sustained (Dantzer, 2004; Hart, 1988).  Further 
research examining decreased physical activity and appropriateness of exercise 
interventions in individuals with cancer is needed. 
Limitations and Future Research 
 Findings from this study were limited by a cross-sectional design, convenience 
sample, and inclusion of patients with different stages of disease receiving multiple 
therapies (surgery, chemotherapy, radiation therapy).  Although other studies have found 
higher inflammatory cytokines and biomarkers in individuals with advanced versus 
localized cancer, this study was not sufficiently powered to provide definitive 
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information about this relationship ((Belluco et al., 2000; Dymicka-Piekarska, et al., 
2007; Kaminska et al., 2005; Kantola et al., 2012; Ueda et al., 1994). 
 Despite these limitations this study provides preliminary evidence that individuals 
with colorectal cancer can experience alterations in levels of inflammatory cytokines and 
biomarkers.  Having colorectal cancer independently predicted TNF-α and CRP after 
controlling for potential covariates.  TNF-α is a pro-inflammatory cytokine that has been 
implicated in the expression of sickness behavior (Dantzer, 2004).   CRP is an indirect 
marker of inflammation and may be a candidate biomarker of sickness behavior in 
individuals with colorectal cancer.  These findings are very important and foundational to 
understanding sickness behavior and appropriate interventions.  Further longitudinal 
studies are needed to assess sickness behavior and the effects of cancer and cancer 
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Sample Characteristics, n (%) (N = 100) 
  Colorectal Cancer Group 
(n = 50) 
Healthy Comparison Group 
(n = 50) 
p 
Demographic Characteristics 
Age (years) Mean (SD) 55 (12) 58 (7) 0.11 








Marital status Married 16 (32%) 10 (20%) 0.25 
Racea White  38 (76%) 42 (84%) 0.72 
 Non-white 10 (20%) 7 (14%)  
Medical Characteristics 
Body Mass Index (kg/m2) Mean (SD) 27.98 (7.80) 28.68 (5.73) 0.61 
Other Health Problems Yes  13 (26%) 6 (12%) 013 
Current Tobacco Use Yes 5 (10%) 7 (14%) 0.76 
Psychological and Symptom Distress 
Total Mood Disturbance Mean (SD) 13.3 (16.14) 0.14 (9.60) < 0.001 
Anxiety Mean (SD) 4.76 (3.24)  2.58 (1.94) < 0.001 
Depressed Mood Mean (SD) 3.00 (3.30) 1.90 (2.30) 0.06 
Anger Mean (SD) 2.98 (3.53) 2.38 (1.98) 0.30 
Vigor Mean (SD) 8.20 (4.92) 12.94 (3.59) < 0.001 
Confusion Mean (SD) 4.56 (2.93) 2.64 (1.65) < 0.001 
Fatigue Mean (SD) 6.20 (4.24) 3.58 (2.48) < 0.001 
Exercise 
Exercise As Much As Usualb Mean (SD) 2.20 (1.16) 3.37 (0.70) < 0.001 







Medical and Treatment Characteristics of Individuals with Colorectal Cancer, n (%) (n  = 50) 
  Colorectal Cancer Group 
(n = 50) 
Time from Diagnosis (day) Mean (SD) 67 (49) 
Tumor Location Colon 27 (54%) 
 Rectum 15 (30%) 
 Rectosigmoid Junction 8 (16%) 
Stage of Cancer Stage I & II 16 (32%) 
 Stage III 19 (38%) 
 Stage IV & Recurrent 15 (30%) 
Treatment After diagnosis and before any treatment 20 (40%) 
 After surgery only 13 (26%) 




















Means and Standard Deviations of Inflammatory Cytokines and Biomarkers (N = 100)a 
 Colorectal Cancer Group 
(n = 50) 
Healthy Comparison Group 
(n = 50) 
t p 
 Mean + SDb Mean + SDb   
Pro-inflammatory Cytokines  
Interleukin-1  0.21 + 0.39 0.19 + 0.46 0.19 0.85 
Tumor Necrosis Factor - α  1.93 + 0.67 1.90 + 0.93 0.23 0.82 
Interleukin-6  1.94 + 0.90 1.53 + 0.93 2.26 0.03 
Indirect Pro-inflammatory Biomarkers  
Interleukin -1 Receptor Antagonist 2.37 + 1.69 2.04 + 2.07 0.87 0.39 
C-Reactive Protein  1.78 + 1.05 1.04 + 0.59 4.36 0.00 
Immunosuppressive Cytokines     
Interleukin-10  2.85 + 0.94 2.40 + 0.99 2.33 0.02 
Transforming Growth Factor - β1  3.26 + 0.33 3.41 + 0.23 - 2.73 0.01 
Inflammatory Cytokine Ratios  
Tumor Necrosis Factor-α/Interleukin-10 0.72 + 0.24 0.91 + 0.47 - 2.62 0.01 
Interleukin-10/Tumor Necrosis Factor-α 1.60 + 0.69 1.34 + 0.60 2.03 < 0.05 
aIndividual assay values below the minimal detectable concentration (Min DC) were assigned a value of  ‘0’.  bInflammatory 













Pearson Correlation Coefficients Between Inflammatory Cytokines and Biomarkers and Immune Function Modifiers (N = 100) 
 Age Education BMI Current 
Tobaccoa  
Anxietyb Depressionb Exercise as 
Usualc    
Pro-inflammatory Cytokines        
Tumor Necrosis Factor - α  0.04 - 0.13 0.00 - 0.02 0.22 * - 0.03 0.14 
Interleukin-6  0.06 - 0.21 * 0.12 0.13 0.11 0.02 - 0.32 * 
Indirect Pro-inflammatory Biomarkers 
C-Reactive Protein  0.06 - 0.21 * 0.18 0.05 0.15 0.18 - 0.39 * 
Immunosuppressive Cytokines        
Interleukin-10  - 0.09 - 0.06 0.11 - 0.07 0.16 0.13 - 0.34 * 
Transforming Growth Factor - β1  - 0.12 0.04 - 0.03 0.12 0.04 0.13 0.14 
Inflammatory Cytokine Ratio        
Tumor Necrosis Factor-α/Interleukin-10 0.12 0.09 - 0.01 0.11 0.01 - 0.09 0.24 * 
Interleukin-10/Tumor Necrosis Factor-α - 0.19 0.15 - 0.04 - 0.05 - 0.04 0.04 - 0.14 
aCurrent tobacco use: no = 0, yes = 1.  bProfile of Mood States-Brief Form subscale.  cItem from Inventory of Functional Status Cancer 
Part C. 















Predictors of Tumor Necrosis Factor-alpha (N = 100) 
Variable B SE B β p 
Group 0.29 0.14 0.25 0.04 
Age 0.01 0.01 0.11 0.26 
Education - 0.02 0.02 - 0.09 0.35 
BMI 0.01 0.01 0.08 0.39 
Current Tobacco Use - 0.25 0.18 - 0.14 0.17 
Anxiety 0.08 0.03 0.40 0.00 
Depressed mood - 0.06 0.03 - 0.28 0.02 
Exercise as Usual - 0.17 0.06 - 0.32 0.01 






Predictors of Interleukin- 6 (N = 100) 
Variable B SE B β p 
Group - 0.05 0.22 - 0.03 0.83 
Age 0.01 0.01 0.10 0.31 
Education - 0.05 0.03 - 0.14 0.16 
BMI 0.00 0.01 0.00 0.97 
Current Tobacco Use 0.24 0.28 0.09 0.39 
Anxiety 0.22 0.04 0.07 0.61 
Depressed mood - 0.07 0.04 - 0.21 0.80 
Exercise as Usual - 0.33 0.10 - 0.40 0.00 





Predictors of C-reactive protein (N = 100) 
Variable B SE B β p 
Group - 0.58 0.20 - 0.31 0.01 
Age 0.01 0.01 0.13 0.16 
Education - 0.03 0.03 - 0.09 0.33 
BMI 0.02 0.01 0.18 0.05 
Current Tobacco Use 0.20 0.26 0.07 0.46 
Anxiety - 0.04 0.04 - 0.13 0.29 
Depressed mood 0.03 0.04 0.81 0.42 
Exercise as Usual - 0.22 0.09 - 0.27 0.02 






Predictors of Interleukin – 10 (N = 100) 
Variable B SE B β p 
Group - 0.09 0.24 - 0.04 0.72 
Age 0.00 0.01 - 0.02 0.86 
Education 0.00 0.04 0.01 0.96 
BMI 0.01 0.01 0.08 0.40 
Current Tobacco Use - 0.28 0.31 - 0.09 0.38 
Anxiety 0.02 0.05 0.36 0.72 
Depressed mood 0 00 0.04 - 0.01 0.93 
Exercise as Usual - 0.26 0.11 - 0.29 0.02 





Predictors of Transforming Growth Factor – beta 1 (N = 100) 
Variable B SE B β p 
Group 0.20 0.07 0.34 0.01 
Age 0.00 0.00 - 0.14 0.18 
Education 0.01 0.01 0.05 0.65 
BMI 0.00 0.00 - 0.08 0.44 
Current Tobacco Use 0.08 0.09 0.09 0.38 
Anxiety 0.00 0.01 0.02 0.88 
Depressed mood 0.02 0.01 0.17 0.19 
Exercise as Usual - 0.01 0.03 - 0.04 0.76 






Predictors of TNF-α/IL-10 ratio (N = 100) 
Variable B SE B β p 
Group 0.24 0.09 0.31 0.01 
Age 0.00 0.00 0.09 0.39 
Education - 0.02 0.02 - 0.13 0.23 
BMI 0.00 0.01 - 0.02 0.86 
Current Tobacco Use 0.04 0.12 0.03 0.78 
Anxiety 0.03 0.02 0.23 0.10 
Depressed mood - 0.03 0.02 - 0.19 0.14 
Exercise as Usual - 0.01 0.04 - 0.02 0.85 





Predictors of IL-10/TNF-α ratio (N = 100) 
Variable B SE B β p 
Group - 0.36 0.16 - 0.27 0.03 
Age - 0.01 0.01 - 0.19 0.07 
Education 0.04 0.03 0.17 0.11 
BMI 0.00 0.01 - 0.02 0.84 
Current Tobacco Use 0.08 0.21 0.04 0.70 
Anxiety - 0.06 0.03 - 0.25 0.08 
Depressed mood - 0.04 0.03 0.16 0.20 
Exercise as Usual 0.03 0.07 0.04 0.72 




COGNITIVE SYMPTOMS AND INFLAMMATION 
Introduction 
 Colorectal cancer affects individuals of all racial and ethnic groups and is the 
third most common cancer for both men and women.  The overall life time risk of 
developing the disease is 1 in 20 (American Cancer Society, 2013). Individuals with 
colorectal cancer can experience cognitive symptoms and impaired function before and 
during treatment for the disease (Patti, Saitta, Cusumano, Termine, & Di Vita, 2011; 
Vardy, 2007; Walker et al., 1996).  Changes in cognitive function can be distressing and 
affect an individual’s ability to learn, work, and achieve personal goals (Boykoff, Moieni, 
& Subramanian, 2009).  At this time, little is known about biologic mechanisms that may 
underlie cognitive changes. One potential mechanism is the immune system’s response to 
the cancer and cancer treatments (Cleeland et al., 2003; Hart, 1988).  Specifically, 
inflammatory cytokines are produced in the tumor microenvironment or in response to 
tissue injury associated with cancer treatments.  These proteins can communicate with the 
brain to induce symptoms and behavioral responses or ‘sickness behaviors’ that generally 
support the immune system and the survival of the individual.  However, persistent or 
excessive production of inflammatory cytokines can be detrimental.  Cognitive symptoms 
and impaired function appear to occur alongside sickness behaviors in individuals with 
cancer and may be a cytokine-induced response to the cancer and/or cancer treatments 
(Cleeland et al., 2003; Meyers, Albitar, & Estey, 2005).   
 123 
Indirect evidence for a role of inflammatory cytokines in cognitive deficits comes 
from studies assessing the side effects of immunotherapy in individuals with chronic 
myelogenous leukemia, colorectal cancer, melanoma, and renal cell carcinoma.  
Specifically, patients treated with interleukin-2 (IL-2) and interferon-alpha (IFN-α) have 
been found to be impaired on measures of global cognition (Mini-Mental State Exam) 
and on measures of specific cognitive domains including directed attention, working 
memory, and long-term memory (Consistent Long-term Retrieval, Controlled Oral Word 
Association Test, Corsi’s Spatial Test, Digit Span Backward, Digit Symbol Test , TMT A 
& B, Spatial Working Memory Test, Stockings of Cambridge, Zazzo’s Attention) 
(Capuron, Ravaud, & Dantzer, 2001; Caraceni et al., 1993; Denicoff et al., 1987; 
Scheibel, Valentine, O'Brien, & Meyers, 2004; Walker et al., 1997).  One study, by 
Bender and colleagues (2000), did not observe significant changes in cognitive function 
in patients treated with immunotherapy for melanoma.  However, researchers did observe 
a non-significant deterioration in directed attention and working memory in individuals 
receiving high dose interferon (Trail Making B).  Finally, serious neurologic events have 
been associated with cytokine therapy including acute confusion, seizures, and altered 
states of consciousness (Buter, de Vries, Sleijfer, Willemse, & Mulder, 1993; Denicoff et 
al., 1987; Kirkwood et al., 1985; Nethersell, Smedley, Katrak, Wheeler, & Sikora, 1984), 
implicating an overexpression of cytokines as a potential mechanism in cognitive 
symptoms.   
 To date, only one study has assessed the relationship between endogenous 
inflammatory cytokine expression and cognitive symptoms in individuals with cancer.  
The study, by Meyers and colleagues (2005), assessed inflammatory cytokine expression 
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(interleukin-1 receptor antagonist, interleukin-6, tumor necrosis factor-α) and cognitive 
symptoms in 54 patients newly diagnosed with acute myelogenous leukemia (AML) and 
myelodysplastic syndrome (MDS) before any treatment.  Researchers found that higher 
levels of interleukin- 6 (IL-6) were associated with poorer performance on a measure of 
directed attention and working memory (Trail Making B).  This study suggests that an 
over expression of inflammatory cytokines may underlie changes in directed attention 
and working memory function in individuals with cancer before any treatment.  
 Thus, the objective of this study was to further explore the relationship between 
cognitive function and endogenous levels of inflammatory cytokine expression in a 
combined group of individuals with and without colorectal cancer.   The study measured 
pro-inflammatory cytokines (interleukin-1β, IL-1β; interleukin-6, IL-6; tumor necrosis 
factor-α, TNF-α), indirect pro-inflammatory biomarkers (interleuking-1 receptor 
antagonist, IL-1RA; C-reactive protein, CRP), and immunosuppressive cytokines 
(interleukin-10, IL-10; transforming growth factor-β1).  The cognitive measures included 
attention (Attention Network Test, ANT), directed or controlled attention and working 
memory (Digit Span, Trail Making, Attentional Function Index), and long-term memory 
(Rey Auditory Verbal Learning Test, Everyday Memory Questionnaire). The study tested 
the hypothesis that lower performance and perceived effectiveness on measures of 
attention, directed attention and working memory, and long-term memory will be related 
to elevated serum levels of pro-inflammatory cytokines, indirect pro-inflammatory 





Study Design, Sample, and Setting 
 This study used a cross-sectional design to assess the relationship between 
cognitive symptoms and inflammatory cytokines and biomarkers. The sample of men and 
women with and without cancer was included to ensure sufficient variance in the key 
cognitive and immune function variables.  One hundred participants were recruited from 
a university medical center in the Midwest.  For individuals with colorectal cancer (n = 
50), participants were assessed within six months of a diagnosis of primary or recurrent 
colorectal cancer.  For individuals without colorectal cancer (n = 50), participants were 
assessed within twelve months of a negative colonoscopy.  Eligibility requirements 
included:  being 30 years of age or older and being able to read and write English.  
Individuals were excluded for conditions that could affect cognitive function including:  a 
history of untreated or unstable mental disorder, learning disability, head injury, drug or 
alcohol abuse, and central nervous system disease.  Individuals were also excluded for a 
diagnosis of malignancy other than the new diagnosis colorectal cancer or a history of 
skin cancer.   
Measures 
Cognitive Measures 
Cognitive Function Screen.  The Mini Mental State Exam (MMSE) was used to 
screen potential participants and ensure that individuals participating in this study had 
intact cognitive functioning.  The MMSE is a brief test consisting of 11 questions that 
measure orientation, memory, attention and language (Folstein, 2000).  Similar to other 
studies assessing cognition in healthy individuals and individuals with cancer, a score of 
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greater than 24 was used to indicate no serious cognitive impairment (Cimprich & Ronis, 
2001; Patti et al., 2011). 
Attention.  The Attention Network Test (ANT) was used to measure overall 
attentional function (Fan, McCandliss, Sommer, Raz, & Posner, 2002).  This 
computerized test assessed three networks of attention including: alerting, orienting, and 
executive control.  Participants are asked to determine if a middle arrow in a group of 
arrows or flankers points to the left or right.  Sometimes the arrows and flankers are 
accompanied by cues that provide information about when or where the middle arrow 
will occur.  An overall mean accuracy and response time for correct answers was 
computed and used for attentional function in the data analyses.  For a detailed 
description of the measure and how it is scored see Fan and colleagues (2002).  The ANT 
has established reliability and validity (Fan et al., 2002; Mahoney, Verghese, Goldin, 
Lipton, & Holtzer, 2010). 
Directed Attention and Working Memory.  Digit Span (DS), the Trail Making 
Test (TMT) and the Attentional Function Index (AFI) were used to measure directed 
attention and working memory.   
Digit Span (DS) is a standardized test with two parts:  Digit Span Forward (DSF) 
and Digit Span Backward (DSB).  DSF asks participants to recall a series of numbers in 
the order presented.  DSB asks participants to recall a series of numbers in reverse order.  
The score is the number of digits recalled before two failed attempts. DS has established 
reliability and validity and is a sensitive measure of directed attention and working 
memory deficits in individuals with cancer (Cimprich, 1998; Cimprich & Ronis, 2001; 
Lezak, 2004; Small et al., 2011). 
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The Trail Making Test (TMT) is a standardized test with two parts:  Trail Making 
Test A (TMT A) and Trail Making Test B (TMT B).  TMT A asks participants to draw a 
line to connect consecutively numbered circles.  TMT B asks participants to draw a line 
to connect consecutively numbered and letter circles, alternating between the two. The 
time taken to complete each part is the score.  TMT has established reliability and 
validity and is a sensitive measure of directed attention and working memory deficits in 
individuals with cancer and in individuals receiving immunotherapy for cancer (Bond, 
Dietrich, & Murphy, 2012; Denicoff et al., 1987; Hermelink et al., 2007; Meyers et al., 
2005; Meyers, Byrne, & Komaki, 1995; Reitan, 1979; Scheibel et al., 2004; Walker et al., 
1997). 
The Attentional Function Index (AFI) is a self-report measure that asks 
participants to rate their function on tasks in daily life that require directed attention and 
working memory from 0 (not at all) to 10 (extremely well or a great deal). The score is 
the mean of all 13 items.  The AFI has established reliability and validity and is a 
sensitive measure in individuals with cancer (Cimprich, Visovatti, & Ronis, 2011).  The 
internal consistency coefficient has been reported as 0.76 to 0.94 in cancer patients and 
healthy individuals (Cimprich et al., 2011).  In this study, the Cronbach alpha was 0.91. 
From these measures, two scores were computed and used in the data analyses:  a 
standardized total composite score for objective measures (DS, TMT) and a total mean 
score for the subjective measure (AFI).  The standardized total composite score was 
determined by transforming scores on DS and TMT to Z scores based on the mean and 
standard deviation of each test for the entire sample and then summing the Z scores. 
 128 
Because higher scores on DS and lower scores on TMT indicate better function, scores 
on the TMT were reversed.   
Long-term Memory.  The Rey Auditory Verbal Learning Test and the Everyday 
Memory Questionnaire were used to measure long-term memory.  The Rey Auditory 
Verbal Learning Test (RAVLT) is a standardized test that asks participants to recall 
words from a 15-word list.  Participants are presented with one word list (List A) five 
times followed by a second word list (List B) once.  After each presentation, participants 
are asked to recall the words on the list.  After recalling the final list (List B), participants 
are asked to immediately recall List A as well after a short 30-minute delay. The number 
of words recalled on the delayed recall condition was the score used for long-term 
memory in this study.  The RAVLT has established reliability and validity (Schmidt, 
1996).  Word list learning is a sensitive measure of long-term memory deficits in 
individuals with cancer and individuals receiving immunotherapy for cancer (Scheibel et 
al., 2004; Wefel, Vardy, Ahles, & Schagen, 2011). 
The Everyday Memory Questionnaire (EMQ) is a self-report measure that asks 
participants to rate the frequency of forgetting on tasks that require long-term memory 
function from 1 (not at all in the last month) to 7 (several times a day). The score is the 
sum of all 28 items.  The EMQ has established reliability and validity and has been 
positively correlated with objective measures of long-term memory in older adults 
(Cornish, 2000; Sunderland, Watts, Baddeley, & Harris, 1986).  It has an internal 




Inflammatory Cytokines and Biomarkers.  
Selected inflammatory cytokines and biomarkers were chosen from previous 
research examining cancer-related symptoms and the acute phase response in colorectal 
cancer (Bellone et al., 2001; Berghella, Pellegrini, Del Beato, Adorno, & Casciani, 1997; 
Lee et al., 2004; Meyers et al., 2005; Narai et al., 2002; Orre et al., 2009; Rich et al., 
2005; Shim, Kim, Han, & Park, 1999; Wang et al., 2010).  The study measured pro-
inflammatory cytokines (IL-1-β, IL-6, TNF-α), indirect pro-inflammatory biomarkers 
(IL-1RA, CRP), and immunosuppressive cytokines (IL-10, TGF-β1).  Blood specimens 
were collected from all participants in the morning or early afternoon to control for 
diurnal variations in inflammatory cytokine expression.  Five milliliters of blood was 
drawn into serum separator tubes by trained phlebotomy staff using sterile technique.  
Collected blood was separated according to standard procedures and stored at  < - 70 °C 
for batch analyses after all participants completed testing.  Serum levels of interleukin-1β 
(IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and interleukin-10 (IL-
10) were measured using Millipore’s High Sensitivity Human Cytokine Magnetic Bead 
panel (HSCYTMAG-60SK), interleukin-1 receptor antagonist (IL-1RA) was measured 
with Millipore’s Human Cytokine/Chemokine Magnetic Bead panel (HCYTOMAG-
60K), transforming growth factor-β1 (TGF-β1) was measured with R & D System’s 
DuoSet ELISA development kit (DY240) and C-reactive protein (CRP) was measured 
with R & D System’s DuoSet ELISA development kit (DY 1707).   
All inflammatory cytokines and biomarkers were assayed in duplicate and results 
are reported as the mean of the two measurements.  An inflammatory cytokine ratio was 
also computed.  Specifically, the pro-inflammatory cytokine ratio was determined by 
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dividing TNF-α levels by IL-10 levels and the anti-inflammatory cytokine ratio was 
determined by dividing IL-10 levels by TNF-α levels. 
Adjunct Measures 
 Patient characteristics that might affect cognitive and immune function were 
measured using:  the Profile of Mood States Brief Form (POMS-BF), the Inventory of 
Functional Status Cancer (IFS-CA), a demographic questionnaire, and a medical chart 
audit form.  Characteristics that have been associated with cognitive deficits as well as 
higher circulating levels of inflammatory cytokines and biomarkers include: age, years of 
education, anxiety, depressed mood, presence of other health problems, changes in 
hormones, current tobacco use, a higher body mass index, and reduced exercise (Ahles et 
al., 2010; Belluco et al., 2000; Bender et al., 2006; Chung & Chang, 2003; Cimprich, 
1998, 1999; Cimprich, So, Ronis, & Trask, 2005; Galizia et al., 2002; Hermelink et al., 
2007; Merriman et al., 2010; Musselman et al., 2001; Narai et al., 2002; O'Connor et al., 
2009; Schilder et al., 2010; Skaali, Fossa, & Dahl, 2011; Vearncombe et al., 2009). 
 The Profile of Mood States-Brief Form (POMS-BF) is a self-report measure that 
asks participants to rate how they have been feeling during the past week from 1 (not at 
all) to 4 (extremely).  The POMS-BF includes six subscales that measure anxiety, 
depression, anger, vigor, fatigue, and confusion.  The anxiety, depression, and fatigue 
subscales were used in this study.  Scores on the subscales are the mean of the five items 
in the subscale.  The internal consistency coefficients for the six subscales have been 
reported from 0.86 to 0.93 in individuals with cancer  (Cimprich, 1999).  In this study, 
the Cronbach alpha was 0.76 for anxiety, 0.81 for depressed mood, and 0.88 for fatigue. 
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 The inventory of Functional Status Cancer (IFS-CA) is a self-report measure that 
asks participants to rate their ability to perform everyday activities (Tulman, Fawcett, & 
McEvoy, 1991).  The IFS-CA includes an item that assesses any changes in usual 
exercise in the past few weeks from 1 (not at all/never exercise as much as usual) to 4 (all 
the time/fully exercise as much as usual. The IFS-CA is a sensitive measure in detecting 
changes in activities of daily living in individuals with cancer (Tulman et al., 1991; 
Visovatti et al., 2009). 
 A demographic questionnaire and medical chart audit form were used to assess 
patient characteristics including:  age, education, presence of other health problems, 
changes in hormones, colorectal cancer history, tobacco use, and body mass index. 
Study Procedures 
 The institutional review board at a midwest university and health system 
approved the study.  All participants provided written informed consent.  Participants 
completed neuropsychological testing and self-report measures in a quiet room and had 
blood specimens drawn by trained staff at the health system.  Most participants 
completed all testing on the same day. However, a few participants had blood specimens 
drawn with routine blood tests on a separate day within 14 days of cognitive and adjunct 
measures.  The principal investigator obtained informed consent and administered 
neuropsychological tests and self-report measures.  Testing procedures included: 
administering the immediate recall trials of the RAVLT followed by other objective 
measures of attention and memory in random order (ANT, DS, TMT) and then the 
delayed recall trial of the RAVLT.   The self-report measures were administered in 
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random order after the objective measures. Time to complete neuropsychological tests 
and self-report measures was approximately 60 minutes. 
Data Analysis 
 Descriptive statistics including means and standard deviations for continuous 
variables and frequencies for categorical variables were used to describe the sample. The 
relationship between each cognitive and immune variable was assessed by Pearson 
Correlation coefficients and only those inflammatory cytokines and biomarkers that had a 
significant relationship with the cognitive variables were included in multiple regression 
models.  Separate multiple linear regression models were constructed to assess the 
relationship between each cognitive variable and each significant inflammatory cytokine 
or biomarker controlling for covariates which may be related to cognitive and immune 
function.  Inflammatory cytokines and biomarkers had a skewed distribution and were 
log transformed using the natural log to be consistent with other biobehavioral studies 
examining inflammatory cytokines and biomarkers in individuals with cancer (Bower et 
al., 2011; Bower et al., 2009). Serum levels of IL-1β and IL-1RA were very low and fell 
outside the detectable range in greater than 20% of participants.  As such, they were not 
included in the correlation or multiple linear regression analyses. 
Results 
Sample Characteristics 
 Demographic characteristics.  The sample consisted of 100 men and women 
including 50 individuals newly diagnosed with primary or recurrent colorectal cancer and 
50 individuals without colorectal cancer.  Participants ranged in age from 36 years to 79 
years and had a mean age of 56 years (SD =10).  Participants were mostly Caucasian 
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(80%), married or in a partnered relationship (80%), and employed outside the home 
(59%).  They were also highly educated with a mean of 16 years (SD = 3) of education.  
See Table 4.1. 
 General health characteristics.  The majority of participants were overweight 
(27%) or obese (37%) and the remaining participants were underweight (3%) or normal 
weight (33%). Most did not smoke (88%).  Of the 51 women included, most were 
postmenopausal (65%).   
Medical characteristics.  The sample consisted of 50 individuals newly diagnosed 
with primary colorectal cancer (96%) or recurrent colorectal cancer (4%).  All 
participants had adenocarcinoma.  Approximately 32% had stage I or II, 38% had stage 
III, and 30% had stage IV disease or recurrent cancer.    Most participants were assessed 
before chemotherapy or radiation therapy (66%). 
 Psychological distress and physical activity characteristics.  Participant scores on 
the POMS-BF and IFS-CA exercise item are presented in Table 4.2.  In general, 
participants reported low to moderate levels of mood disturbance including anxiety (M = 
3.67, SD 2.87), depressed mood (M = 2.45, SD 2.88), and fatigue (M = 4.89, SD 3.70).  
For the IFS-CA exercise item, 64% of participants reported exercising as much as usual 
most or all of the time. 
Relationship Between Cognitive and Immune Function Variables 
 Scores on cognitive and immune variables are described in paper 2 and 3.  
Significant correlations between cognitive and immune variables tended to be domain 
specific and are presented in Table 4.3.  For directed attention and working memory, 
bivariate correlation analyses found that higher serum levels of IL-6 and CRP were 
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associated with poorer performance on the Standardized Total Composite Score (r = - 
0.29, p < 0.001; r = - 0.37, p < 0.001 respectively).  Additionally, bivariate correlation 
analyses found that higher serum levels of CRP and lower serum levels of TGF-β1 were 
associated with lower scores on the AFI indicating perceptions of poorer directed 
attention and working memory function (r = - 0.29, p  < 0.001; r = 0.30, p < 0.001 
respectively).  Finally for long-term memory, bivariate correlation analyses found that 
higher serum levels of TNF-α and IL-6 were associated with poorer performance on the 
RAVLT delayed recall score with small to moderate correlations (r = - 0.20, p < 0.05; r = 
- 0.28, p < 0.01 respectively).  There were no significant relationships between 
inflammatory cytokines and biomarkers and the ANT overall accuracy and response time 
scores or scores on the EMQ. 
Immune Predictors of Attention and Memory Function 
Multiple linear regression analyses were performed to further assess the 
relationship between cognitive variables and immune variables controlling for possible 
covariates. Only those cognitive measures that had a significant relationship with one or 
more immune variables were examined. Specifically, three separate multiple linear 
regression models were constructed using the Standardized Total Composite Score, the 
Attentional Function Index (AFI), and the Rey Auditory Verbal Learning Test delayed 
recall condition (RAVLT-delayed recall) as the dependent variables.  Scores from the 
Attention Network Test and the Everyday Memory Questionnaire were not correlated 
with immune variables and were not included in the regression analyses. See Table 4.3 
for correlations between cognitive and immune function variables.  Possible covariates 
included age, gender, education, medication that can affect cognitive function, colorectal 
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cancer, anxiety, depressed mood, fatigue, and exercise as usual.  See Table 4.4 for 
correlations between cognitive function variables and possible covariates. See Table 4.5 
for correlations between immune function variables and possible covariates.  See Tables 
4.8, 4.11, and 4.14 for final regression models. 
The model for the Standardized Total Composite Score included immune 
variables that were significantly related to the Standardized Total Composite Score (IL-6, 
CRP) as well as other variables that were related to the Standardized Total Composite 
Score, IL-6, and/or CRP (age, education, medication that can affect cognitive function, 
colorectal cancer diagnosis, depressed mood, exercise as usual) as determined by 
bivariate correlation analyses. Independent variables for the AFI self-report model 
differed from the Standardized Total Composite Score model.  In particular, TGF- β1, 
anxiety, and fatigue were correlated with the AFI and included in the model.  In contrast, 
age was not correlated with the AFI and thus not included in the model.  Finally, 
independent variables for the RAVLT delayed recall condition model differed from both 
the Standardized Total Composite Score and the AFI models.  In comparison to the 
Standardized Total Composite Score model, TNF-α, gender, and anxiety were correlated 
with the RAVLT and included in the RAVLT model. Depressed mood was not correlated 
with the RAVLT and thus not included in the RAVLT model.  In comparison to the AFI 
model, age and gender were correlated with the RAVLT and included in the RAVLT 
model.  CRP, TGF-β1, depressed mood, and fatigue were not correlated with the RAVLT 
and therefore not included in the RAVLT model.  
Standardized Total Composite Score.  To determine possible predictors of 
performance on tasks requiring directed attention and working memory measures, 
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separate multiple linear regression models were constructed using the standardized total 
composite score as the dependent variable. Each significant immune variable (IL-6, CRP) 
was entered separately as well as together with selected covariates as independent 
variables.  See Tables 4.6 to 4.8.  CRP was the only immune variable that predicted 
scores on the standardized total composite score.  Specifically, higher serum levels of 
CRP (t = - 2.24, p = 0.03), older age (t = - 3.22, p < 0.01), and fewer years of education (t 
= 3.21, p < 0.01) predicted lower scores on the standardized total composite score 
accounting for 32% of the variance, multiple R = 0.567 F (7, 91) = 6.17, p < 0.001. CRP 
also predicted scores on the standardized total composite score when both IL-6 and CRP 
were entered as independent variables.  Findings from this regression model were similar 
to the regression model that included only CRP as an independent variable.  See Table 
4.8.  Interestingly, although bivariate correlation analyses found that IL-6 and the 
standardized total composite score were significantly related, IL-6 did not independently 
predict scores on the standardized total composite score after controlling for possible 
covariates.  It is possible that IL-6 may have shared the variance with other independent 
variables in the model reducing it’s unique contribution to the standardized total 
composite score.  Inflammatory processes have been associated with a number of 
biobehavioral factors as well as stressful life events (new diagnosis of cancer) and 
depression (O’Connor et al., 2009).  In particular, higher IL-6 levels have been found in 
cancer patients with depression compared to cancer patients without depression and 
healthy controls (Musselman et al., 2001).  
Attentional Function Index.  To determine possible predictors of perceived 
effectiveness on common tasks of directed attention and working memory, separate 
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multiple linear regression models were constructed using the AFI score as the dependent 
variable.  Each significant immune variable (CRP, TGF-β1) was entered separately as 
well as together with selected covariates as independent variables.  See Table 4.9 to 4.11.  
TGF-β1 was the only immune variable that predicted scores on the Attentional Function 
Index when entered individually.  Specifically, lower serum levels of TGF-β1 (t = 3.51, p 
< 0.01) and greater fatigue (t = - 4.11, p < 0.01) predicted lower scores on the AFI 
accounting for 45% of the variance, multiple R = 0.67, F (8, 90) = 9.24, p < 0.001.  
However, when both CRP and TGF-β1were entered as independent variables in the 
model, both significantly predicted scores on the AFI.  Specifically, higher serum levels 
of CRP (t = - 2.18, p = 0.03), lower serum levels of TGF-β1 (t = 4.11, p < 0.01), and 
greater fatigue (t = - 4.02, p < 0.01) predicted lower scores on the AFI accounting for 
47% of the variance, multiple R = 0.69, F (8, 90) = 9.92, p < 0.001.  See Table 4.11.  The 
increase in R squared of this regression model suggests that the inclusion of both CRP 
and TGF-β1 in the model predicted more fully scores on the AFI (i.e. better model than 
CRP alone). 
Rey Auditory Verbal Learning Test – delayed recall.  To determine possible 
predictors on tasks requiring long-term memory, separate multiple linear regression 
models were constructed using the RAVLT 30-minute delayed word recall condition as 
the dependent variable.  Each significant immune variable (TNF-α, IL-6) was entered 
separately as well as together with selected covariates as independent variables.  See 
Table 4.12 to 4.14.  IL-6 was the only immune variable that predicted the number of 
words recalled on the delayed recall condition of the RAVLT.  Specifically, higher IL-6 
levels (t = - 2.09, p = 0.04), older age (t = - 2.98, p < 0.01), fewer years of education (t = 
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2.30, p = 0.02), and male gender (t = 3.50, p < 0.01) predicted lower scores on the 
RAVLT- delayed recall condition accounting for 35% of the variance, multiple R = 0.59, 
F (8, 89) = 5.92, p < 0.001).   Interestingly, when both TNF-α and IL-6 were included in 
the regression model, neither pro-inflammatory cytokine predicted scores on the 
RAVLT-delayed recall condition. Regression analyses showed no multicollinearity.  As 
such, a likely explanation is that IL-6 shared the variance with TNF-α reducing its unique 
contribution to scores on the RAVLT.  
Discussion 
 One potential mechanism underlying cognitive symptoms in individuals with 
cancer is an over expression of inflammatory cytokines related to the immune system’s 
response to the cancer and cancer treatments. Given that little research has examined the 
relationship between physiologic levels of inflammatory cytokine expression and 
cognitive symptoms, the goal of this study was to begin to characterize this relationship.  
The sample included individuals with and without colorectal cancer.  The inclusion of 
individuals without cancer allowed for the assessment of this relationship in a larger 
population of individuals who may be experiencing cognitive symptoms and/or elevated 
cytokines from other non-cancer factors (i.e. aging, other health problems and behaviors). 
The study found that serum levels of IL-6, CRP, TGF-β1 and TNF-α were associated 
with performance on cognitive measures and/or subjective perceptions of cognitive 
function.  Furthermore, the associations tended to be domain specific.  In particular, when 
controlling for possible covariates, 1) higher serum levels of CRP predicted poorer 
performance on tasks requiring directed attention and working memory and 2) higher 
serum levels of CRP and lower serum levels of TGF-β1 predicted poorer self-report of 
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directed attention and working memory function.  In addition, TNF-α and IL-6 were 
correlated with performance on the RAVLT, however after controlling for covariates 
neither pro-inflammatory cytokine predicted scores on the RAVLT-delayed recall 
condition in the final regression model. These findings will be discussed below. 
Relationships between inflammatory cytokines and biomarkers and cognitive 
function 
Pro-inflammatory cytokines and indirect pro-inflammatory biomarkers:  IL-6, 
TNF-α and CRP.  Consistent with previous studies examining the relationship between 
inflammatory cytokines and cognitive function, this study found that higher circulating 
levels of IL-6 were associated with poorer performance on measures of directed attention 
and working memory as well as long-term memory (Krabbe et al., 2005; Meyers et al., 
2005; Vollmer-Conna et al., 2004).  Interestingly, after controlling for possible 
covariates, IL-6 did not predict performance on measures of directed attention and 
working memory (individually or together with CRP) or performance on a measure of 
long-term memory.  However, after controlling for covariates, IL-6 did predict 
performance on the long-term memory measure when entered individually.  One possible 
explanation for these findings is that IL-6 shared the variance with other immune 
variables and biobehavioral factors. IL-6 is one of the primary cytokines that is induced 
in response to an immune challenge and operates as part of a cascade of cytokines to 
amplify and maintain a pro-inflammatory response (Cavaillon, Adib-Conquy, Fitting, 
Adrie, & Payen, 2003; Mant et al. 2008).  IL-6 is also thought to have a primary role in 
inducing symptom and behavioral responses that support the immune system and the 
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survival of the individual (Konsman, Parnet, & Dantzer, 2002).  As such, further research 
is needed to clarify the relationship between IL-6 and cognitive symptoms. 
No prior studies were found that examined the relationship between TNF-α or 
CRP and cognitive function.  Bivariate correlation analyses found that higher serum 
levels of TNF-α were associated with poorer performance on a measure of long-term 
memory.  However, after controlling for possible covariates, TNF-α did not predict 
performance on the long-term memory measure (individually or together with IL-6).  
Similar to IL-6, this finding may suggest that TNF-α shared the variance with other 
immune variables and biobehavioral factors in the model.  TNF-α is an important 
cytokine in the initiation of the inflammatory response and along with IL-6 has been 
associated with the amplification and maintenance of the inflammatory response 
(Cavaillon, Adib-Conquy, Fitting, Adrie, & Payen, 2003; Mant et al. 2008).  Indirect 
markers of TNF-α have been associated with fatigue in individuals with cancer 
suggesting a role for this cytokine in symptoms and behavioral changes that accompany 
the systemic inflammatory response (Bower et al., 2002; Bower et al., 2011; Wang et al., 
2012).   
Bivariate correlation analyses also found that higher serum levels of CRP were 
associated with poorer performance and perceived effectiveness on tasks requiring 
directed attention and working memory.  When controlling for covariates, CRP remained 
a significant predictor of performance on measures of directed attention and working 
memory (individually and together with IL-6) and perceived effectiveness on cognitive 
tasks (with TGF-β1).  This novel finding is important and suggests a role for this CRP in 
the expression of cognitive symptoms.  CRP is an acute phase protein that is induced by 
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pro-inflammatory cytokines (primarily IL-6) as part of the systemic inflammatory 
response to an immune challenge (Pepys & Hirschfield, 2003).   It has an important role 
in binding to/recognizing foreign pathogens and damaged cells (Gabay & Kushner, 1999; 
Pepys & Hirschfield, 2003).   Additionally, it can activate the complement system and 
induce inflammatory cytokines (Gabay & Kushner, 1999; Pepys & Hirschfield, 2003).  
CRP has been associated with fatigue in cancer survivors suggesting a role for this 
protein in the expression of sickness behaviors (Bower et al., 2009; Orre et al., 2009, 
Wratten et al., 2009).   
Immunosuppressive cytokines:  Transforming Growth Factor-β1.  To date, no 
research studies were found that examined the relationship between TGF-β1 and 
cognitive function.  In this study, higher serum levels of TGF-β1 were associated with 
better perceived effectiveness on tasks that require directed attention and working 
memory.  When controlling for possible covariates, TGF-β1 remained an independent 
predictor of scores on the self-report measure of directed attention and working memory 
(individually and together with CRP).  This was an unexpected finding and may suggest 
that some inflammatory cytokines are associated with neuroprotective processes. TGF-β1 
is critical for the development and maintenance of human tissue and has an important role 
in regulating the response as well as tissue remodeling and repair (wound healing) (Ariel 
& Timor, 2012).  Importantly, preclinical studies suggest that TGF-β1 may support the 
survival of adult neurons as well as control microglial activation and inflammation within 
the brain (Caraci, 2009).  TGF-β1 has not yet been associated with sickness behaviors or 
ameliorating sickness behaviors.  Further research is needed to confirm this finding and 
further assess the relationship between TGF-β1 and cognitive function. 
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Other inflammatory cytokines, biomarkers, and ratios:  IL-1β, IL-1RA, IL-10, 
TNF-α/IL-10, and IL-10/TNF-α.   In this study correlation and multiple regression 
analyses did not include IL-1β or IL-1RA because serum levels of these cytokines were 
very low and fell outside the detectable range in greater than 20% of the sample.  
However, IL-10 and the inflammatory cytokine ratios were included in bivariate 
correlation analyses but no significant relationships were found between these immune 
variables and cognitive variables.  As such, IL-10 and the inflammatory cytokine ratios 
were not included in regression analyses.  Further research in larger samples is needed to 
assess the relationship between IL-1β, IL-1RA, IL-10, and the inflammatory cytokine 
ratios and cognitive symptoms. 
Immune Predictors of Cognitive function:  Final Regression Models 
Separate multiple linear regression models were constructed to assess the 
relationship between each cognitive variables and each significant immune variable 
controlling for colorectal cancer, medications that may affect cognitive function and other 
possible covariates significantly related to cognitive and immune variables in the model.  
See Tables 4.8, 4.11, and 4.12.  When controlling for possible covariates, age, education, 
gender, and fatigue were found to be significant predictors of cognitive performance and 
self-report along with the inflammatory cytokines and biomarkers described below 
indicating the importance of considering these covariates in future analyses. Patient 
characteristics that did not predict cognitive performance or perceived performance on 
measures of attention and memory included having colorectal cancer, body mass index, 
current tobacco use, taking medication that might affect cognitive function, depressed 
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mood, anxiety, or exercising as much as usual.  Demographic and biobehavioral 
predictors have been discussed in previous papers. 
C-reactive protein.  After controlling for possible covariates and significant 
immune variables, higher serum CRP levels predicted poorer performance and 
perceptions of performance on tasks requiring directed attention and working memory. 
This finding is congruent with the study’s hypothesis that higher levels of inflammatory 
cytokines and biomarkers would be associated with poorer performance on cognitive 
measures.  Interestingly, this study found that CRP was a significant predictor of a single 
cognitive domain suggesting that different cytokines may be associated with different 
cognitive symptoms or losses in function.  
Transforming Growth Factor-β1.  After controlling for possible covariates and 
significant immune variables, higher serum levels of TGF-β1 were associated with better 
perceived effectiveness on tasks requiring directed attention and working memory.  This 
was an unexpected finding and may suggest that some inflammatory cytokines are 
associated with reduced vulnerability to cognitive symptoms.  TGF-β1 was also a 
significant predictor of a specific cognitive domain lending further support for the idea 
that specific cytokines may influence specific cognitive domains.   
Limitations and Future Research 
 Limitations of this study include a cross-sectional design, convenience sample, 
and inclusion of a combined group of individuals with and without colorectal cancer. 
Findings from this study cannot be generalized to individuals with cancer without further 
replication and clarification in larger samples. 
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Despite these limitations this study provides preliminary evidence of a 
relationship between cognitive symptoms and an over expression of inflammatory 
cytokines and biomarkers. Additionally, findings from this study suggest that an 
overexpression of specific cytokines may predict domain-specific losses in function and 
symptoms.  Finally, this study found a relationship between higher levels of an 
immunosuppressive cytokine and better cognitive function suggesting that some 
inflammatory cytokines may have a neuroprotective role in inflammation. Further 
research is needed to examine the relationship between specific inflammatory cytokines 






Ahles, T. A., Saykin, A. J., McDonald, B. C., Li, Y., Furstenberg, C. T., Hanscom, B. S., 
. . . Kaufman, P. A. (2010). Longitudinal assessment of cognitive changes 
associated with adjuvant treatment for breast cancer: impact of age and cognitive 
reserve.  Journal of Clinical Oncology, 28, 4434-4440. 
 doi: 10.1200/JCO.2009.27.0827 
 




Ariel, A., & Timor, O.  (2013).  Hanging in the balance:  endogenous anti-inflammatory 
mechanisms in tissue repair and fibrosis.  Journal of Pathology, 229, 250 - 263. 
doi:  10.1002/path.408 
 
Bellone, G., Carbone, A., Tibaudi, D., Mauri, F., Ferrero, I., Smirne, C., . . . Rodeck, U. 
(2001). Differential expression of transforming growth factors-beta1, -beta2 and -
beta3 in human colon carcinoma. European Journal of Cancer, 37, 224-233.  
 
Belluco, C., Nitti, D., Frantz, M., Toppan, P., Basso, D., Plebani, M., . . . Jessup, J. M. 
(2000). Interleukin-6 blood level is associated with circulating carcinoembryonic 
antigen and prognosis in patients with colorectal cancer. Annals of Surgical 
Oncology, 7, 133-138.  
 
Bender, C. M., Sereika, S. M., Berga, S. L., Vogel, V. G., Brufsky, A. M., Paraska, K. K., 
& Ryan, C. M. (2006). Cognitive impairment associated with adjuvant therapy in 
breast cancer. Psycho-oncology, 15, 422-430. doi: 10.1002/pon.964 
 
Bender, C. M., Yasko, J. M., Kirkwood, J. M., Ryan, C., Dunbar-Jacob, J., & Zullo, T. 
(2000). Cognitive function and quality of life in interferon therapy for melanoma.  
Clinical Nursing Research, 9, 352-363.  
 
Berghella, A. M., Pellegrini, P., Del Beato, T., Adorno, D., & Casciani, C. U. (1997). IL-
10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the 
passage from adenoma to colorectal cancer. Cancer Biotherapy & 
Radiopharmaceuticals, 12, 265-272.  
 
Bond, S. M., Dietrich, M. S., & Murphy, B. A. (2012). Neurocognitive function in head 
and neck cancer patients prior to treatment. Supportive Care in Cancer, 20, 149-
157. doi: 10.1007/s00520-010-1081-9 
 
Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L.  (2002).  Fatigue and Proinflammatory 




Bower, J. E., Ganz, P. A., Irwin, M. R., Kwan, L., Breen, E. C., & Cole, S. W. (2011). 
Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, 
depression, and sleep disturbance share a common underlying mechanism? 
Journal of Clinical Oncology, 29, 3517-3522. doi: 10.1200/JCO.2011.36.1154 
 
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., . . . Aziz, N. 
(2009). Inflammatory biomarkers and fatigue during radiation therapy for breast 
and prostate cancer.  Clinical Cancer Research, 15, 5534-5540.  
doi: 10.1158/1078-0432.CCR-08-2584 
 
Boykoff, N., Moieni, M., & Subramanian, S. K. (2009). Confronting chemobrain: an in-
depth look at survivors' reports of impact on work, social networks, and health 
care response. Journal of Cancer Survivorship:  Research and Practice, 3, 223-
232. doi: 10.1007/s11764-009-0098-x 
 
Buter, J., de Vries, E. G., Sleijfer, D. T., Willemse, P. H., & Mulder, N. H. (1993). 
Neuropsychiatric symptoms during treatment with interleukin-2. Lancet, 341, 
628.  
 
Capuron, L., Ravaud, A., & Dantzer, R. (2001). Timing and specificity of the cognitive 
changes induced by interleukin-2 and interferon-alpha treatments in cancer 
patients. Psychosomatic Medicine, 63, 376-386.  
 
Caraceni, A., Martini, C., Belli, F., Mascheroni, L., Rivoltini, L., Arienti, F., & 
Cascinelli, N. (1993). Neuropsychological and neurophysiological assessment of 
the central effects of interleukin-2 administration.  European Journal of Cancer, 
29A, 1266-1269.  
 
Caraci, F., Battaglia, G., Bruno, V., Bosco, P., Carbonaro, V., …Copani, A.  (2009).  
TGF-β1 Pathwas as a new target for nueroprotection in Alzheimer's Disease.  
CNS Neuroscience & Therapuetics, 17, 237 - 249.   
doi 10.1111/j.1755-5949.2009.0015.x 
 
Cavaillon, J. M.,  Abid-Conquy, M., Fitting, C., & Payen, D.  (2003).  Cytokine cascade 
in sepsis.  Scandinavian Journal of Infectious Disease, 35, 353-544. 
 
Chung, Y. C., & Chang, Y. F. (2003). Significance of inflammatory cytokines in the 
progression of colorectal cancer. Hepato-gastroenterology, 50, 1910-1913.  
 
Cimprich, B. (1998). Age and extent of surgery affect attention in women treated for 
breast cancer.  Research in Nursing & Health, 21, 229-238.  
 
Cimprich, B. (1999). Pretreatment symptom distress in women newly diagnosed with 
breast cancer.  Cancer Nursing, 22, 185-194.  
 
 147 
Cimprich, B., & Ronis, D. L. (2001). Attention and symptom distress in women with and 
without breast cancer. Nursing Research, 50, 86-94.  
 
Cimprich, B., So, H., Ronis, D. L., & Trask, C. (2005). Pre-treatment factors related to 
cognitive functioning in women newly diagnosed with breast cancer. Psycho-
oncology, 14, 70-78. doi: 10.1002/pon.821 
 
Cimprich, B., Visovatti, M., & Ronis, D. L. (2011). The Attentional Function Index--a 
self-report cognitive measure.  Psycho-oncology, 20, 194-202.  
doi: 10.1002/pon.1729 
 
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. 
A., . . . Lee, B. N. (2003). Are the symptoms of cancer and cancer treatment due 
to a shared biologic mechanism? A cytokine-immunologic model of cancer 
symptoms. Cancer, 97, 2919-2925. doi: 10.1002/cncr.11382 
 
Cornish, I. M. (2000). Factor structure of the everyday memory questionnaire. British 
Journal of Psychology, 91, 427-438.  
 
Dantzer, R., & Kelley, K. W.  (2007).  Twenty years of research on cytokine-induced 
sickness behavior.  Brain, Behavior, and Immunity, 21, 153 - 160. 
 
Denicoff, K. D., Rubinow, D. R., Papa, M. Z., Simpson, C., Seipp, C. A., Lotze, M. T., . . 
. Rosenberg, S. A. (1987). The neuropsychiatric effects of treatment with 
interleukin-2 and lymphokine-activated killer cells. Annals of Internal Medicine, 
107, 293-300.  
 
Fan, J., McCandliss, B. D., Sommer, T., Raz, A., & Posner, M. I. (2002). Testing the 
efficiency and independence of attentional networks.  Journal of Cognitive 
Neuroscience, 14, 340-347. doi: 10.1162/089892902317361886 
 
Folstein, M. F., Folstein, S. E., Fanjiang, G. (2000). Mini-Mental State Examination 
Clinical Guide. Lutz, FL: Psychological Assessment Resources, Inc. 
 
Gabay, C., & Kushner, I.  (1999).  Acute phase proteins and other systemic response to 
inflammation.  The New England Journal of Medicine, 340, 448 - 454. 
 
Galizia, G., Orditura, M., Romano, C., Lieto, E., Castellano, P., Pelosio, L., . . . De Vita, 
F. (2002). Prognostic significance of circulating IL-10 and IL-6 serum levels in 
colon cancer patients undergoing surgery. Clinical Immunology, 102, 169-178. 
doi: 10.1006/clim.2001.5163 
 
Goshen, I., & Yirmiya, R.  (2007).  The role of pro-inflammatory cytokines in memory 
processes and neural plasticity. In R. Ader (Ed),  Psychoneuroimmunology (pp 
337 -378).  Burlington, MA:  Elsevier Academic Press. 
 
 148 
Hart, B. L. (1988). Biological basis of the behavior of sick animals.  Neuroscience and 
Biobehavioral Reviews, 12, 123-137.  
 
Hermelink, K., Untch, M., Lux, M. P., Kreienberg, R., Beck, T., Bauerfeind, I., & 
Munzel, K. (2007). Cognitive function during neoadjuvant chemotherapy for 
breast cancer: results of a prospective, multicenter, longitudinal study.  Cancer, 
109, 1905-1913. doi: 10.1002/cncr.22610 
 
Kirkwood, J. M., Ernstoff, M. S., Davis, C. A., Reiss, M., Ferraresi, R., & Rudnick, S. A. 
(1985). Comparison of intramuscular and intravenous recombinant alpha-2 
interferon in melanoma and other cancers.  Annals of Internal Medicine, 103, 32-
36.  
 
Konsman, J. P., Parnet, P., & Dantzer, R.  (2002).  Cytokine-induced sickness behaviour 
mechanisms and implications.  Trends in Neuroscience, 25, 154-159. 
 
Krabbe, K. S., Reichenberg, A., Yirmiya, R., Smed, A., Pedersen, B. K., & Bruunsgaard, 
H. (2005). Low-dose endotoxemia and human neuropsychological functions. 
Brain, Behavior, and Immunity, 19, 453-460. doi: 10.1016/j.bbi.2005.04.010 
 
Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., . . . 
Cleeland, C. S. (2004). A cytokine-based neuroimmunologic mechanism of 
cancer-related symptoms.  Neuroimmunomodulation, 11, 279-292.  
doi: 10.1159/000079408 
 
Lezak, Muriel Deutsch. (2004). Neuropsychological Assessment (4th ed.). Oxford ; New 
York: Oxford University Press. 
 
Liu, L., Mills, P. J., Rissling, M., Fiorentino, L., Natarajan, L., Dimsdale, J. E., …Ancoli-
Israel, S.  (2012).  Fatigue and sleep quality are associated with changes in 
inflammatory markes in breast cancer patients undergoing chemotherapy.  Brain, 
Behavior, & Immunity, 26, 706-713.   
 
Mahoney, J. R., Verghese, J., Goldin, Y., Lipton, R., & Holtzer, R. (2010). Alerting, 
orienting, and executive attention in older adults.  Journal of the International 
Neuropsychological Society  16, 877-889. doi: 10.1017/S1355617710000767 
 
Mant, M., Song, C., Lin, A., De Jongh, R., Van Gastel, A., Kenis, G., …Smith, R. S.  
(1998).  The effects of psychological stress on humans:  increased production of 
pro-inflammatory cytokines and a Th-1like response in stress-induced anxiety, 
Cytokine, 10, 313-318. 
 
Mantovani, M., Maccio, A., Lai, P., Massa, E., Ghiani, M., & Santona, M. C.  (1998).  
Cytokine involvement in cancer anorexia/cachexia:  Role of megestrol acetate and 
medroxyprogesterone acetate on cytokine downregulation and improvement of 
clinical symptoms.  Critical Reviews in Oncogenesis, 9, 99 - 106. 
 149 
 
Merriman, J. D., Jansen, C., Koetters, T., West, C., Dodd, M., Lee, K., . . . Miaskowski, 
C. (2010). Predictors of the trajectories of self-reported attentional fatigue in 
women with breast cancer undergoing radiation therapy. Oncology Nursing 
Forum, 37, 423-432. doi: 10.1188/10.ONF.423-432 
 
Meyers, C. A., Albitar, M., & Estey, E. (2005). Cognitive impairment, fatigue, and 
cytokine levels in patients with acute myelogenous leukemia or myelodysplastic 
syndrome. Cancer, 104, 788-793. doi: 10.1002/cncr.21234 
 
Meyers, C. A., Byrne, K. S., & Komaki, R. (1995). Cognitive deficits in patients with 
small cell lung cancer before and after chemotherapy. Lung Cancer, 12, 231-235.  
 
Musselman, D. L., Miller, A. H., Porter, M. R., Manatunga, A., Gao, F., Penna, S., . . . 
Nemeroff, C. B. (2001). Higher than normal plasma interleukin-6 concentrations 
in cancer patients with depression: preliminary findings.  The American Journal 
of Psychiatry, 158, 1252-1257.  
 
Narai, S., Watanabe, M., Hasegawa, H., Nishibori, H., Endo, T., Kubota, T., & Kitajima, 
M. (2002). Significance of transforming growth factor beta1 as a new tumor 
marker for colorectal cancer. International Journal of Cancer, 97, 508-511.  
 
Nethersell, A., Smedley, H., Katrak, M., Wheeler, T., & Sikora, K. (1984). Recombinant 
interferon in advanced breast cancer. British Journal of Cancer, 49, 615-620.  
 
O'Connor, M. F., Bower, J. E., Cho, H. J., Creswell, J. D., Dimitrov, S., Hamby, M. E., . . 
. Irwin, M. R. (2009). To assess, to control, to exclude: effects of biobehavioral 
factors on circulating inflammatory markers. Brain, Behavior, and Immunity, 23, 
887-897. doi: 10.1016/j.bbi.2009.04.005 
 
Orre, I. J., Murison, R., Dahl, A. A., Ueland, T., Aukrust, P., & Fossa, S. D. (2009). 
Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in 
long-term survivors of testicular cancer with chronic cancer-related fatigue. 
Brain, Behavior, and Immunity, 23, 868-874. doi: 10.1016/j.bbi.2009.04.003 
 
Patti, R., Saitta, M., Cusumano, G., Termine, G., & Di Vita, G. (2011). Risk factors for 
postoperative delirium after colorectal surgery for carcinoma. European Journal 
of Oncology Nursing, 15, 519-523. doi: 10.1016/j.ejon.2011.01.004 
 
Reitan, R. M. (1979). Trail Making Test Manual for Administration and Scoring. Tucson, 
Az: Reitan Neuropsychology Laboratory. 
 
Rich, T., Innominato, P. F., Boerner, J., Mormont, M. C., Iacobelli, S., Baron, B., . . . 
Levi, F. (2005). Elevated serum cytokines correlated with altered behavior, serum 
cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with 




Scheibel, R. S., Valentine, A. D., O'Brien, S., & Meyers, C. A. (2004). Cognitive 
dysfunction and depression during treatment with interferon-alpha and 
chemotherapy. The Journal of Neuropsychiatry and Clinical Neurosciences, 16, 
185-191. doi: 10.1176/appi.neuropsych.16.2.185 
 
Schilder, C. M., Seynaeve, C., Linn, S. C., Boogerd, W., Beex, L. V., Gundy, C. M., . . . 
Schagen, S. B. (2010). Cognitive functioning of postmenopausal breast cancer 
patients before adjuvant systemic therapy, and its association with medical and 
psychological factors. Critical Reviews in Oncology/Hematology, 76, 133-141. 
doi: 10.1016/j.critrevonc.2009.11.001 
 
Schmidt, M. (1996). Rey Auditory Verbal Learning Test.  A Handbook. Torrance, CA: 
Western Psychological Services. 
 
Shim, K. S., Kim, K. H., Han, W. S., & Park, E. B. (1999). Elevated serum levels of 
transforming growth factor-beta1 in patients with colorectal carcinoma: its 
association with tumor progression and its significant decrease after curative 
surgical resection. Cancer, 85, 554-561.  
 
Skaali, T., Fossa, S. D., & Dahl, A. A. (2011). A prospective study of cognitive 
complaints in patients with testicular cancer. Clinical Genitourinary Cancer, 9, 6-
13. doi: 10.1016/j.clgc.2011.04.002 
 
Small, B. J., Rawson, K. S., Walsh, E., Jim, H. S., Hughes, T. F., Iser, L., . . . Jacobsen, 
P. B. (2011). Catechol-O-methyltransferase genotype modulates cancer treatment-
related cognitive deficits in breast cancer survivors. Cancer, 117, 1369-1376.  
doi: 10.1002/cncr.25685 
 
Sunderland, A., Watts, K., Baddeley, A. D., & Harris, J. E. (1986). Subjective memory 
assessment and test performance in elderly adults. Journal of Gerontology, 41, 
376-384.  
 
Tulman, L., Fawcett, J., & McEvoy, M. D. (1991). Development of the inventory of 
functional status-cancer. Cancer Nursing, 14, 254-260.  
 
Vardy, J. L., Rourke, S, Pond, G. R., Galica, J., Park, A., Dhillon, H., Clarke, S. J., & 
Tannock, I. F. (2007). Cognitive function and fatigue in cancer patients after 
chemotherapy:  A longitudinal cohort study in patients with colorectal cancer 
[Abstract]. Journal of Clinical Oncology, 25, 18S.  
 
Vearncombe, K. J., Rolfe, M., Wright, M., Pachana, N. A., Andrew, B., & Beadle, G. 
(2009). Predictors of cognitive decline after chemotherpy in breast cancer 
patients.  Journal of the International Neuropsychological Society, 15, 951 -962. 
doi:  10.1017/S1355617709990567 
 151 
 
Visovatti, M., Cimprich, B., & Metzger, B. . (2009). A biobehavioral model of illness and 
immune response in women with breast cancer [Abstract]. Oncology Nursing 
Forum, 36, 49.  
 
Vollmer-Conna, U., Fazou, C., Cameron, B., Li, H., Brennan, C., Luck, L., . . . Lloyd, A. 
(2004). Production of pro-inflammatory cytokines correlates with the symptoms 
of acute sickness behaviour in humans. Psychological Medicine, 34, 1289-1297.  
 
Walker, L. G., Walker, M. B., Heys, S. D., Lolley, J., Wesnes, K., & Eremin, O. (1997). 
The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical 
trial. Psycho-oncology, 6, 290-301.  
doi: 10.1002/(SICI)1099-1611(199712)6:4<290::AID-PON283>3.0.CO;2-G 
 
Walker, L. G., Wesnes, K. P., Heys, S. D., Walker, M. B., Lolley, J., & Eremin, O. 
(1996). The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a 
controlled clinical trial using computerised assessments.  European Journal of 
Cancer, 32A, 2275-2283.  
 
Wang, X. S., Shi, Q., Williams, L. A., Mao, L., Cleeland, C. S., Komaki, R. R., . . . Liao, 
Z. (2010). Inflammatory cytokines are associated with the development of 
symptom burden in patients with NSCLC undergoing concurrent chemoradiation 
therapy.  Brain, Behavior, and Immunity, 24, 968-974. 
 doi: 10.1016/j.bbi.2010.03.009 
 
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International Cognition and 
Cancer Task Force recommendations to harmonise studies of cognitive function 
in patients with cancer. The Lancet Oncology, 12, 703-708. 
 doi: 10.1016/S1470-2045(10)70294-1 
 
Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C. S., O'brien, P. C., & 
Denham J. W.  (2004).  Fatigue during breast radiotherapy and its relationship to 
biological factors.  International Journal of Radiation Oncology, Biology, and 





Sample Characteristics (N = 100) 
 % 
Demographic characteristics 
Age, years 36-79, mean 56, standard deviation 10  
Education, years 9-22, mean 16, standard deviation 3  
Gender Female 49 
 Male 51 
Marital status Single 26 
 Married/Partner 74 
Racea White  80 
 Non-white 14 
Employed outside home  Yes 59 
Medical characteristics 
Body mass index, kg/m2 17-57, mean 28, standard deviation 7  
Colorectal cancer Yes 50  
Other health problemsb Yes 81 
Taking medication that affects cognitive functionc Yes 38 
Taking Medication that affects immune functiond Yes 68 
Current Tobacco Use Yes 12 
aThree participants declined to answer.  bOther health problems include: benign skin lesions, cardiovascular disease(Hypertension, hyperlipidemia), endocrine 
disease (diabetes mellitus, hypothyroidism), gastrointestinal disease (GERD, diverticulosis, hemorrhoids), immune disorders (allergies, arthritis), musculoskeletal 
disease (lower back pain, osteoporosis), pulmonary disease (COPD, Sleep Apnea), renal disease (nephrolithiasis) and mood disorders (depression, anxiety).  
cMedications that could affect cognitive function included:  antianxiety, antidepressants, narcotics, and medications for insomnia.  dMedications that could affect 
immune function included:  allergy medications, aspirin and other NSAIDs, statins, ophthalmic cyclosporine, inhaled corticosteroids, prednisone, antibiotics, 









Means and Standard Deviations of Physical and Psychological Symptoms (N = 100) 
 Mean + SD Range 
Profile of Mood States: Brief Forma 
     Total Mood Disturbance  6.72 + 14.78  -19 - 51 
     Anxiety  3.67 + 2.87 0 - 14 
     Depression  2.45 + 2.88 0 - 14 
     Anger  2.68 + 2.86 0 - 17 
     Vigor  10.57  + 4.90  0 -20 
     Fatigue  4.89 + 3.70  1 - 17 
     Confusion  3.60 + 2.55 0 - 13 
Inventory of Functional Status: Cancerb 
     Exercise as Much as Usual 2.78 + 1.21 1 - 4 
aTotal Mood Disturbance Scale computed by summing the anxiety, depressed mood, anger, confusion and fatigue subscales and 
subtracting the vigor subscale.  Total range of scores for the Total Mood Disturbance Scale is between – 20 and 100.  Total range of 


















Pearson Correlation Coefficients Between Cognitive Function Variables and Inflammatory Cytokines and Biomarkers (N = 100) 
Variablesa 1 2 3 4 5 6 7 8 9 10 11 12 
1. TNF-α 
 
- - - - - - - - - - -  
2. IL-6 
 
0.46* - - - - - - - - - -  
3. CRP 
 
- 0.08 - 0.30* - - - - - - - - -  
4. IL-10 
 
0.37* 0.56* 0.14 - - - - - - - -  
5. TGF -β1 
 
0.00 - 0.04 0.13 - 0.05 - - - - - - -  
6. TNF-α/IL-10  
 
0.35* - 0.04 - 0.21* - 0.59* 0.03 - - - - - -  
7. IL-10/TNF-α 
 
- 0.49* 0.12 0.15 0.51* - 0.05 - 0.77* - - - - -  
8. ANT Error rate  
 
0.08 - 0.12 - 0.11 - 0.14 - 0.03 0.13 - 0.16 - - - -  
9. ANT Reaction Time  
 
- 0.07 0.19 0.19 0.06 - 0.13 - 0.08 0.04 - 0.23* - - -  
10. Standardized Total 
      Composite Score  
- 0.10 - 0.29* - 0.37* - 0.18 - 0.04 0.11 - 0.04 0.25* - 0.34* - -  
11. Attentional Function Index 
 
- 0.05 - 0.14 - 0.29* - 0.14 0.30* 0.07 - 0.07 0.01 - 0.10 0.13 -  
12. RAVLT delayed recall  
 
- 0.20* - 0.28* - 0.09 - 0.11 0.00 - 0.09 0.08 0.19 - 0.14 0.33* 0.01 - 
13. EMQ 
 
0.01 0.08 - 0.09 0.15 - 0.15 - 0.04 0.10 0.02 0.00 0.07 - 0.43* - 0.03 
Note.  ANT = Attention Network Test; Standardized Total Composite Score = zDSF + zDSB – zTMTa – zTMTb; RAVLT delayed recall = Rey Auditory Verbal 
Learning Test 30 minute delayed recall condition; EMQ = Everyday Memory Questionnaire. 
aNumbers in Columns correspond to numbers in top row 






Pearson Correlation Coefficients Between Cognitive Function Variables and Potential Cognitive Function Modifiers (N = 100) 
Variables a 1 2 3 4 5 6 7 8 9 10 11 12 13 14 
1. Age - - - - - - - - - - - - - - 
2. Education -0.02 - - - - - - - - - - - - - 
3. Genderb  -0.18 -0.12 - - - - - - - - - - - - 
4. Medication:  CFc 0.06 -0.12 0.27* - - - - - - - - - - - 
5.  Colorectal Cancerd 0.16 0.13 -0.02 -0.29* - - - - - - - - - - 
6.  Other Health Problemse 0.26* 0.06 0.04 0.12 0.18 - - - - - - - - - 
7. Anxiety -0.26* -0.18 0.03 0.00 -0.38* -0.06 - - - - - - - - 
8. Depressed Mood -0.15 -0.21 * -0.03 0.04 -0.19 -0.10 0.60* - - - - - - - 
9. Fatigue -0.12 -0.12 0.09 0.14 -0.36* -0.02 0.53* 0.56* - - - - - - 
10. ANT Accuracy  -0.09 -0.06 -0.06 -0.11 0.15 -0.02 -0.10 -0.11 0.06 - - - - - 
11. ANT Reaction Time 0.45* -0.20 0.04 0.25* -0.19 0.07 0.03 -0.01 0.02 -0.23* - - - - 
12 Standardized Total  
     Composite Score 
-0.25* -0.38* 0.07 -0.08 0.20* -0.03 -0.08 -0.21* -0.09 -0.25* -0.34* - - - 
13. AFI 0.07 0.22* -0.17 -0.21* 0.32* 0.03 -0.37* -0.35* -0.57* 0.01 -0.10 0.13 - - 
14. RAVLT delayed recall -0.39* 0.21* 0.31* -0.14 -0.02 -0.09 0.14 0.08 0.14 0.19 -0.14 0.33 0.01 - 
15. EMQ -0.13 -0.02 0.10 0.15 -0.10 0.24* 0.23* 0.12 0.19 0.02 0.00 0.07 - 0.43* -0.03 
Note. Med: CF = taking medication that may affect cognitive function; ANT = Attention Network Test; Total Composite Score = Standardized Total composite 
Score = zDSF + zDSB – TMTa –zTMTb; AFI = Attentional Function Index; RAVLT delayed recall condition = Rey Auditory Verbal Learning Test 30 minute 
delayed recall condition; EMQ = Everyday Memory Questionnaire. 
a Numbers in Columns correspond to numbers in top row.  b Gender: 1 = male, 2 = female.  c Medication:  CF:  0 = no, 1 = yes.  d Colorectal cancer: 1 = yes, 2 = 
no.  e Other health Problems: 0 = no, 1 = yes. 






Pearson Correlation Coefficients Between Serum Levels of Inflammatory Cytokines and Biomarkers and Potential Immune Function Modifiers 
Variablea 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
1. Age - - - - - - - - - - - - - - - - 
2. Education -0.02 - - - - - - - - - - - - - - - 
3. BMI  -0.03 -0.06 - - - - - - - - - - - - - - 
4. Med:  CFb 0.06 -0.12 0.05 - - - - - - - - - - - - - 
5. Med:  IFc  0.15 0.01 -0.02 0.14 - - - - - - - - - - - - 
6. CRCd 0.16 0.13 0.05 -0.29* -0.09 - - - - - - - - - - - 
7. Tobaccoe 0.01 -0.13 -0.03 0.03 -0.08 0.06 - - - - - - - - - - 
8. Anxiety -0.26* -0.18 0.09 0.00 -0.02 -0.38* 0.22* - - - - - - - - - 
9. Depressed -0.15 -0.21* 0.14 0.04 -0.05 0.19 0.03 -0.60* - - - - - - - - 
10. Exercise 0.12 0.22* -0.06 -0.35* -0.08 0.52 0.04 -0.37* -0.33* - - - - - - - 
11.  TNF-α 0.04 -0.13 0.12 0.10 0.05 -0.02 -0.02 0.22* 0.02 -0.26* - - - - - - 
12. IL-6 0.06 -0.21* 0.00 0.12 0.07 -0.22* 0.13 0.11 -0.03 -0.38* 0.49* - - - - - 
13. CRP 0.06 -0.21* 0.18 0.33* 0.14 -0.40* 0.05 0.15 0.18 -0.43* -0.08 0.30* - - - - 
14. IL-10 -0.09 -0.06 0.11 0.13 0.01 -0.23* -0.07 0.16 0.13 -0.33* 0.37* 0.56* 0.14 - - - 
15. TGF -β -0.12 0.04 -0.03 - 0.17 -0.08 -0.27* 0.12 0.04 0.13 0.08 -0.00 -0.04 0.13 -0.05 - - 
16.Pro-ratio  -0.12 -0.09 -0.01 - 0.16 -0.04 -0.26* 0.11 0.01 -0.09 0.10 -0.35* - .04 -0.21* -0.60* 0.03 - 
17. Anti-ratio -0.19 0.15 -0.04 0.17 -0.03 -0.20* -0.05 - 0.04 0.04 - 0.05 -0.49* 0.12 0.15 -0.51* -0.05 -0.77* 
Note.  BMI = body mass index; Med:  CF = taking medication that can affect cognitive function; Med:  IF = taking medication that can affect immune function; 
CRC = colorectal cancer, Tobacco = current tobacco use, Pro-ratio = TNF-α/IL-10; Anti-ratio = IL-10/TNF-α. 
a Numbers in columns correspond to numbers in top row.  b Med:  CF, 0 = no, 1 = yes.  c Med:  IF, 0 = no, 1 = yes.  dCRC, 1 = yes, 2 = no. e Tobacco, 0 = no, 1 = 
yes. 





Predictors of Standardized Total Composite Score with IL-6 (N = 100) 
Variable B SE B β p 
IL-6 - 0.40 0.27 0.15 0.14 
Age - 0.08 0.02 - 0.29 < 0.01 
Education 0.27 0.09 0.29 < 0.01 
Medication:  CF 0.36 0.50 0.07 0.47 
Depressed Mood - 0.15 0.09 - 0.17 0.09 
Exercise as Usual 0.16 0.27 0.07 0.54 
Colorectal Cancer 0.57 0.53 0.11 0.28 







Predictors of Standardized Total Composite Score with CRP (N = 100) 
Variable B SE B β p 
CRP - 0.63 0.28 - 0.23 0.03 
Age - 0.08 0.02 - 0.29 < 0.01 
Education 0.27 0.08 0.29 < 0.01 
Medication:  CF 0.59 0.50 0.11 0.24 
Depressed Mood - 0.11 0.08 - 0.13 0.19 
Exercise As Usual 0.19 0.25 0.08 0.46 
Colorectal Cancer 0.34 0.53 0.07 0.52 





Predictors of Standardized Total Composite Score with IL-6 and CRP (N = 100) 
Variable B SE B β p 
IL-6 - 0.33 0.27 - 0.12 0.22 
CRP - 0.58 0.28 - 0.21 < 0.05 
Age - 0.07 0.02 - 0.27 < 0.01 
Education 0.26 0.09 0.27 < 0.01 
Medication:  CF 0.54 0.50 0.10 0.28 
Depressed Mood - 0.13 0.08 - 0.15 0.12 
Exercise as Usual 0.08 0.27 0.04 0.76 
Colorectal Cancer 0.34 0.53 0.07 0.53 








Predictors of Attentional Function Index with CRP (N = 100) 
Variable B SE B β p 
CRP - 0.14 0.17 - 0.08 0.41 
Education 0.07 0.05 0.11 0.21 
Medication:  CF - 0.25 0.31 - 0.08 0.42 
Anxiety - 0.04 0.06 - 0.08 0.51 
Depressed mood 0.01 0.06 0.02 0.88 
Fatigue - 0.20 0.05 - 0.45 < 0.01 
Exercise as Usual 0.12 0.16 0.08 0.48 
Colorectal Cancer 0.08 0.34 0.02 0.82 
R = 0.62, R2 = 0.38, F = 6.90, p < 0.001. 
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Table 4.10 
Predictors of Attentional Function Index with TGF-β1 (N = 100) 
Variable B SE B β p 
TGF-β1 1.62 0.46 0.29 < 0.01 
Education 0.06 0.05 0.11 0.19 
Medication:  CF - 0.19 0.29 - 0.06 0.51 
Anxiety - 0.05 0.06 - 0.09 0.41 
Depressed mood - 0.02 0.06 - 0.04 0.73 
Fatigue - 0.19 0.05 - 0.43 < 0.01 
Exercise as Usual 0.18 0.15 0.12 0.25 
Colorectal Cancer - 0.16 0.32 - 0..05 0.62 








Predictors of Attentional Function Index with CRP and TGF-β1 (N = 100) 
Variable B SE B β p 
CRP - 0.36 0.16 - 0.20 0.03 
TGF-β1 1.94 0.47 0.35 < 0.01 
Medication:  CF - 0.08 0.29 - 0.02 0.78 
Anxiety - 0.07 0.06 - 0.12 0.26 
Depressed mood - 0.02 0.06 - 0.04 0.68 
Fatigue - 0.18 0.05 - 0.42 < 0.01 
Exercise as Usual 0.13 0.15 0.09 0.37 
Colorectal Cancer -0.37 0.33 - 0.12 0.26 
R = 0.69, R2 = 0.47, F = 9.91, p < 0.01. 
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Table 4.12 
Predictors of RAVLT delayed recall with TNF-α (N = 99) 
Variable B SE B β p 
TNF-α - 0.97 0.51 - 0.18 0.06 
Age - 0.09 0.03 - 0.28 < 0.01 
Education 0.25 0.10 0.22 0.02 
Gender 2.02 0.58 0.32 < 0.01 
Medication:  CF - 1.21 0.64 - 0.19 0.06 
Anxiety 0.16 0.11 0.15 0.14 
Exercise as Usual 0.22 0.32 0.08 0.49 
Colorectal Cancer - 0.34 0.68 - 0.05 0.62 








Predictors of RAVLT delayed recall with IL-6 (N = 99) 
Variable B SE B β p 
IL-6 - 0.67 0.32 - 0.20 0.04 
Age - 0.09 0.03 - 0.28 < 0.01 
Education 0.24 0.10 0.21 0.02 
Gender 2.03 0.58 0.33 < 0.01 
Medication-CF - 1.06 0.63 - 0.16 0.10 
Anxiety 0.12 0.11 0.11 0.28 
Exercise as Usual 0.17 0.33 0.06 0.61 
Colorectal Cancer - 0.54 0.67 - 0.09 0.42 




Predictors of RAVLT delayed recall with TNF-α and IL-6 (N = 99) 
Variable B SE B β p 
TNF-α - 0.47 0.56 - 0.09 0.41 
IL-6 - 0.55 0.36 - 0.16 0.13 
Age - 0.10 0.03 - 0.27 < 0.01 
Education 0.22 0.10 0.19 0.04 
Gender 1.98 0.58 0.32 < 0.01 
Medication-CF - 1.26 0.63 - 0.20 0.05 
Exercise as Usual 0.04 0.32 0.01 0.91 
Colorectal Cancer - 0.64 0.66 - 0.10 0.33 







 Individuals with cancer can experience cognitive symptoms at diagnosis, during 
primary and adjuvant therapy, and up to 20 years after treatment for the disease 
(Cimprich, 1998; Cimprich & Ronis, 2001; Koppelmans et al., 2012; Wefel, Vardy, 
Ahles, & Schagen, 2011).  Few research studies have examined cognitive symptoms in 
individuals with colorectal cancer and little is known about mechanisms that may 
underlie cognitive symptoms in cancer survivors.  One potential mechanism is the 
immune system’s response to the cancer and cancer treatments (Cleeland et al., 2003; 
Hart, 1988; Kent, Bluthe, Kelley, & Dantzer, 1992).  Specifically, inflammatory 
cytokines produced in response to an immune challenge can communicate with the brain 
to induce symptoms and behaviors or ‘sickness behavior’ that generally support the 
immune system’s response and the survival of the individual (Konsman, Parnet, & 
Dantzer, 2002).  Sickness behavior responses include fatigue, malaise, anorexia, 
hyperalgesia, decreased physical and social activity and changes in sleep pattern and 
architecture (Cleeland et al., 2003; Hart, 1988; Kent, Bluthe, Kelley, & Dantzer, 1992; 
Watkins & Maier, 2000).  These sickness behavior responses appear to occur alongside 
cognitive changes (Cleeland et al., 2003).  Thus, this study hypothesized that cognitive 
symptoms reported by colorectal cancer survivors may be a part of the immune system’s 
response to the colorectal cancer and associated treatments.  The goal of this dissertation 
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study was to describe cognitive and immune function in individuals with colorectal 
cancer and to begin to characterize the relationship between cognitive symptoms and 
inflammatory cytokine and biomarker expression.  The study used a cross-sectional 
comparative design and included individuals newly diagnosed with primary or recurrent 
colorectal cancer and healthy individuals without colorectal cancer.  The following 
section will review findings, discuss limitations, make recommendations for future 
research, and discuss implications for future nursing practice. 
Improving Colorectal Cancer Survivorship 
Cognitive Symptoms in Colorectal Cancer 
When assessing cognitive function in colorectal cancer survivors, this study found 
that patients with colorectal cancer performed and perceived their function to be 
significantly worse on tasks requiring directed attention and working memory but not 
long-term memory when compared to individuals without colorectal cancer.  It is not 
clear why individuals with colorectal cancer did not have deficits in long-term memory 
given findings from preclinical studies suggesting that inflammatory cytokine expression 
can impair hippocampal dependent memory processes.   
Further analyses found that after controlling for covariates, having colorectal 
cancer remained an independent predictor of worse performance on objective measures 
of directed attention and working memory.  Additionally, fatigue was found to be an 
independent predictor of performance on a self-report measure of directed attention and 
working memory after controlling for covariates.  These findings are important because 
they are the first to identify deficits in a specific cognitive domain in individuals with 
colorectal cancer. Directed attention and working memory are cognitive processes that 
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allow an individual to focus on important information in the environment and to hold and 
manipulate information so that higher cognitive activities can be achieved. As such, they 
are critical to learning, reasoning, and problem solving.  Problems with directed attention 
and working memory can make it difficult for an individual newly diagnosed with cancer 
to make treatment decisions, manage work demands and family needs, and cope with the 
illness.  The finding that fatigue severity predicted worse perceived effectiveness on 
common tasks that require directed attention and working memory was an unexpected 
finding that may provide a window into potential mechanisms that underlie cognitive 
symptoms in colorectal cancer survivors.  Specifically, multiple factors may influence the 
expression of cognitive symptoms and some of these factors may share a common 
biological mechanism while other factors may be associated with different mechanisms 
and make unique contributions.  Understanding the mechanisms associated with 
cognitive symptoms is important for colorectal cancer survivorship as it will allow for the 
application and/or development of targeted interventions to support attention and memory 
function, reduce distress and improve quality of life.   
Inflammatory Cytokines and Biomarkers Expression in Colorectal Cancer 
 When assessing immune function in colorectal cancer, this study found that 
patients with colorectal cancer had significantly higher serum levels of IL-6, CRP and IL-
10 and significantly lower serum levels of TGF-β1 compared to individuals without 
colorectal cancer.  However, after controlling for covariates, having colorectal cancer was 
an independent predictor of higher serum levels of TNF-α and CRP.  Interestingly, 
indirect makers of TNF-α activity and CRP also have been associated with sickness 
behaviors such as fatigue in individuals with cancer (Bower, et al., 2002; Bower et al., 
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2011; Bower, et al., 2009; Orre, et al., 2009; Wang, et al., 2010; Wang, et al., 2012; 
Wratten, et al., 2004).  These findings are important because few studies examining 
immune function in colorectal cancer have controlled for biobehavioral factors that may 
affect inflammatory cytokine and biomarker expression making it difficult to interpret 
results.  In this regard, findings from this study that controlled for biobehavioral factors 
provide preliminary evidence that TNF-α and CRP are associated with a systemic 
inflammatory response or an acute phase response in individuals with colorectal cancer.  
These findings also suggest that TNF-α and CRP may be sensitive biomarkers of 
sickness behavior including cognitive symptoms in individuals with colorectal cancer.  
As such, they are very important and foundational to understanding immune mediated 
responses in individuals with colorectal cancer. 
Cognitive Symptoms and Inflammatory Cytokines and Biomarkers in Colorectal 
Cancer 
  Cognitive and immune function was assessed in the combined group of 
individuals with and without cancer to ensure sufficient variance on cognitive and 
immune variables.  When assessing the relationship between cognitive symptoms and the 
expression of inflammatory cytokines and biomarkers, this study found that serum levels 
of TNF-α, IL-6, CRP, and TGF-β1 were associated with performance on cognitive 
measures and/or perceptions of cognitive function on self-report measures.  Further, the 
study found that 1) higher levels of CRP specifically predicted poorer performance on 
tasks requiring directed attention and working memory and 2) higher serum levels of 
CRP and lower serum levels of TGF-β1 predicted poorer self-report of directed attention 
and working memory function.  This study is the first to report a relationship between 
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higher circulating levels of CRP and specific cognitive domain – namely directed 
attention and working memory.  CRP is an indirect marker of pro-inflammatory activity 
and findings suggest that cognitive symptoms may be associated with the systemic 
inflammatory response and immune-mediated symptoms and behaviors.  This study is 
also the first to report a relationship between lower circulating levels of TGF-β1 and 
poorer perceived effectiveness on tasks requiring directed attention and working memory.  
Interestingly, preclinical studies suggest that TGF-β1 may be necessary for regulation of 
the inflammatory response, neuroplasticity and neurogenesis (Ariel & Timor, 2012).  As 
such, this finding may suggest that this immunosuppressive cytokine has a 
neuroprotective role.  Finally findings from this study may suggest that different 
cytokines may be associated with different cognitive symptoms or losses.  Together these 
findings raise important questions about the relationship between cognitive symptoms 
and inflammatory cytokine expression and provide a direction for future research. 
Limitations 
This study has certain limitations that need to be considered when interpreting 
results.  First, the study used a convenience sample.  As such, patients who enrolled in 
this study may have differed in an important way from patients who declined to 
participate.  Of the 30% who declined to participate, the main reasons for refusal was 
feeling overwhelmed.  Given that psychological distress can affect both cognitive 
function and the expression of inflammatory cytokines and biomarkers, individuals who 
declined to participate may have been more likely to experience cognitive symptoms as 
well as have higher levels of inflammatory cytokines and biomarkers.  Therefore, 
findings from this study may have been conservative and not fully captured the 
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differences in cognitive and immune variables between individuals with and without 
cancer. 
Second, this study used a cross-sectional design and collected data at one time 
point within six months of a new diagnosis of primary or recurrent cancer.  Most patients 
were assessed after colonoscopy and before any treatment, some individuals were 
assessed after surgery only, and the rest were receiving chemotherapy and/or radiation 
therapy at the time of the research visit.  Findings indicate that individuals with colorectal 
cancer were impaired on measures of directed attention and working memory and had 
higher serum levels of inflammatory cytokines and biomarkers.  However, it is unclear 
whether the expression of cognitive symptoms or inflammatory cytokines and biomarkers 
may be associated with the cancer and cancer diagnosis or the cancer treatments or some 
combination of both. 
The study results were limited by sample size.  Although, this study had sufficient 
power to detect medium effects in group differences on most cognitive and immune 
measures, a larger sample would have been required to detect differences in two 
inflammatory cytokines and biomarkers that had lower levels of detection.  Specifically, 
IL-1β was detected in 26% of individuals with colorectal cancer and 20% of individuals 
without colorectal cancer.  IL-1RA was detected in 50% of individuals with colorectal 
cancer and 40% of individuals without colorectal cancer.   
Finally, this study included individuals with varying stages of cancer but  did not 
permit analyses of differences by stage of disease.  A larger sample size of individuals 
with colorectal cancer would have allowed for the analyses and possible detection of 
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cognitive and immune differences amongst individuals with varying stages of colorectal 
cancer. 
Recommendations for Future Research 
There are multiple recommendations for future research.  First, there is a need to 
continue to describe cognitive symptoms in individuals with colorectal cancer using 
neuroscience theory to guide the assessment.  This study found alterations in directed 
attention and working memory but not long-term memory.  These are novel findings that 
need to be confirmed in a larger sample using a combination of domain specific 
neuropsychological measures that take into consideration gender differences. 
Second, this study assessed inflammatory cytokine and biomarker expression as a 
first step toward examining the relationship between cognitive and immune function in 
individuals with colorectal cancer.  The study found that TNF-α and CRP were over 
expressed in individuals with colorectal cancer compared to healthy controls after 
controlling for biobehavioral factors that may affect the immune variables.  Few studies 
in colorectal cancer have assessed inflammatory cytokines and biomarkers while 
controlling for possible covariates making it difficult to interpret findings.  As such, 
future research is needed to confirm findings and clarify patterns of inflammatory 
cytokine and biomarker expression in individuals with colorectal cancer. 
Third, this study found a relationship between CRP and TGF-β and a specific 
domain of cognitive function, namely direction attention and working memory function. 
Further, this study found that higher levels of TGF-β were associated with better 
cognitive function suggesting that some inflammatory cytokines may support attention 
and memory function.  These novel findings need to be confirmed.  Additionally, further 
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research that assesses and describes patient characteristics associated with an increase in 
the expression of inflammatory cytokines and cognitive deficits would be helpful in 
identifying vulnerable individuals.  
Fourth, individuals with colorectal cancer reported greater psychological and 
symptom distress and reduced physical exercise.  In particular fatigue was found to 
independently predict self-report directed attention and working memory function.  This 
was an interesting and unexpected finding. Further research is needed to examine 
specifically the relationship between fatigue and cognitive function as well as more 
broadly the relationship between distress and reduced physical activity and cognitive and 
immune function in individuals with colorectal cancer.  Additionally, these findings need 
to be further examined within the context of sickness behavior responses in colorectal 
cancer.   
Fifth, there is a need to assess cognitive and immune function in a larger sample 
of colorectal cancer survivors.  In particular, the present study had difficulty detecting 
group differences in IL-1β and IL-1RA.  Future studies with a larger sample would also 
allow for the assessment of the effects of advanced cancer on the expression of cognitive 
symptoms and inflammatory cytokines and biomarkers.  It is possible that individuals 
with advanced colorectal cancer are more vulnerable to cognitive symptoms given prior 
studies finding greater inflammatory cytokine and biomarker expression in patients with 
advanced cancer compared to individuals with localized disease. 
Finally, this cross sectional study examined cognitive and immune function 
during the first six months after diagnosis with primary or recurrent cancer and found that 
individuals with colorectal cancer may experience deficits in directed attention and 
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working memory and an overexpression of inflammatory cytokines and biomarkers.  
Future longitudinal studies are needed to confirm these preliminary findings and to 
examine the effects of diagnosis and treatment on cognitive and immune function over 
the illness trajectory.   
Implications for Nursing Practice and Research 
The goal of nursing is to optimize the health and abilities of an individual and to 
alleviate suffering (American Nurses Society, 2013).  In oncology, nurses have an 
important role in assessing symptoms and behavioral responses to the cancer and cancer 
treatments and intervening to improve function and reduce distress.  This study provides 
preliminary evidence that individuals newly diagnosed with primary or recurrent 
colorectal cancer can experience deficits in directed attention and working memory.  
Cognitive symptoms can interfere with daily functioning including an individual’s ability 
to learn, work, and attain personal goals (Boykoff, Moieni, & Subramanian, 2009)  
Cognitive symptoms have also been associated with significant distress, feelings of 
helplessness, and reduced quality of life (Boykoff et al., 2009).  Additionally, this study 
found an association between cognitive symptoms and an over expression of 
inflammatory cytokines and biomarkers suggesting that cognitive symptoms may be a 
part of a systemic immune response to the cancer and cancer treatments. Understanding 
the expression of cognitive symptoms within this context has important implications for 
both the development of targeted interventions as well the timing of interventions as 
poorly timed interventions have the potential of exacerbating an already stressed immune 
system bringing harm to the individual.   Assessing cognitive function and intervening to 
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improve cognitive function in colorectal cancer survivors as well as directions for future 
nursing research will be discussed further below. 
Assessing Cognitive Symptoms in Colorectal Cancer 
Cognitive assessments of individuals with colorectal cancer should include 
sensitive measures of both cognitive performance and self-report.  Unfortunately, at this 
time there are no recommended cognitive assessments for nurses in the clinical setting.  
Findings from this study and findings from other studies examining cognitive symptoms 
in individuals with cancer,  suggest that some neuropsychological tests are sensitive to 
detecting deficits in cognitive performance in cancer survivors (Wefel et al., 2011).  
However, these tests can be lengthy and require advanced training and skills in the 
administration and interpretation of findings.  Thus, these tests are not suitable for the 
clinical setting.   Further research is needed to develop a sensitive objective test for 
oncology nurses to use to screen for cognitive symptoms in the clinical setting.    
Self-report measures of cognitive performance are also a critical component of 
cognitive assessments and can provide important information about an individual’s 
performance on daily activities that require directed attention and working memory.  This 
study used the Attentional Function Index (AFI) and found it to be a sensitive measure in 
detecting cognitive problems in individuals with colorectal cancer.  The AFI has 
established reliability and validity in individuals with cancer (Cimprich, Visovatti, & 
Ronis, 2010).  Further, it is brief, and easy to score and interpret.  As such, it would be a 
useful self-report measure to be included alongside neuropsychological measure (s) in a 
cognitive assessment for cancer-related cognitive symptoms.   
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In summary, this study found preliminary evidence of cognitive problems in the 
domains of directed attention and working memory in individuals with colorectal cancer.  
At this time there are no recommended tests or questionnaires to assess cognitive 
function in cancer survivors in the clinical setting.  As such, there is a critical need for 
research to develop a sensitive cognitive assessment that includes measures of both 
cognitive performance and self-report.  The AFI was a sensitive self-report measure in 
this study and is recommended for inclusion in a cognitive assessment for individuals 
with colorectal cancer. 
Intervening to Improve Cognitive Function and Reduce Distress in Colorectal 
Cancer 
  Interventions to improve cognitive function in cancer survivors require an 
understanding of potential mechanisms that may underlie symptoms.  In this regard, there 
were three important findings from this study.  First, this study found that individuals 
with cancer experienced an overexpression of inflammatory cytokines and biomarkers.  
Second, this study found a significant relationship between cognitive symptoms and 
inflammatory cytokine expression.  Finally, this study found that both cognitive 
symptoms and an overexpression of inflammatory cytokines were associated with other 
biobehavioral factors. These are important findings because they suggest that an 
overexpression of inflammatory cytokines may underlie cognitive symptoms in 
individuals with colorectal cancer.  Additionally, they also suggest possibilities for 
interventions such as modifying biobehavioral factors to improve cognitive function 
and/or reduce inflammatory cytokine expression.  Specifically, interventions to decrease 
psychological distress, decrease fatigue, and/or increase physical activity may hold 
 173 
promise in reducing inflammatory cytokine expression and improving cognitive function.  
Promoting healthy behaviors may also be an important intervention as body mass index, 
tobacco use, and alcohol intake have been associated with an over expression of 
inflammatory cytokines (O’Connor et al., 2008).  However, in developing interventions 
to reduce inflammation and improve cognitive function researchers must consider 
whether the intervention has the potential to add additional stress to the immune system 
and/or compromise cancer control.  For example, although cardiovascular fitness has 
been shown to lower circulating levels of inflammatory cytokines, acute exercise has 
been associated with an exponential increase in inflammatory cytokines (O’Connor et al. 
2009).  If the intervention has the potential to alter the immune response and harm the 
individual important questions about the doses of the intervention and the timing of the 
intervention need to be asked.  With this in mind interventions aimed at optimizing 
cognitive function and not aimed at altering the immune response may be most 
appropriate for individuals with advanced disease and/or individuals newly diagnosed 
with cancer during the initial phase of the illness when the immune system is responding 
to both the presence of malignant cells and tissue injury associated with cancer 
treatments.  One potential intervention aimed at reducing mental or attentional fatigue is 
having the individual engage in activities that rest and/or restore directed or controlled 
attention such as spending time in nature or enjoying a scenic view from a window 
(Cimprich, 2003).  This intervention has proven efficacy in women with breast cancer, 
who like individuals with colorectal cancer, can experience mental or attentional fatigue 
related to the many cognitive demands associated with a diagnosis and treatment of 
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cancer.  Further research is needed to evaluate the efficacy of this intervention in 
colorectal cancer. 
 In summary, this study suggests that there may be a relationship between 
cognitive symptoms and inflammatory cytokine and biomarker expression in individuals 
with colorectal cancer.  This study also found that certain biobehavioral factors were 
associated with the expression of cognitive symptoms and inflammatory cytokine 
expression.  As such, modification of some of these biobehavioral factors including 
psychological distress, fatigue and physical activity may reduce the expression of 
cognitive symptoms and/or inflammatory cytokine expression.  However, the relationship 
between cognitive and immune function also suggests that interventions need to be 
appropriately timed and dosed so as to not to harm the individual.  Interventions that 
focus on optimizing an individual’s cognitive function such as spending time in nature 
may be most appropriate for individuals with advanced disease and/or individuals newly 
diagnosed with colorectal cancer undergoing treatment for the disease. 
Directions for Future Nursing Research 
 This study provided new information about the role of immune responses in 
cognitive symptoms in cancer survivors and suggests that such symptoms may be a part 
of a cluster of immune mediated sickness behavior responses. Future research examining 
symptom clusters is needed to increase knowledge of immune responses in colorectal 
cancer and to allow for the development of new strategies for symptom management. 
 More broadly, current findings from this study suggest that biological 
mechanisms may underlie symptoms and behavioral responses.  This has important 
implications for nurse researchers who are assessing and developing interventions for 
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symptoms and behaviors in other acute and chronic illnesses.  Increased knowledge of 
biological mechanisms associated with symptoms will allow for the development of 
interventions to manage symptoms and improve quality of life across the trajectory of the 
illnesses.  It may also allow for the design of personalized interventions to address the 




















American Nurses Society.  2013.  What is nursing?  Retrieved from 
http://nursingworld.org /EspeciallyForYou/What-is-Nursing 
 
Ariel, A., & Timor, O.  (2013).  Hanging in the balance:  endogenous anti-inflammatory 
mechanisms in tissue repair and fibrosis.  Journal of Pathology, 229, 250 – 263.  
doi:  10.1002/path.408 
 
Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002). Fatigue and proinflammatory 
cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64, 604-
611.  
 
Bower, J. E., Ganz, P. A., Irwin, M. R., Kwan, L., Breen, E. C., & Cole, S. W. (2011). 
Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, 
depression, and sleep disturbance share a common underlying mechanism? 
Journal of Clinical Oncology, 29, 3517-3522. doi: 10.1200/JCO.2011.36.1154 
 
Bower, J. E., Ganz, P. A., Tao, M. L., Hu, W., Belin, T. R., Sepah, S., . . . Aziz, N. 
(2009). Inflammatory biomarkers and fatigue during radiation therapy for breast 
and prostate cancer. Clinical Cancer Research, 15, 5534-5540. 
 doi: 10.1158/1078-0432.CCR-08-2584 
 
Boykoff, N., Moieni, M., & Subramanian, S. K.  (2009).  Confronting chemobrain:  an 
in-depth look at survivors' report of impact on work, social networks, and healthy 
care response.  Journal of Cancer Survivorship, 3, 223-232.   
doi:  10.1007/s11764-009-0098-x 
 
Cimprich, B. (1998). Age and extent of surgery affect attention in women treated for 
breast cancer.  Research in Nursing & Health, 21, 229-238.  
 
Cimprich, B., & Ronis, D. L. (2001). Attention and symptom distress in women with and 
without breast cancer.  Nursing Research, 50, 86-94.  
 
Cleeland, C. S., Bennett, G. J., Dantzer, R., Dougherty, P. M., Dunn, A. J., Meyers, C. 
A., . . . Lee, B. N. (2003). Are the symptoms of cancer and cancer treatment due 
to a shared biologic mechanism? A cytokine-immunologic model of cancer 
symptoms.  Cancer, 97, 2919-2925. doi: 10.1002/cncr.11382 
 
Collado-Hidalgo, A., Bower, J. E., Ganz, P. A., Cole, S. W., & Irwin, M. R. (2006). 
Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clinical 
Cancer Research, 12, 2759-2766. doi: 10.1158/1078-0432.CCR-05-2398 
 
Goshen, I., & Yirmiya,R. (2007). The role of pro-inflammatory cytokines in mmeory 
processes and neural plasticity. In R. Ader (Ed.), Psychoneuroimmunology (4 th 
ed., Vol. 1, pp. 337 - 378). Burlington, MA: Elsevier Academic Press. 
 177 
 
Hart, B. L. (1988). Biological basis of the behavior of sick animals.  Neuroscience and 
Biobehavioral Reviews, 12, 123-137.  
 
Inagaki, M., Isono, M., Okuyama, T., Sugawara, Y., Akechi, T., Akizuki, N., . . . 
Uchitomi, Y. (2008). Plasma interleukin-6 and fatigue in terminally ill cancer 
patients. Journal of Pain and Symptom Management, 35, 153-161.  
doi:  10.1016/j.jpainsymman.2007. 03.009 
 
Kent, S., Bluthe, R. M., Kelley, K. W., & Dantzer, R. (1992). Sickness behavior as a new 
target for drug development.  Trends in Pharmacological Sciences, 13, 24-28.  
 
Konsman, J. P., Parnet, P., & Dantzer, R. (2002). Cytokine-induced sickness behaviour: 
mechanisms and implications. Trends in Neurosciences, 25, 154-159.  
 
Koppelmans, V., Breteler, M. M., Boogerd, W., Seynaeve, C., Gundy, C., & Schagen, S. 
B. (2012). Neuropsychological performance in survivors of breast cancer more 
than 20 years after adjuvant chemotherapy.  Journal of Clinical Oncology, 30, 
1080-1086. doi: 10.1200/JCO.2011.37.0189 
 
Musselman, D. L., Miller, A. H., Porter, M. R., Manatunga, A., Gao, F., Penna, S., . . . 
Nemeroff, C. B. (2001). Higher than normal plasma interleukin-6 concentrations 
in cancer patients with depression: preliminary findings.  The American Journal 
of Psychiatry, 158, 1252-1257. 
 
O'Connor, M. F., Bower, J. E., Cho, H. J., Creswell, J.D.,  Dimitrov, S., Hamby, M. E., 
…Irwin, M. R.  (2009).  To assess, to control, to exclude:  Effects of 
biobehavrioal facotrs on circulating inflammatory makers.  Brain, Behavior, and 
Immunity, 23, 887-897.  doi  10.1016/j.bbi.2009.04.005 
 
Orre, I. J., Murison, R., Dahl, A. A., Ueland, T., Aukrust, P., & Fossa, S. D. (2009). 
Levels of circulating interleukin-1 receptor antagonist and C-reactive protein in 
long-term survivors of testicular cancer with chronic cancer-related fatigue.  
Brain, Behavior, and Immunity, 23, 868-874. doi: 10.1016/j.bbi.2009.04.003 
 
Wang, X. S., Shi, Q., Williams, L. A., Mao, L., Cleeland, C. S., Komaki, R. R., . . . Liao, 
Z. (2010). Inflammatory cytokines are associated with the development of 
symptom burden in patients with NSCLC undergoing concurrent chemoradiation 
therapy. Brain, Behavior, and Immunity, 24, 968-974.  
doi: 10.1016/j.bbi.2010.03.009 
 
Wang, X. S., Williams, L. A., Krishnan, S., Liao, Z., Liu, P., Mao, L., . . . Cleeland, C. S. 
(2012). Serum sTNF-R1, IL-6, and the development of fatigue in patients with 
gastrointestinal cancer undergoing chemoradiation therapy.  Brain, Behavior, and 
Immunity, 26, 699-705. doi: 10.1016/j.bbi.2011.12.007 
 
 178 
Watkins, L. R., & Maier, S. F.  (2000).  The pain of being sick:  implication of immune-
to-brain communication for understanding pain.  Annual Review of Psychology, 
51, 29 - 57. 
 
Wefel, J. S., Vardy, J., Ahles, T., & Schagen, S. B. (2011). International Cognition and 
Cancer Task Force recommendations to harmonise studies of cognitive function 
in patients with cancer. The Lancet Oncology, 12, 703-708. doi: 10.1016/S1470-
2045(10)70294-1 
 
Wratten, C., Kilmurray, J., Nash, S., Seldon, M., Hamilton, C. S., O'Brien, P. C., & 
Denham, J. W. (2004). Fatigue during breast radiotherapy and its relationship to 
biological factors. International Journal of Radiation Oncology, Biology, and 
Physics, 59, 160-167. doi: 10.1016/j.ijrobp.2003.10.008 
 
